<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0079">
    <title>62 Borrelia*</title>
    <sect1 id="ch0079s0001">
      <title>62 Borrelia*</title>
      <anchor id="ch0079s0001a0001"/>
      <anchor id="ch0079s0001a0002"/>
      <anchor id="ch0079s0001a0003"/>
      <para role="chapterAuthor"><phrase role="center">MARIA E. AGUERO-ROSENFELD AND EVA RUŽIĆ SABLJIĆ</phrase>
      </para>
      <para id="ch0079s0001p0001"><emphasis>Borrelia</emphasis> species constitute a heterogeneous group of organisms that are maintained in nature in animal reservoirs and are transmitted via arthropod vectors. Most species are restricted to this enzootic cycle, and only a few can cause human disease through the bite of an infected vector. Investigations of <emphasis>Borrelia</emphasis> phylogeny, microbial populations, and their intimate relationship to their arthropod and animal reservoirs have provided insights into their evolution, plasticity, and adaptation to the different ecological niches where they exist (<link linkend="ch0079s0024s0003li0001">1</link>, <link linkend="ch0079s0024s0003li0002">2</link>). New species in vectors and animal reservoirs, as well as new species causing human disease, have been described (<link linkend="ch0079s0024s0003li0003">3</link>–<link linkend="ch0079s0024s0003li0007">7</link>).</para>
      <para id="ch0079s0001p0002">The complex genomic structure of these organisms allows them to adapt to different environments by expressing different antigens on their surface. Some of these antigens have been associated with virulence and invasion as well as evasion of the host immune system (<link linkend="ch0079s0024s0003li0008">8</link>).</para>
      <para id="ch0079s0001p0003"><emphasis>Borrelia</emphasis> species are agents of relapsing fever (RF), caused by the RF <emphasis>Borrelia</emphasis> group<emphasis>,</emphasis> and Lyme disease (referred to here as Lyme borreliosis [LB]), caused by the LB <emphasis>Borrelia</emphasis> group (<link linkend="ch0079s0024s0003li0009">9</link>). The latter is the most common vector-borne disease in Europe and the United States and is caused by a group of genetically related species referred to as <emphasis>Borrelia burgdorferi sensu lato</emphasis> (<link linkend="ch0079s0024s0003li0007">7</link>, <link linkend="ch0079s0024s0003li0008">8</link>). Due to differences in disease associations and biological features in the tick vector, among other characteristics, there have been proposals to separate the RF and LB groups into two genera, but this has created controversies, as discussed below (<link linkend="ch0079s0024s0003li0009">9</link>). Although <emphasis>B. burgdorferi sensu lato</emphasis> species are found in arthropod vectors in the Southern Hemisphere, Lyme borreliosis has been described only in the Northern Hemisphere. Important aspects of these arthropod-borne diseases are the potential pathogenic properties of the microorganism, the presence of a suitable reservoir, a competent vector(s), and a susceptible human host that becomes a dead-end host. If these factors are not in concert, disease development in humans does not occur.</para>
      <sect2 id="ch0079s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0079s0001s0001a0001"/>
        <anchor id="ch0079s0001s0001a0002"/>
        <para id="ch0079s0001s0001p0001">Borreliae belong to the order<emphasis>Spirochaetales</emphasis>, which includes the families <emphasis>Spirochaetaceae</emphasis> and <emphasis>Leptospiraceae.</emphasis> The family <emphasis>Spirochaetaceae</emphasis> includes the genera <emphasis>Borrelia</emphasis> and <emphasis>Treponema.</emphasis> While borreliae are vector borne and cause human disease from a zoonotic source, <emphasis>Treponema pallidum</emphasis>, which causes syphilis, is acquired from infected humans (<link linkend="ch0079s0024s0003li0010">10</link>). On the basis of sequence analysis of highly conserved proteins of members of the order <emphasis>Spirochaetales</emphasis>, it was proposed that the genus <emphasis>Borrelia</emphasis> be elevated to the family <emphasis>Borreliaceae</emphasis> (<link linkend="ch0079s0024s0003li0011">11</link>). Furthermore, Adeolu and Gupta (<link linkend="ch0079s0024s0003li0012">12</link>) proposed a division of the genus <emphasis>Borrelia</emphasis> into two separate genera: genus <emphasis>Borrelia</emphasis>, containing the causative agents of relapsing fever, and a novel genus, <emphasis>Borreliella</emphasis> gen. nov., containing the causative agents of Lyme borreliosis (<link linkend="ch0079s0024s0003li0012">12</link>).</para>
        <para id="ch0079s0001s0001p0002">Although the proposed division was based on phenotypic and genotypic characteristics, supported by acceptable molecular markers, and encouraged by specific observations regarding specific spirochete-vector-host association and clinical presentation, the proposed separation opened extensive scientific and medical debate (<link linkend="ch0079s0024s0003li0009">9</link>, <link linkend="ch0079s0024s0003li0012">12</link>–<link linkend="ch0079s0024s0003li0015">15</link>). Available data suggest that millions of years ago, RF <emphasis>Borrelia</emphasis> strains were associated with ancient tick species and were probably symbiotic with primitive ticks. After the Argasidae-Ixodidae tick split, environmental pressures created two <emphasis>Borrelia</emphasis> lineages, one associated with Argasidae (soft ticks) and another associated with Ixodidae (hard ticks). These clades adapted to a tick vector, vertebrate reservoir, and complex lifestyle that is reflected by the modern <emphasis>Borrelia</emphasis> complex genome compositions (<link linkend="ch0079s0024s0003li0007">7</link>, <link linkend="ch0079s0024s0003li0009">9</link>, <link linkend="ch0079s0024s0003li0013">13</link>, <link linkend="ch0079s0024s0003li0015">15</link>, <link linkend="ch0079s0024s0003li0016">16</link>). Similarities and differences between RF and LB <emphasis>Borrelia</emphasis> groups were complicated by the discovery of a third <emphasis>Borrelia</emphasis> lineage described as an intermediate taxon between RF and LB, a reptile- and echidna-associated group (<link linkend="ch0079s0024s0003li0003">3</link>, <link linkend="ch0079s0024s0003li0007">7</link>, <link linkend="ch0079s0024s0003li0015">15</link>). Since changes to <emphasis>Borrelia</emphasis> taxonomic nomenclature are still under discussion and not uniformly accepted, we use <emphasis>Borrelia</emphasis> as the genus name for all three groups in this chapter.</para>
        <para id="ch0079s0001s0001p0003">The genus<emphasis>Borrelia</emphasis> currently comprises 45 named species, including 21 species within the RF group, 21 within the LB group, and 3 within the third reptile- and echidna-associated group (<link linkend="ch0079s0024s0003li0007">7</link>, <link linkend="ch0079s0024s0003li0009">9</link>).</para>
        <table id="ch0079s0001s0001t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0079s0001s0001a0003"/><link linkend="ch0079s0001s0001a0006">TABLE 1</link></phrase></emphasis> Relapsing fever and Lyme borreliosis <emphasis>Borrelia</emphasis> species causing human diseases, with their vectors and geographic distribution<superscript><emphasis><anchor id="ch0079s0001s0001a0004"/><link linkend="ch0079s0001s0001a0005">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="6">
            <tbody>
              <row>
                <entry><phrase role="center">Disease</phrase>
                </entry>
                <entry><phrase role="center">Group</phrase>
                </entry>
                <entry><phrase role="center">Species</phrase>
                </entry>
                <entry><phrase role="center">Vector(s)</phrase>
                </entry>
                <entry><phrase role="center">Hosts</phrase>
                </entry>
                <entry><phrase role="center">Distribution</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Relapsing fever</phrase>
                </entry>
                <entry><phrase role="left">Louse-borne RF <emphasis>Borrelia</emphasis> (LBRF)</phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>B. recurrentis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Pediculus humanus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Humans</phrase>
                </entry>
                <entry><phrase role="left">East Africa and worldwide</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">Soft-tick-borne RF <emphasis>Borrelia</emphasis></phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>B. baltazardii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left"><emphasis>Ornithodoros tholozani</emphasis> (?), unknown</phrase>
                </entry>
                <entry><phrase role="left">Humans</phrase>
                </entry>
                <entry><phrase role="left">Iran</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. brasiliensis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros brasiliensis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Humans</phrase>
                </entry>
                <entry><phrase role="left">Brazil</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. caucasica</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros verrucosus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Caucasus, Iraq</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. crocidurae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros sonrai</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, insectivores, humans</phrase>
                </entry>
                <entry><phrase role="left">Western and North Africa (Morocco, Libya, Egypt), Iran, Senegal, Kenya</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. duttonii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left"><emphasis>Ornithodoros moubata sensu lato</emphasis> complex</phrase>
                </entry>
                <entry><phrase role="left">Humans</phrase>
                </entry>
                <entry><phrase role="left">Eastern, central, southern Africa, Madagascar</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. graingeri</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornitodoros graingeri</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Kenya</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. hermsii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros hermsi</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Western United States and Canada</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. hispanica</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros erraticus, Ornithodoros marocanus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, insectivores, humans</phrase>
                </entry>
                <entry><phrase role="left">Spain, Portugal, Greece, Cyprus, Morocco, Algeria, Tunisia</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. latyschewii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros tartakovskyi</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Central Asia, Middle East, former USSR</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. mazzottii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros talaje</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents? Unknown</phrase>
                </entry>
                <entry><phrase role="left">Central and South America, Mexico, Guatemala</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. microti</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros erraticus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Humans</phrase>
                </entry>
                <entry><phrase role="left">Iran</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. parkeri</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros parkeri</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Western United States</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. persica</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros tholozani</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Middle East (Israel, Syria), Egypt, Iran, Central Asia, India</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. turicatae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros turicata</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Southwestern United States, Canada</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. venezuelensis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ornithodoros rudis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents? Unknown</phrase>
                </entry>
                <entry><phrase role="left">Central and South America</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">Hard-tick-borne RF <emphasis>Borrelia</emphasis></phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>B. miyamotoi</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes persulcatus, Ixodes scapularis, Ixodes ricinus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, birds, humans</phrase>
                </entry>
                <entry><phrase role="left">Asia, Europe, United States</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Lyme borreliosis</phrase>
                </entry>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. burgdorferi sensu lato</emphasis>
                  </phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. afzelii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes ricinus, Ixodes persulcatus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Europe, Asia</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. bavariensis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes ricinus, Ixodes persulcatus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Europe, Asia</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. bissettiae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes pacificus, Ixodes spinipalpis, Ixodes scapularis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, birds, humans</phrase>
                </entry>
                <entry><phrase role="left">United States, Europe (exceptionally)</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. burgdorferi sensu stricto</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes scapularis, Ixodes pacificus, Ixodes ricinus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, birds, humans</phrase>
                </entry>
                <entry><phrase role="left">United States, Europe (rare)</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. garinii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes ricinus, Ixodes persulcatus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Birds, humans</phrase>
                </entry>
                <entry><phrase role="left">Europe, Asia</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. lusitaniae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes ricinus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, lizards, humans</phrase>
                </entry>
                <entry><phrase role="left">Southern and southeastern Europe</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. mayonii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes scapularis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Midwestern United States</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. spielmanii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes ricinus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, humans</phrase>
                </entry>
                <entry><phrase role="left">Europe</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry/>
                <entry><phrase role="left">
                    <emphasis>B. valaisiana</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes ricinus, Ixodes nipponensis, Ixodes columnae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">Rodents, birds, humans</phrase>
                </entry>
                <entry><phrase role="left">Europe, Asia</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0001s0001a0005"/><link linkend="ch0079s0001s0001a0004">a</link></emphasis></superscript>Adapted from references <link linkend="ch0079s0024s0003li0004">4</link> and <link linkend="ch0079s0024s0003li0223">223</link>.</para>
        <para id="ch0079s0001s0001p0004">The RF<emphasis>Borrelia</emphasis> group encompasses species transmitted by different arthropod vectors but predominantly by (argasid) ticks of the genus <emphasis>Ornithodoros.</emphasis> Contrary to LB <emphasis>Borrelia</emphasis>, RF <emphasis>Borrelia</emphasis> species have a wider geographic distribution and cause disease in both hemispheres (<anchor id="ch0079s0001s0001a0006"/><link linkend="ch0079s0001s0001a0003">Table 1</link>) (<link linkend="ch0079s0024s0003li0004">4</link>). Members of the LB group of <emphasis>Borrelia</emphasis> share many characteristics but vary in their ability to cause disease and clinical manifestations. Three genospecies of the <emphasis>B. burgdorferi sensu lato</emphasis> complex, <emphasis>B. burgdorferi sensu stricto</emphasis> (referred as <emphasis>B. burgdorferi</emphasis> in this chapter), <emphasis>B. afzelii</emphasis>, and <emphasis>B. garinii</emphasis>, are the species that most frequently cause Lyme borreliosis in the United States and Europe (<link linkend="ch0079s0024s0003li0017">17</link>, <link linkend="ch0079s0024s0003li0018">18</link>). Other genospecies of the <emphasis>B. burgdorferi sensu lato</emphasis> complex that also cause human disease are <emphasis>B. bavariensis, B. bissettiae, B. lusitaniae, B. spielmanii, B. valaisiana</emphasis>, and <emphasis>B. mayonii</emphasis> (<link linkend="ch0079s0024s0003li0019">19</link>–<link linkend="ch0079s0024s0003li0022">22</link>). The third <emphasis>Borrelia</emphasis> group, reptile- and echidna-associated <emphasis>Borrelia</emphasis>, has not been described as causing infections in humans (<link linkend="ch0079s0024s0003li0007">7</link>, <link linkend="ch0079s0024s0003li0009">9</link>).</para>
        <anchor id="ch0079s0001s0001a0007"/>
        <beginpage pagenum="1177"/>
        <anchor id="ch0079s0001s0001a0008"/>
        <beginpage pagenum="1178"/>
      </sect2>
      <sect2 id="ch0079s0001s0002">
        <title>DESCRIPTION OF THE GENUS</title>
        <anchor id="ch0079s0001s0002a0001"/>
        <anchor id="ch0079s0001s0002a0002"/>
        <para id="ch0079s0001s0002p0001">All borreliae have common characteristics: they are motile spirochetes, helical with pointed ends, 10 to 40 μm in length, and 0.2 to 0.3 μm in diameter (<link linkend="ch0079s0024s0003li0023">23</link>, <link linkend="ch0079s0024s0003li0024">24</link>). As in other spirochetes, an outer membrane surrounds a thin peptidoglycan layer and the cytoplasmic contents are enclosed with an inner membrane. The diderm membrane differs from that of Gram-negative bacteria, particularly in lipopolysaccharide content; the majority of proteins anchored in borrelial outer and inner membranes are lipoproteins. Lipoproteins from the inner membrane are in close association with the peptidoglycan layer, while those on the outer membrane are surface exposed (<link linkend="ch0079s0024s0003li0023">23</link>). As described below, many of these surface proteins are involved in host-pathogen interactions. Flagella are located in the periplasmic space, between the inner and outer membrane, and are attached at opposite poles of the cell at one end and overlap in the center. They are wrapped around the protoplasmic cylinder and are responsible for typical spirochete rotational motion and flexing (<link linkend="ch0079s0024s0003li0023">23</link>, <link linkend="ch0079s0024s0003li0024">24</link>). <emphasis>Borrelia</emphasis> species are microaerophilic with very limited metabolic capacity and metabolize carbohydrates or amino acids as carbon and energy sources. They divide by transverse binary fission (<link linkend="ch0079s0024s0003li0011">11</link>, <link linkend="ch0079s0024s0003li0013">13</link>, <link linkend="ch0079s0024s0003li0023">23</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0002">
      <title>Genomes</title>
      <anchor id="ch0079s0002a0001"/>
      <anchor id="ch0079s0002a0002"/>
      <para id="ch0079s0002p0001">A hallmark of<emphasis>Borrelia</emphasis> species is a segmented genome consisting of a linear chromosome and a mix of linear and circular plasmids. The linear DNA genome structure found in the <emphasis>Borrelia</emphasis> genus is uncommon in bacteria (<link linkend="ch0079s0024s0003li0007">7</link>, <link linkend="ch0079s0024s0003li0013">13</link>, <link linkend="ch0079s0024s0003li0016">16</link>, <link linkend="ch0079s0024s0003li0025">25</link>–<link linkend="ch0079s0024s0003li0028">28</link>). Their G+C content is 27 to 32 mol% (<link linkend="ch0079s0024s0003li0025">25</link>). Data suggest that all three <emphasis>Borrelia</emphasis> groups (RF, LB, and reptile and echidna associated) have genomes of similar sizes, about 1.5 Mb. Strains from particular groups differ in plasmid number per cell as well as plasmid molecular masses (<link linkend="ch0079s0024s0003li0026">26</link>, <link linkend="ch0079s0024s0003li0029">29</link>, <link linkend="ch0079s0024s0003li0030">30</link>). Among all sequenced <emphasis>Borrelia</emphasis> strains, those within the LB group harbor the largest number of plasmids reported in any bacterial species; strain B31 has up to 12 linear plasmids and 11 circular plasmids with molecular masses of 5 to 84 kb. RF <emphasis>Borrelia</emphasis> group strains harbor smaller numbers of plasmids, with molecular masses ranging from 5 to 165 kb; e.g., <emphasis>B. recurrentis</emphasis> (A1 strain) has only 7 linear plasmids, while <emphasis>B. duttonii</emphasis> (Ly strain) has 15 linear plasmids and 1 circular plasmid. Comparison of the genomes of these two RF <emphasis>Borrelia</emphasis> strains reveals that their chromosomes are colinear and that, although reduced in number, all <emphasis>B. recurrentis</emphasis> plasmids have a counterpart in <emphasis>B. duttonii.</emphasis> It is postulated that because of genome similarities, <emphasis>B. recurrentis</emphasis> is a strain of <emphasis>B. duttonii</emphasis> and that the loss of genetic material in the former might be related to its increased virulence (<link linkend="ch0079s0024s0003li0031">31</link>). Furthermore, comparison of RF <emphasis>Borrelia</emphasis> genomes by sequence analysis revealed <emphasis>B. recurrentis, B. duttonii</emphasis>, and <emphasis>B. crocidurae</emphasis> to be closely related but unique genospecies, as seems to be the case for North American <emphasis>B. hermsii</emphasis> and <emphasis>B. parkeri.</emphasis> Further work on complete genome sequencing will likely clarify the taxonomy of these organisms (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0012">12</link>, <link linkend="ch0079s0024s0003li0032">32</link>). Members of the reptile- and echidna-associated <emphasis>Borrelia</emphasis> group (A-FGy1 isolate) harbor plasmids from 30 to 130 kb in size (<link linkend="ch0079s0024s0003li0003">3</link>).</para>
      <para id="ch0079s0002p0002">Contrary to the requirements of most bacteria, plasmids are essential for<emphasis>Borrelia.</emphasis> While the <emphasis>Borrelia</emphasis> chromosome contains genes that predominantly encode proteins for housekeeping functions with very limited metabolic capacity, genes encoding proteins with functions needed for arthropod vector and vertebrate host interactions, as well as for adaptation and invasion, are located in plasmids. This is why linear plasmids also are referred to as minichromosomes (<link linkend="ch0079s0024s0003li0026">26</link>, <link linkend="ch0079s0024s0003li0029">29</link>).</para>
      <para id="ch0079s0002p0003">Chromosomal sequence homology is quite conserved among the different<emphasis>B. burgdorferi sensu lato</emphasis> species sequenced, except at one end of the linear chromosome, where there are plasmid-like sequences. However, there are differences among the different <emphasis>B. burgdorferi sensu lato</emphasis> species in the number of plasmids present as well as in the genetic traits encoded by them. Among plasmids, linear plasmid 54 (lp54), circular plasmid 26 (cp26), and cp32 are found in all <emphasis>B. burgdorferi sensu lato</emphasis> species sequenced (<link linkend="ch0079s0024s0003li0016">16</link>). Many genes on these plasmids are essential for interactions with arthropod vectors and for virulence in animal hosts (<link linkend="ch0079s0024s0003li0033">33</link>). Plasmid lp54 encodes outer surface proteins OspA and -B, important in the tick environment, as well as decorin-binding proteins DbpA and -B, important in host interactions (<link linkend="ch0079s0024s0003li0026">26</link>, <link linkend="ch0079s0024s0003li0027">27</link>). OspC, which is upregulated during tick feeding, is encoded on cp26. Analysis of OspC sequences from different strains suggests that gene exchange might be important for antigenic diversity and immune evasion (<link linkend="ch0079s0024s0003li0034">34</link>). Analysis of the plasmids reveals that they contain pseudogenes and genes in evolutionary decay, some with prophage-like sequences that would allow recombination and DNA rearrangement (<link linkend="ch0079s0024s0003li0026">26</link>, <link linkend="ch0079s0024s0003li0027">27</link>). Plasmid lp28-1 contains a contiguous set of 15 silent gene cassettes in the variable major protein-like sequence (<emphasis>vls</emphasis>) locus. Small stretches of genetic material from these silent cassettes are transferred to an expression site, <emphasis>vlsE</emphasis>, located on the same plasmid. This generates a mosaic <emphasis>vlsE</emphasis> gene that allows continuous modification and antigenic diversity of the VlsE (variable major protein-like sequences expressed) outer surface lipoprotein needed for pathogen-host interaction (<link linkend="ch0079s0024s0003li0035">35</link>), allowing the pathogen to remain one step ahead of the acquired immune response and enabling persistent infection (<link linkend="ch0079s0024s0003li0016">16</link>, <link linkend="ch0079s0024s0003li0035">35</link>).</para>
      <para id="ch0079s0002p0004">The linear plasmids of<emphasis>B. hermsii</emphasis> and <emphasis>B. turicatae</emphasis> contain genes encoding outer membrane lipoproteins, called variable major proteins (VMPs). As seen in LB <emphasis>Borrelia</emphasis>, these genes are silent except when they are translocated to an expression site immediately adjacent to one of the linear plasmid telomeres, as described for VlsE (<link linkend="ch0079s0024s0003li0016">16</link>, <link linkend="ch0079s0024s0003li0035">35</link>).</para>
      <sect2 id="ch0079s0002s0001">
        <title>SPECIES</title>
        <anchor id="ch0079s0002s0001a0001"/>
        <anchor id="ch0079s0002s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0003">
      <title>Relapsing Fever Borrelia Group</title>
      <anchor id="ch0079s0003a0001"/>
      <anchor id="ch0079s0003a0002"/>
      <para id="ch0079s0003p0001">Although<emphasis>B. anserina</emphasis>, described in 1891, is the prototype of <emphasis>Borrelia</emphasis> species, it does not cause illness in humans. <emphasis>B. anserina</emphasis> found its host in birds, is transmitted by <emphasis>Arga</emphasis>s sp. soft ticks, and is distributed worldwide (<link linkend="ch0079s0024s0003li0004">4</link>). Other RF species are transmitted by <emphasis>Ornithodoros</emphasis> tick spp. or <emphasis>Ixodes</emphasis> spp. (<emphasis>B. miyamotoi</emphasis>). Based on DNA sequence analysis, there are currently 21 published species within the RF group (<link linkend="ch0079s0001s0001a0003">Table 1</link>). The current systematic approach regarding the RF <emphasis>Borrelia</emphasis> sp. reflects vector-<emphasis>Borrelia</emphasis>-host associations and geographic distributions of species and recognizes four groups (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0032">32</link>).</para>
      <anchor id="ch0079s0003a0003"/>
      <beginpage pagenum="1179"/>
      <orderedlist role="decimal">
        <listitem id="ch0079s0003li0001">
          <para><emphasis>B. recurrentis</emphasis> is the only RF species distributed worldwide and transmitted by the louse <emphasis>Pediculus humanus</emphasis>. Undoubtedly, it is the <emphasis>Borrelia</emphasis> species that caused the most epidemics in the past. Although personal hygiene and sanitary conditions have improved, there are still cases in impoverished areas of the world and places where individuals from these areas have emigrated (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0036">36</link>–<link linkend="ch0079s0024s0003li0038">38</link>).</para>
        </listitem>
        <listitem id="ch0079s0003li0002">
          <para>The Old World RF<emphasis>Borrelia</emphasis> species, such as <emphasis>B. duttonii, B. crocidurae, B. caucasica, B. persica</emphasis>, etc., are distributed in Africa, the Middle East, the Mediterranean, Central Asia, and India and are transmitted by <emphasis>Ornithodoros</emphasis> ticks (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0039">39</link>).</para>
        </listitem>
        <listitem id="ch0079s0003li0003">
          <para>The New World RF<emphasis>Borrelia</emphasis> species, such as <emphasis>B. hermsii, B. coriaceae, B. parkeri, B. turicatae</emphasis>, etc., are distributed in North, Central, and South America and are also transmitted by <emphasis>Ornithodo</emphasis><emphasis>ros</emphasis> ticks.</para>
        </listitem>
        <listitem id="ch0079s0003li0004">
          <para>The ixodid-borne<emphasis>Borrelia</emphasis> sp. <emphasis>B. miyamotoi</emphasis> is found in the Northern Hemisphere (Asia, Europe, and North America). <emphasis>B. miyamotoi</emphasis> was first isolated from <emphasis>Ixodes persulcatus</emphasis> in Japan in the mid-1990s (<link linkend="ch0079s0024s0003li0040">40</link>). Since then, it has been found to cause human disease in Russia and subsequently in North America, Europe, and Japan. In North America and Europe, it is transmitted by <emphasis>I. scapularis</emphasis> and <emphasis>I. ricinus</emphasis>, respectively (<link linkend="ch0079s0024s0003li0005">5</link>, <link linkend="ch0079s0024s0003li0041">41</link>–<link linkend="ch0079s0024s0003li0044">44</link>). Other non-human-infective <emphasis>Borrelia</emphasis> species present in ixodid ticks are <emphasis>B. lonestari</emphasis>, transmitted by <emphasis>Amblyomma americanum in</emphasis> North America, and <emphasis>B. theileri</emphasis>, transmitted by <emphasis>Rhipicephalus</emphasis> spp. in North and South America, Africa, and Australia (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0045">45</link>).</para>
        </listitem>
      </orderedlist>
      <para id="ch0079s0003p0002">The characteristic presentation of RF infection correlates with the appearance of new immunogenic variants of their outer membrane lipoprotein, called VMPs. Genes encoding VMPs make up two distinct multigene families:<emphasis>vlp</emphasis> genes, encoding variable large proteins, and <emphasis>vsp</emphasis> genes, encoding variable small proteins. Genes of both families are located on linear plasmids. Genetic variation involved in VMP shifting results either from random fixation via genetic drift or from <emphasis>vlp</emphasis> and <emphasis>vsp</emphasis> polymorphisms selected by the host immune system (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0008">8</link>, <link linkend="ch0079s0024s0003li0046">46</link>).</para>
    </sect1>
    <sect1 id="ch0079s0004">
      <title>LB Borrelia Group</title>
      <anchor id="ch0079s0004a0001"/>
      <anchor id="ch0079s0004a0002"/>
      <para id="ch0079s0004p0001">Over 20 genospecies of<emphasis>B. burgdorferi sensu lato</emphasis> complex are transmitted by ixodid ticks of the genus <emphasis>Ixodes</emphasis>, but only a few of these species cause Lyme borreliosis in humans (<link linkend="ch0079s0024s0003li0001">1</link>, <link linkend="ch0079s0024s0003li0009">9</link>) (<link linkend="ch0079s0001s0001a0003">Table 1</link>). Among them, <emphasis>B. burgdorferi</emphasis> and, in a very few cases, <emphasis>B. mayonii</emphasis> have been found to cause infection in North America (<link linkend="ch0079s0024s0003li0006">6</link>, <link linkend="ch0079s0024s0003li0017">17</link>, <link linkend="ch0079s0024s0003li0047">47</link>). In Europe, <emphasis>B. afzelii</emphasis> is the dominant human pathogen, followed by <emphasis>B. garinii, B. burgdorferi, B. bavariensis</emphasis>, and <emphasis>B. spielmanii.</emphasis> Less frequently, <emphasis>B. bissettiae, B. valaisiana</emphasis>, and <emphasis>B. lusitaniae</emphasis> can cause human infection (<link linkend="ch0079s0024s0003li0048">48</link>–<link linkend="ch0079s0024s0003li0050">50</link>)<emphasis>. B. bavariensis</emphasis>, which utilizes rodents as reservoir hosts, was raised to species level in 2009 after having been included in the species <emphasis>B. garinii</emphasis>; the latter species utilizes birds as reservoir hosts (<link linkend="ch0079s0024s0003li0020">20</link>). Both these species and <emphasis>B. afzelii</emphasis> are also present across Eurasia, but in Asia they have adapted to different <emphasis>Ixodes</emphasis> vectors (<link linkend="ch0079s0024s0003li0020">20</link>, <link linkend="ch0079s0024s0003li0051">51</link>, <link linkend="ch0079s0024s0003li0052">52</link>). In addition to the species that cause disease in humans, there are other species found in ticks and reservoir hosts from different geographic areas that are nonpathogenic for humans. These include <emphasis>B. americana, B. andersonii, B. bissettiae, B. californiensis, B. carolinensis, B. kurtenbachii, B. lanei</emphasis>, and <emphasis>B. maritima</emphasis> in North America, <emphasis>B. finlandensis</emphasis> in Europe, and <emphasis>B. japonica, B. sinica, B. tanukii, B. turdi</emphasis>, and <emphasis>B. yangtzensis</emphasis> in Asia (<link linkend="ch0079s0024s0003li0053">53</link>). In addition, <emphasis>B. chilensis</emphasis>, a new <emphasis>Borrelia</emphasis> species genetically distinct from other LB group species, was found in South America (<link linkend="ch0079s0024s0003li0054">54</link>).</para>
      <para id="ch0079s0004p0002">Although members of LB group of<emphasis>Borrelia</emphasis> have similar characteristics, they vary in their ability to cause disease in humans as well as in clinical manifestations. Their obligate parasitism makes their biology intimately related to the arthropod vector and animal host reservoir where they reside (<link linkend="ch0079s0024s0003li0008">8</link>).</para>
      <sect2 id="ch0079s0004s0001">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0079s0004s0001a0001"/>
        <anchor id="ch0079s0004s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0005">
      <title>Relapsing Fever Borrelia Group</title>
      <anchor id="ch0079s0005a0001"/>
      <anchor id="ch0079s0005a0002"/>
      <para id="ch0079s0005p0001">Relapsing fever<emphasis>Borrelia</emphasis> exist in many different geographic areas worldwide. They are mostly transmitted by soft and hard-bodied ticks, therefore the disease they cause is known as Tick-borne Relapsing Fever (TBRF). Most species causing TBRF are transmitted by <emphasis>Argasid</emphasis> soft-bodied ticks in the genus <emphasis>Ornithodoros</emphasis> (<link linkend="ch0079s0024s0003li0055">55</link>). These ticks take blood meals at night and feed rapidly; they do not remain attached to the host for prolonged intervals (<link linkend="ch0079s0024s0003li0056">56</link>, <link linkend="ch0079s0024s0003li0057">57</link>). The main characteristic of <emphasis>Ornithodoros</emphasis> ticks is their longevity, up to 7 years for <emphasis>Ornithodoros turicata</emphasis> and 5 to 10 years for <emphasis>O. tholozani,</emphasis> while the spirochetes harbored by this tick remain viable over a 5-year period of tick starvation (<link linkend="ch0079s0024s0003li0058">58</link>). Once <emphasis>Ornithodoros</emphasis> ticks are infected, they remain infectious for life, and because of vertical transovarian transmission, the progeny emerge infected. Thus, these ticks not only are vectors but also serve as reservoirs for RF <emphasis>Borrelia.</emphasis> They also have several nymph stages, and females feed several times to complete a life cycle that might take many years. In addition, RF <emphasis>Borrelia</emphasis> spp. are located in the tick salivary gland at the onset of feeding; therefore, transmission can occur rapidly after tick attachment. Reservoirs include wild rodents, insectivores, foxes, domestic animals, and other mammals, particularly chipmunks (<emphasis>Tamias</emphasis> spp.) and squirrels (<emphasis>Tamiasciurus</emphasis> spp.) in North America, and particularly rodents of the genera <emphasis>Mastomys</emphasis> and <emphasis>Praomys</emphasis> and shrews (<emphasis>Crocidura olivieri</emphasis> in West and North Africa) (<link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0059">59</link>). Birds and bats are also reservoirs; their major role might be to disperse ticks and their spirochetes over wider geographic areas. <emphasis>Ornithodoros</emphasis> ticks typically live close to their hosts, in their nests and burrows, allowing them a secure food source. Human infection usually occurs in regions of endemicity where humans are in close proximity to rodents and ticks, in mountain cabins, man-made shelters, caves, and ruins or when camping or sleeping outdoors (<link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0060">60</link>). In East Africa, typical traditional dwellings known as tembes, as well as burrows in West and North Africa, can be heavily infested with <emphasis>Ornithodoros</emphasis> ticks (<link linkend="ch0079s0024s0003li0032">32</link>, <link linkend="ch0079s0024s0003li0059">59</link>).</para>
      <para id="ch0079s0005p0002">In the western United States, the disease typically occurs in forests at high elevation where<emphasis>O. hermsii</emphasis> ticks live, frequently caused by <emphasis>B. hermsii</emphasis> (<link linkend="ch0079s0024s0003li0057">57</link>). <emphasis>O. turicata</emphasis> prefers lower elevation and drier habitats and transmits <emphasis>B. turicata</emphasis>, which parasitizes numerous free-living animals but also dogs, pigs, and cattle. <emphasis>B. parkeri</emphasis>, which is rarely associated with human infection, is transmitted by <emphasis>O. parkeri</emphasis>, found in the western United States (<link linkend="ch0079s0024s0003li0057">57</link>). Tick-borne RF (TBRF) is reportable in 12 states in the United States, and most reported cases are from California, Washington, and Colorado. A total of 504 cases were reported between 1990 and 2011; the median number was 20 per year (<link linkend="ch0079s0024s0003li0060">60</link>). The largest outbreak occurred in Arizona in 1973, when 62 persons acquired the disease near the Grand Canyon. Other reports from Arizona include an outbreak among high school football team members who acquired tick bites, and subsequently TBRF, while cleaning cabins in preparation for a youth event (<link linkend="ch0079s0024s0003li0061">61</link>, <link linkend="ch0079s0024s0003li0062">62</link>), and cases in the White Mountains near Phoenix and Tucson (<link linkend="ch0079s0024s0003li0063">63</link>). All were caused by <emphasis>B. hermsii.</emphasis> TBRF caused by <emphasis>B. turicatae</emphasis> is described; two patients were infected in the Mojave Desert, Nevada, in association with excavation in areas of tortoise burrows (<link linkend="ch0079s0024s0003li0064">64</link>). An additional case due to <emphasis>B. turicatae</emphasis> was reported from Austin, Texas (<link linkend="ch0079s0024s0003li0065">65</link>).</para>
      <anchor id="ch0079s0005a0003"/>
      <beginpage pagenum="1180"/>
      <para id="ch0079s0005p0003">In Europe, tick-borne RF occurs in the Mediterranean regions of Spain, Portugal, Greece, and Cyprus.<emphasis>B. hispanica</emphasis> is responsible for the majority of cases and is transmitted by <emphasis>O. erraticus</emphasis> ticks, which are predominant in this region (<link linkend="ch0079s0024s0003li0055">55</link>). Relapsing fever is rare in Europe; many cases are imported by patients traveling from regions of endemicity. Recently, European physicians reported imported cases related to refugees from parts of Africa where RF is endemic, making the clinical distinction of tick- and louse-borne RF difficult, because both are present in these African countries (<link linkend="ch0079s0024s0003li0033">33</link>, <link linkend="ch0079s0024s0003li0055">55</link>, <link linkend="ch0079s0024s0003li0059">59</link>, <link linkend="ch0079s0024s0003li0066">66</link>, <link linkend="ch0079s0024s0003li0067">67</link>).</para>
      <para id="ch0079s0005p0004">In North Africa and northwestern Africa, from Egypt to Senegal, the dominant RF<emphasis>Borrelia</emphasis> species is <emphasis>B. crocidurae</emphasis>, which is transmitted by the tick <emphasis>O. sonrai.</emphasis> In certain regions, <emphasis>B. crocidurae</emphasis> coexists with <emphasis>B. hispanica</emphasis> (Morocco and Tunisia) as well as with <emphasis>B. merionesi</emphasis> (Morocco and Western Sahara), but the latter two species are transmitted by a different <emphasis>Ornithodoros</emphasis> sp. tick (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0055">55</link>, <link linkend="ch0079s0024s0003li0059">59</link>). In eastern, central, and southern Africa, <emphasis>B. duttonii</emphasis>, transmitted by <emphasis>O. moubata</emphasis> ticks, coexists with <emphasis>B. recurrentis</emphasis>, transmitted by the human body louse, <emphasis>Pediculus humanus.</emphasis> Furthermore, in northern Africa, <emphasis>B. duttonii</emphasis> coexists with <emphasis>B. crocidurae. B. crocidurae, B. duttonii</emphasis>, and <emphasis>B. recurrentis</emphasis> share 99% identity, suggesting that they are derived from one species that adapted to different vectors. Moreover, humans are the only reservoirs for <emphasis>B. recurrentis</emphasis> and <emphasis>B. duttonii</emphasis> (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0031">31</link>, <link linkend="ch0079s0024s0003li0055">55</link>, <link linkend="ch0079s0024s0003li0068">68</link>). Tick-borne RF is usually associated with rural locations, agricultural work, infested houses, and crowded populations. It remains endemic in West, South, and East African regions and is reported as the most common bacterial infection in Senegal despite many cases being classified as malaria on clinical grounds. RF remains a significant cause of mortality and morbidity in Tanzania, where it is associated with pregnancy loss or premature deliveries in pregnant women and is usually listed among the top 10 causes of mortality in children under 5 years. The incidence of RF in North Africa seems to be much lower than the incidence in West Africa, probably because of better quality of housing (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0058">58</link>, <link linkend="ch0079s0024s0003li0068">68</link>, <link linkend="ch0079s0024s0003li0069">69</link>).</para>
      <para id="ch0079s0005p0005">TBRF in Eurasia is mainly attributed to<emphasis>B. persica</emphasis>, although other <emphasis>Borrelia</emphasis> species are described. <emphasis>O. tholozani</emphasis> is the most important tick vector for TBRF in Eurasia and can be found in India and Kashmir, the southern countries of the former Soviet Union, Iran, Iraq, Syria, Jordan, Turkey, Israel, Egypt, and Cyprus. A majority of cases are related to outbreaks in young people, military personnel, herdsmen, tourists, and researchers who have entered caves or bunkers without personal protective measures. As in Mediterranean countries, relapsing fever is rare in Eurasia (<link linkend="ch0079s0024s0003li0058">58</link>, <link linkend="ch0079s0024s0003li0070">70</link>).</para>
      <para id="ch0079s0005p0006">While most RF<emphasis>Borrelia</emphasis> spp. are transmitted by argasid ticks, a few species are transmitted by ixodid ticks. These include <emphasis>B. miyamotoi,</emphasis> transmitted by <emphasis>Ixodes</emphasis> spp., and <emphasis>B. turcica</emphasis>, otherwise associated with reptile reservoirs and not yet described in humans, which is transmitted by <emphasis>Hyalomma aegyptium</emphasis> (<link linkend="ch0079s0024s0003li0071">71</link>, <link linkend="ch0079s0024s0003li0072">72</link>)<emphasis>. B. miyamotoi</emphasis> has been found in ticks in Japan through Russia (mostly in <emphasis>I. persulcatus</emphasis>), in Eurasia (<emphasis>I. persulcatus</emphasis> and <emphasis>I. ricinus</emphasis>), in European countries (<emphasis>I. ricinus</emphasis>), and in North America (<emphasis>I. scapularis</emphasis> and <emphasis>I. pacificus</emphasis>), but at low infection rates (<link linkend="ch0079s0024s0003li0005">5</link>, <link linkend="ch0079s0024s0003li0073">73</link>, <link linkend="ch0079s0024s0003li0074">74</link>). Although <emphasis>B. miyamotoi</emphasis> and LB <emphasis>Borrelia</emphasis> species share the same animal reservoir and vector, the former can be present <emphasis>in</emphasis> larvae due to transovarial transmission in the tick vector (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0071">71</link>).</para>
      <para id="ch0079s0005p0007">The proportion of<emphasis>Ixodes</emphasis> ticks carrying <emphasis>B. miyamotoi</emphasis> varies across the United States. While <emphasis>B. burgdorferi</emphasis> predominates over <emphasis>B. miyamotoi</emphasis> in <emphasis>I. scapularis</emphasis> in the Northeast, the opposite is true in <emphasis>I. pacificus</emphasis> on the West Coast (<link linkend="ch0079s0024s0003li0071">71</link>).</para>
      <para id="ch0079s0005p0008"><emphasis>B. recurrentis</emphasis> is transmitted by the human body louse, <emphasis>Pediculus humanus,</emphasis> and is restricted to areas where clothing lice persist. With the reduction of the vector <emphasis>P. humanus</emphasis>, and due to improved living standards and insecticide introduction, infection declined and finally disappeared from most parts of the world. Therefore, although it was once prevalent throughout the world and a cause of epidemics, it is now mostly endemic to sub-Saharan Africa, especially Tanzania, Ethiopia, and Sudan, where poverty and crowded living conditions exist. In these areas, <emphasis>B. recurrentis</emphasis> coexists with the closely related species <emphasis>B. duttonii</emphasis> and <emphasis>B. crocidurae</emphasis> (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0036">36</link>, <link linkend="ch0079s0024s0003li0058">58</link>, <link linkend="ch0079s0024s0003li0068">68</link>). Nevertheless, louse-borne RF <emphasis>Borrelia</emphasis> (LBRF) is observed in Europe among African refugees, and local transmission is reported. The refugee crisis, with thousands of people from areas of endemicity arriving in Europe and living in precarious conditions, led to an increase of LBRF cases. In 2015, 28 cases among African refugees were reported from different European countries; the majority were reported in Germany (<link linkend="ch0079s0024s0003li0038">38</link>, <link linkend="ch0079s0024s0003li0075">75</link>). A study conducted among 930 homeless people during a 4-year period in Marseilles, France, found that 15/930 (1.6%) had antibodies to <emphasis>B. recurrentis</emphasis> compared to 0/467 controls (<link linkend="ch0079s0024s0003li0076">76</link>).</para>
    </sect1>
    <sect1 id="ch0079s0006">
      <title>B. burgdorferi sensu lato (LB Borrelia Group)</title>
      <anchor id="ch0079s0006a0001"/>
      <anchor id="ch0079s0006a0002"/>
      <para id="ch0079s0006p0001"><emphasis>B. burgdorferi sensu lato</emphasis> species cause LB, the most common vector-borne disease in the Northern Hemisphere (<link linkend="ch0079s0024s0003li0047">47</link>, <link linkend="ch0079s0024s0003li0077">77</link>). It is estimated that over 300,000 cases occur annually in the United States (<link linkend="ch0079s0024s0003li0047">47</link>), although the annual reportable incidence was 10.69/100,000 population in 2019 (<link linkend="ch0079s0024s0003li0078">78</link>). Most cases in the United States are reported from Northeast, Mid-Atlantic, and Upper Midwest states (<link linkend="ch0079s0024s0003li0077">77</link>). The incidence of Lyme borreliosis in Europe ranges from 0.7/100,000 in the United Kingdom to &gt;300/100,000 in Slovenia (<link linkend="ch0079s0024s0003li0019">19</link>). On the basis of data from Germany, with a population of about 82 million inhabitants, a number of annual Lyme borreliosis cases of about 215,000 can be extrapolated (<link linkend="ch0079s0024s0003li0079">79</link>).</para>
      <para id="ch0079s0006p0002">These organisms are transmitted by ticks in the<emphasis>I. ricinus</emphasis> complex, and rodents are the primary reservoir (<link linkend="ch0079s0001s0001a0003">Table 1</link>). <emphasis>B. garinii</emphasis> uses birds as a reservoir (<link linkend="ch0079s0024s0003li0020">20</link>). In the northeastern and upper midwestern United States, the vector is <emphasis>I. scapularis,</emphasis> while <emphasis>I. pacificus</emphasis> is the vector in the western United States. In Europe, the tick vector is <emphasis>I. ricinus,</emphasis> and in Asia, it is <emphasis>I. persulcatus</emphasis>.</para>
      <para id="ch0079s0006p0003"><emphasis>I. ricinus</emphasis> complex ticks usually have a 2-year life span and obtain three blood meals over that span, as larvae, nymphs, and adult females. While larvae prefer to obtain a meal from small mammals and birds, nymphs and adults prefer larger mammals, including humans. At each blood meal, the tick can acquire <emphasis>B. burgdorferi sensu lato</emphasis> from an infected animal reservoir (<link linkend="ch0079s0024s0003li0047">47</link>). In most European regions where Lyme borreliosis is endemic, the average infection rates of <emphasis>I. ricinus</emphasis> ticks range between 10 and 30% (<link linkend="ch0079s0024s0003li0080">80</link>–<link linkend="ch0079s0024s0003li0082">82</link>). Transovarial transmission has not been confirmed as documented for RF <emphasis>Borrelia. B. burgdorferi sensu lato</emphasis> species colonize the midgut of the infected tick, and efficient transmission of the pathogen to a susceptible human requires prolonged feeding over 24 to 48 h. Therefore, prompt removal of an attached tick is an efficient method to prevent Lyme borreliosis (<link linkend="ch0079s0024s0003li0047">47</link>). <emphasis>B. burgdorferi</emphasis> is the most common species causing Lyme borreliosis in the northeast, mid-Atlantic, and upper midwestern United States. A few cases associated with <emphasis>B. bissettiae</emphasis> have been described in the southeastern and West Coast regions of the United States (<link linkend="ch0079s0024s0003li0021">21</link>). In 2016, a novel species of the <emphasis>B. burgdorferi sensu lato</emphasis> group was described in the midwestern United States. This species, named <emphasis>B. mayonii</emphasis> due to its identification at the Mayo Clinic, has been found only in the upper midwestern United States (<link linkend="ch0079s0024s0003li0083">83</link>). It is also transmitted by <emphasis>I. scapularis</emphasis>, and its reservoir also includes rodents. In contrast to other <emphasis>Borrelia</emphasis> spp. that cause LB, spirochetemia can reach detectable microscopic levels with <emphasis>B. mayonii</emphasis> (<link linkend="ch0079s0024s0003li0006">6</link>).</para>
      <anchor id="ch0079s0006a0003"/>
      <beginpage pagenum="1181"/>
      <para id="ch0079s0006p0004">Lyme borreliosis in Europe and Asia is caused by<emphasis>B. burgdorferi sensu lato</emphasis> genospecies with greater heterogeneity (<link linkend="ch0079s0024s0003li0084">84</link>, <link linkend="ch0079s0024s0003li0085">85</link>) than those that cause disease in the United States. This leads to different clinical manifestations associated with different species in Europe (<emphasis>B. afzelii, B. garinii, B. bavariensis, B. burgdorferi sensu stricto, and B. spielmanii</emphasis>). The main species causing skin infections is <emphasis>B. afzelii</emphasis> (80 to 90%), while up to 70% of neurological disorders with LB in Europe are caused by <emphasis>B. garinii</emphasis> (including <emphasis>B. bavariensis</emphasis>). <emphasis>B. burgdorferi sensu stricto is rarely reported in European patients</emphasis> (<link linkend="ch0079s0024s0003li0018">18</link>). Original studies in Europe found differences sufficient to define at least eight OspA serotypes (<link linkend="ch0079s0024s0003li0086">86</link>), which correlate closely with genetic classification of the species. This complex serotyping method has been replaced by genotyping that more simply delineates human pathogen species and other species from <emphasis>B. burgdorferi sensu lato</emphasis> complex found in ticks and reservoir hosts (<link linkend="ch0079s0024s0003li0087">87</link>). <emphasis>B. afzelii</emphasis> and <emphasis>B. garinii</emphasis> are distributed all over Eurasia, while <emphasis>B. burgdorferi sensu stricto</emphasis> is restricted to European countries (<link linkend="ch0079s0024s0003li0018">18</link>). Comparative studies on European and North American <emphasis>B. burgdorferi sensu stricto</emphasis> strains revealed that they vary in virulence, inflammatory potential, and clinical manifestations and that European <emphasis>B. burgdorferi sensu stricto</emphasis> strains share similar characteristics with the other species causing LB in Europe (<link linkend="ch0079s0024s0003li0088">88</link>).</para>
      <sect2 id="ch0079s0006s0001">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0079s0006s0001a0001"/>
        <anchor id="ch0079s0006s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0007">
      <title>Relapsing Fever Borrelia Group</title>
      <anchor id="ch0079s0007a0001"/>
      <anchor id="ch0079s0007a0002"/>
      <para id="ch0079s0007p0001">Relapsing fever caused by RF<emphasis>Borrelia</emphasis> is characterized by recurring spirochetemia associated with recurrent episodes of high fever. The recurrence of spirochetemia and associated clinical findings are related to the development of antibodies to <emphasis>Borrelia</emphasis> VMPs, leading to a reduction of organisms in circulation. When spirochetes are eliminated from the blood, they survive in extravascular sites, tissue and organs. <emphasis>Borrelia</emphasis> organisms with altered expression of VMP surface antigens evade newly developed antibodies, leading to rebound bacteremia (<link linkend="ch0079s0024s0003li0055">55</link>, <link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0060">60</link>). This can occur several times, leading to the relapsing presentation. Up to 13 recurrences of fever in untreated patients with TBRF have been reported (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0068">68</link>, <link linkend="ch0079s0024s0003li0089">89</link>).</para>
      <para id="ch0079s0007p0002">Individual variability in clinical presentation is frequent. In addition to fever, patients might experience headaches, myalgia, and arthralgia; some may present as having meningitis, flu-like illness, or gastrointestinal illness. One common laboratory abnormality is thrombocytopenia. LBRF can present with hemorrhagic diathesis and have a higher lethality than TBRF, which has an estimated case fatality rate of 2 to 5% (<link linkend="ch0079s0024s0003li0037">37</link>, <link linkend="ch0079s0024s0003li0090">90</link>); myocarditis has been prominent in fatal cases (<link linkend="ch0079s0024s0003li0036">36</link>, <link linkend="ch0079s0024s0003li0037">37</link>, <link linkend="ch0079s0024s0003li0068">68</link>, <link linkend="ch0079s0024s0003li0089">89</link>). Since RF <emphasis>Borrelia</emphasis> organisms coexist with other pathogens in areas of Africa where they are endemic, it is likely that coinfections exist more frequently than they are documented. Simultaneous malaria caused by <emphasis>Plasmodium falciparum</emphasis> and RF caused by <emphasis>B. crocidurae</emphasis> have been reported in patients in Senegal (<link linkend="ch0079s0024s0003li0091">91</link>).</para>
      <para id="ch0079s0007p0003">Infection with<emphasis>B. miyamotoi</emphasis>, first described in Russian patients in 2011, commonly presented as acute febrile illness with high fever (40°C), lasting less than a week and accompanied by headache, myalgia, arthralgia, and chills. Patients experienced a maximum of three febrile episodes. Although clinical presentations of RF caused by <emphasis>B. miyamotoi</emphasis> and other RF borreliae are similar, the latter can present with more febrile episodes and longer duration (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0005">5</link>, <link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0068">68</link>, <link linkend="ch0079s0024s0003li0071">71</link>). Although earlier reports described <emphasis>B. miyamotoi</emphasis> infection associated with central nervous system disorders in immunocompromised individuals, it has also been described in immunocompetent individuals (<link linkend="ch0079s0024s0003li0092">92</link>). Some differences in <emphasis>B. miyamotoi</emphasis> infection occurring in different geographic areas include the presence of thrombocytopenia and leukopenia, seen in U.S. patients but not in European or Asian patients (<link linkend="ch0079s0024s0003li0044">44</link>, <link linkend="ch0079s0024s0003li0074">74</link>, <link linkend="ch0079s0024s0003li0093">93</link>). Differences in clinical presentation of patients infected with <emphasis>B. miyamotoi</emphasis> in the United States and Eurasia appear to indicate that they may be related to genetic and antigenic differences between strains (<link linkend="ch0079s0024s0003li0005">5</link>). <emphasis>B. miyamotoi sensu stricto</emphasis> has been proposed as the name for strains found in Asia and <emphasis>B. miyamotoi sensu lato</emphasis> for those in North America (<link linkend="ch0079s0024s0003li0028">28</link>).</para>
      <para id="ch0079s0007p0004">A skin lesion designated STARI (southern tick-associated rash illness), sometimes confused with erythema migrans (EM), has been described in patients from the southern United States. This skin rash is associated with the bite of<emphasis>A. americanum,</emphasis> and its infectious etiology, if any, is currently unknown. It was once thought to be caused by <emphasis>B. lonestari,</emphasis> but this is currently disputed (<link linkend="ch0079s0024s0003li0045">45</link>, <link linkend="ch0079s0024s0003li0094">94</link>).</para>
    </sect1>
    <sect1 id="ch0079s0008">
      <title>Borrelia burgdorferi sensu lato (LB Borrelia Group)</title>
      <anchor id="ch0079s0008a0001"/>
      <anchor id="ch0079s0008a0002"/>
      <para id="ch0079s0008p0001">The hallmark of early Lyme borreliosis is the development of an expanding erythematous skin lesion at the site of the tick bite, known as EM (<link linkend="ch0079s0024s0003li0017">17</link>, <link linkend="ch0079s0024s0003li0018">18</link>) (<anchor id="ch0079s0008a0003"/><link linkend="ch0079s0008a0005">Table 2</link>). Because it happens soon after the tick bite, EM is observed primarily in the spring and summer, when ticks are actively biting. The diagnosis of early Lyme borreliosis with EM is clinical and relies on the presence of the characteristic skin lesion in individuals living in areas of endemicity who are exposed to <emphasis>Ixodes</emphasis> tick bites (<link linkend="ch0079s0024s0003li0095">95</link>). EM often occurs alone, but it can be accompanied by fever, fatigue, headache, mild stiff neck, arthralgia, or myalgia. European early Lyme borreliosis with EM is less frequently accompanied by constitutional symptoms than that in the United States (<link linkend="ch0079s0024s0003li0019">19</link>, <link linkend="ch0079s0024s0003li0096">96</link>, <link linkend="ch0079s0024s0003li0097">97</link>).</para>
      <para id="ch0079s0008p0002">If untreated, the infection can disseminate mainly by hematogenous spread but also via peripheral nerves (<link linkend="ch0079s0024s0003li0098">98</link>), leading to manifestations of early disseminated infection within days or weeks of the initial EM. Different levels of spirochetemia between U.S. and European patients have also been documented (<link linkend="ch0079s0024s0003li0099">99</link>). Early dissemination leads to infection at other skin sites with multiple EM lesions, neurologic manifestations (meningitis, cranial nerve palsies, and meningoradiculoneuritis, seen in Europe and known as Bannwarth syndrome) (<link linkend="ch0079s0024s0003li0100">100</link>), or cardiac involvement (myocarditis and atrioventricular block) (<link linkend="ch0079s0024s0003li0017">17</link>, <link linkend="ch0079s0024s0003li0018">18</link>). Dissemination is associated with specific antigenic and molecular characteristics of <emphasis>B. burgdorferi</emphasis> (<link linkend="ch0079s0024s0003li0101">101</link>). In Europe, multiple EM lesions are seen more frequently in children (<link linkend="ch0079s0024s0003li0102">102</link>, <link linkend="ch0079s0024s0003li0103">103</link>).</para>
      <para id="ch0079s0008p0003">Late complications of Lyme borreliosis also differ between the United States and Europe. In the United States, the most common manifestation is intermittent or persistent mono- or oligoarthritis that develops in months to a few years after infection (<link linkend="ch0079s0024s0003li0017">17</link>). Arthritis also occurs in European patients; however, spontaneous remission of arthritis is frequent and transition to chronic manifestations is rather rare (<link linkend="ch0079s0024s0003li0104">104</link>).</para>
      <anchor id="ch0079s0008a0004"/>
      <beginpage pagenum="1182"/>
      <table id="ch0079s0008t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0079s0008a0005"/><link linkend="ch0079s0008a0003">TABLE 2</link></phrase></emphasis> Clinical manifestations of LB and recommended laboratory tests<superscript><emphasis><anchor id="ch0079s0008a0006"/><link linkend="ch0079s0008a0007">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="4">
          <tbody>
            <row>
              <entry><phrase role="center">Disease</phrase>
              </entry>
              <entry><phrase role="center">Manifestations</phrase>
              </entry>
              <entry><phrase role="center">Laboratory tests</phrase>
              </entry>
              <entry><phrase role="center">Comments</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Early</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">EM</phrase>
              </entry>
              <entry><para id="ch0079s0008p0004"><phrase role="left">Expanding erythematous skin lesion of at least 5-cm diam at the site of tick bite that appears within 1–4 wks after the tick bite, with or without fever, malaise, arthralgias, headache</phrase>
                </para>
                <para id="ch0079s0008p0005"><phrase role="left">Diagnosis is clinical.</phrase>
                </para>
              </entry>
              <entry><para id="ch0079s0008p0006"><phrase role="left">PCR and culture of EM skin lesion (only relevant for and performed best in research settings)</phrase>
                </para>
                <para id="ch0079s0008p0007"><phrase role="left">Antibodies by STTT or MTTT; better performance if done in acute and convalescent phases</phrase>
                </para>
              </entry>
              <entry><para id="ch0079s0008p0008"><phrase role="left">Diagnosis is clinical (in the appropriate epidemiological setting).</phrase>
                </para>
                <para id="ch0079s0008p0009"><phrase role="left">Laboratory tests might be needed if EM is atypical.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Borrelial lymphocytoma</phrase>
              </entry>
              <entry><phrase role="left">Painless red-bluish nodule or plaque on ear lobe or nipple</phrase>
              </entry>
              <entry><phrase role="left">Same as EM</phrase>
              </entry>
              <entry><phrase role="left">Rare manifestation; almost exclusively seen in Europe</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Early disseminated</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">Multiple EMs</phrase>
              </entry>
              <entry><phrase role="left">Several expanding EM lesions distributed on different areas of the skin; fever, headache, myalgias</phrase>
              </entry>
              <entry><phrase role="left">Antibodies by STTT or MTTT for all manifestations of early disseminated disease</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">Lyme neuroborreliosis</phrase>
              </entry>
              <entry><phrase role="left">Meningitis, cranial nerve palsies, meningoradiculoneuritis</phrase>
              </entry>
              <entry><para id="ch0079s0008p0010"><phrase role="left">Antibodies by STTT or MTTT</phrase>
                </para>
                <para id="ch0079s0008p0011"><phrase role="left">CSF analysis for cytology (lymphoplasma cellular pleocytosis), total IgG, IgM, detection of intrathecal production of IgG antibodies to <emphasis>B. burgdorferi sensu lato</emphasis> (AI), CXCL13 detection</phrase>
                </para>
              </entry>
              <entry><para id="ch0079s0008p0012"><phrase role="left">Lyme neuroborreliosis most frequently seen in Europe</phrase>
                </para>
                <para id="ch0079s0008p0013"><phrase role="left">CXCL13 measurement is diagnostically supportive only in very early disease without pleocytosis, before antibiotic treatment, and at very high concentration (pg/ml).</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Carditis</phrase>
              </entry>
              <entry><phrase role="left">Conduction defects, atrioventricular block</phrase>
              </entry>
              <entry><phrase role="left">Antibodies by STTT or MTTT for all manifestations of early disseminated disease</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">Late</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">Arthritis</phrase>
              </entry>
              <entry><phrase role="left">Recurrent attacks or persistent joint swelling in one or more large joints</phrase>
              </entry>
              <entry><para id="ch0079s0008p0014"><phrase role="left">Antibodies by STTT or MTTT</phrase>
                </para>
                <para id="ch0079s0008p0015"><phrase role="left">PCR of joint fluid or synovium (research settings)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Arthritis more commonly seen in the United States</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">ACA</phrase>
              </entry>
              <entry><phrase role="left">Long-standing bluish or red-bluish lesions on extensor surfaces of extremities; eventually becoming atrophic</phrase>
              </entry>
              <entry><para id="ch0079s0008p0016"><phrase role="left">Antibodies by STTT or MTTT</phrase>
                </para>
                <para id="ch0079s0008p0017"><phrase role="left">Histology, PCR, and culture (in research settings)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Rare manifestation; almost exclusively seen in Europe</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Late Lyme borreliosis</phrase>
              </entry>
              <entry><phrase role="left">Monophasic, slowly progressive encephalomyelitis</phrase>
              </entry>
              <entry><para id="ch0079s0008p0018"><phrase role="left">CSF analysis for cytology, total IgG, IgM, detection of intrathecal production of IgG antibodies to <emphasis>B. burgdorferi sensu lato</emphasis> (AI)</phrase>
                </para>
                <para id="ch0079s0008p0019"><phrase role="left">Antibodies by STTT or MTTT</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Rare late manifestation mostly in Europe</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0008a0007"/><link linkend="ch0079s0008a0006">a</link></emphasis></superscript>Adapted from reference <link linkend="ch0079s0024s0003li0018">18</link>. STTT, standard two-tier testing; MTTT, modified two-tier testing.</para>
      <para id="ch0079s0008p0020">Acrodermatitis chronica atrophicans (ACA) is a common late manifestation of Lyme borreliosis in Europe. ACA starts as a skin infiltration that occurs after a long incubation period (months to years), followed by characteristic atrophic changes of the skin, which appears pleated, like shriveled tissue paper, with livid discoloration and prominent veins. It usually starts on one extremity, often the extensor side, but may become symmetrical over time (<link linkend="ch0079s0024s0003li0018">18</link>). In contrast to EM and borrelial lymphocytoma, ACA does not heal spontaneously.</para>
      <para id="ch0079s0008p0021">Rarely, late Lyme borreliosis might present with neurological manifestations such as encephalopathy or encephalomyelitis. Lyme encephalopathy is seldom encountered now; it was originally described in patients with long-standing Lyme borreliosis with arthritis. This entity consists of difficulties with memory, cognition, and intellectual function (<link linkend="ch0079s0024s0003li0105">105</link>). These manifestations are nonspecific to Lyme borreliosis and might be observed in association with inflammatory or other infectious diseases (<link linkend="ch0079s0024s0003li0106">106</link>).</para>
      <para id="ch0079s0008p0022">While<emphasis>B. burgdorferi</emphasis> in the United States causes mostly EM in early infection and arthritis as a late manifestation, there are other important species-specific manifestations or associations. <emphasis>B. afzelii</emphasis>, the most common cause of Lyme borreliosis in Europe, causes EM in early stages and ACA as a late manifestation (<link linkend="ch0079s0024s0003li0017">17</link>, <link linkend="ch0079s0024s0003li0018">18</link>) (<link linkend="ch0079s0008a0005">Table 2</link>). <emphasis>B. garini</emphasis> and <emphasis>B. bavariensis</emphasis> are associated with Lyme neuroborreliosis. Lyme neuroborreliosis is frequently manifested by the involvement of cranial and/or peripheral nerves associated with lymphocytic meningitis. Typical manifestation in adult European patients with neuroborreliosis is Bannwarth syndrome, which is extremely rare in North American patients (<link linkend="ch0079s0024s0003li0107">107</link>). <emphasis>B. burgdorferi sensu stricto</emphasis> infection in Europe, although rare, is associated with clinical mani-festations similar to those caused by other European species and not with arthritis, as is characteristic in North America (<link linkend="ch0079s0024s0003li0088">88</link>). Lyme carditis is reported in approximately 1% of U.S. and European patients. Other differences between Lyme borreliosis occurring in the United States and Europe include more frequent central clearing of EM in Europe, presence of systemic symptoms in patients with early disease in the United States, development of borrelial lymphocytoma in European patients, and significantly more asymptomatic infection in European than North American patients (<link linkend="ch0079s0024s0003li0097">97</link>). Based on LB borrelia seroprevalence among hunters in Europe, who rarely recall a history of clinical Lyme borreliosis, it is likely that many individuals experience asymptomatic infections (<link linkend="ch0079s0024s0003li0108">108</link>). It is not known if these asymptomatic infections are species specific.</para>
      <anchor id="ch0079s0008a0008"/>
      <beginpage pagenum="1183"/>
      <para id="ch0079s0008p0023">The existence of “chronic” Lyme borreliosis, in which the organism persists despite a course of conventional antibiotic therapy, is not supported by extensive microbiological, double-blind, placebo-controlled clinical studies (<link linkend="ch0079s0024s0003li0109">109</link>, <link linkend="ch0079s0024s0003li0110">110</link>). This diagnosis has been used to explain nonspecific symptoms such as myalgias, arthralgias, and concentration problems in individuals in whom no objective evidence of ongoing <emphasis>B. burgdorferi</emphasis> infection can be documented (<link linkend="ch0079s0024s0003li0111">111</link>).</para>
      <para id="ch0079s0008p0024"><emphasis>B. mayonii,</emphasis> described in 2016 in patients from the upper Midwest of the United States, has a different clinical picture than the other members of the Lyme borreliosis group. Of the six cases originally described, most presented with a febrile illness and maculopapular skin rash. Most striking was the presence of detectable spirochetemia on peripheral blood smears, documented by quantitative PCR tests, which is not seen in Lyme borreliosis caused by other genospecies of <emphasis>B. burgdorferi sensu lato</emphasis> (<link linkend="ch0079s0024s0003li0006">6</link>).</para>
      <sect2 id="ch0079s0008s0001">
        <title>LABORATORY DIAGNOSIS</title>
        <anchor id="ch0079s0008s0001a0001"/>
        <anchor id="ch0079s0008s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0009">
      <title>Samples</title>
      <anchor id="ch0079s0009a0001"/>
      <anchor id="ch0079s0009a0002"/>
      <sect2 id="ch0079s0009s0001">
        <title>Relapsing Fever Borrelia Group</title>
        <anchor id="ch0079s0009s0001a0001"/>
        <anchor id="ch0079s0009s0001a0002"/>
        <para id="ch0079s0009s0001p0001">RF<emphasis>Borrelia</emphasis> can be detected in peripheral blood with blood films prepared from blood collected with EDTA. This specimen can also be used for PCR and culture. Occasionally, other samples, such as cerebrospinal fluid (CSF), have been useful in cases of <emphasis>B. miyamotoi</emphasis> infection with meningoencephalitis.</para>
        <para id="ch0079s0009s0001p0002">Blood for serum preparation should also be collected during the acute and convalescent phases for<emphasis>Borrelia</emphasis> serology.</para>
      </sect2>
      <sect2 id="ch0079s0009s0002">
        <title>Borrelia burgdorferi sensu lato (LB Borrelia Group)</title>
        <anchor id="ch0079s0009s0002a0001"/>
        <anchor id="ch0079s0009s0002a0002"/>
        <anchor id="ch0079s0009s0002a0003"/>
        <para id="ch0079s0009s0002p0001">For culture and nucleic acid detection of<emphasis>Borrelia</emphasis>, collection and preparation of specimens under sterile conditions are of utmost importance. Body fluids should be transported without any additives, and biopsy specimens should be placed in a small quantity of sterile saline or suitable culture medium (see “Culture” below). Samples should reach the laboratory as quickly as possible, ideally within 2 to 4 h. Culture is rarely performed in clinical laboratories in regions of endemicity but is available in some public health and research laboratories.</para>
        <para id="ch0079s0009s0002p0002">Skin biopsy samples of EM, ACA, or borrelial lymphocytoma cutis lesions can be used for culture or nucleic acid amplification tests (NAATs) such as PCR. Nevertheless, culture and PCR of EM lesions have mostly been utilized in research settings, since laboratory testing is not required to establish the diagnosis at this early stage (<link linkend="ch0079s0024s0003li0112">112</link>, <link linkend="ch0079s0024s0003li0113">113</link>). Prompt inoculation of biopsy samples into medium has led to successful culture of <emphasis>B. burgdorferi</emphasis> in research settings (our unpublished experience).</para>
        <para id="ch0079s0009s0002p0003">Whole blood collected in EDTA can be used to perform culture or PCR during the early disseminated phase of the disease. As for standard bacterial blood culture methods, large volumes of blood (9 ml of plasma) have been used to more effectively isolate<emphasis>B. burgdorferi sensu lato</emphasis> in culture (<link linkend="ch0079s0024s0003li0114">114</link>). It has been reported that blood collected in citrate anticoagulant might be superior to EDTA to recover <emphasis>B. burgdorferi</emphasis> in culture (<link linkend="ch0079s0024s0003li0115">115</link>).</para>
        <para id="ch0079s0009s0002p0004">Serum should be collected in the acute and convalescence phases, separated by at least 2 weeks, to detect the presence of diagnostic antibodies in serum, the most common means to support the clinical diagnosis (<link linkend="ch0079s0024s0003li0112">112</link>).</para>
        <para id="ch0079s0009s0002p0005">Cerebrospinal fluid collected in patients with neurological manifestations might be of utility to detect<emphasis>B. burgdorferi sensu lato</emphasis> in culture or by PCR, although the sensitivity of such testing is low, as discussed below. As indicated above, prompt delivery of samples to the laboratory and prompt inoculation into media improve the recovery in culture in research settings.</para>
        <para id="ch0079s0009s0002p0006">CSF and serum should be collected simultaneously to test for the production of intrathecal antibodies expressed in a CSF/serum antibody index (<link linkend="ch0079s0024s0003li0112">112</link>, <link linkend="ch0079s0024s0003li0113">113</link>). However, although this method is more frequently used in Europe, it is offered by very few laboratories in the United States (<link linkend="ch0079s0024s0003li0116">116</link>).</para>
        <para id="ch0079s0009s0002p0007">Synovial fluid or tissue is useful for diagnosing patients suspected of having Lyme arthritis and for monitoring treatment efficacy. These can be tested by PCR or, less often, by culture, a method restricted to research settings.</para>
      </sect2>
      <sect2 id="ch0079s0009s0003">
        <title>METHODS</title>
        <anchor id="ch0079s0009s0003a0001"/>
        <anchor id="ch0079s0009s0003a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0010">
      <title>Microscopy</title>
      <anchor id="ch0079s0010a0001"/>
      <anchor id="ch0079s0010a0002"/>
      <sect2 id="ch0079s0010s0001">
        <title>Relapsing Fever Borrelia Group</title>
        <anchor id="ch0079s0010s0001a0001"/>
        <anchor id="ch0079s0010s0001a0002"/>
        <para id="ch0079s0010s0001p0001">Most RF<emphasis>Borrelia</emphasis> organisms can be present at high levels in blood, exceeding 10<superscript>6</superscript> organisms/ml. This feature allows their detection in routine blood smears stained with Wright-Giemsa stain (<link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0117">117</link>) (<anchor id="ch0079s0010s0001a0003"/><link linkend="ch0079s0011a0003">Fig. 1</link>). Microscopic detection has also been achieved in cerebrospinal fluid of patients infected with <emphasis>B. miyamotoi</emphasis> who experience meningoencephalitis.</para>
        <para id="ch0079s0010s0001p0002">Other microscopic preparations used for the diagnosis of RF infection include thick smear preparations, such as those used for malaria screening, wet mounts to detect motile spirochetes with dark-field microscopy, and the quantitative buffy coat (QBC) method, which is commonly used to detect malaria parasites (<link linkend="ch0079s0024s0003li0118">118</link>). The sensitivities of these methods have been estimated at 25% for routine blood smear examination (detecting spirochetemia of at least 10<superscript>5</superscript>/ml) and 50 to 70% for the thick smear (sensitivity of approximately 10<superscript>4</superscript> spirochetes/ml), and QBC has a better sensitivity, detecting spirochetes at about 10<superscript>3</superscript>/ml (<link linkend="ch0079s0024s0003li0118">118</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0011">
      <title>Borrelia burgdorferi sensu lato (LB Borrelia Group)</title>
      <anchor id="ch0079s0011a0001"/>
      <anchor id="ch0079s0011a0002"/>
      <para id="ch0079s0011p0001">Lyme borreliosis with EM is a clinical diagnosis. However, laboratory evidence of infection is needed for patients with all manifestations except for typical EM (<link linkend="ch0079s0024s0003li0095">95</link>, <link linkend="ch0079s0024s0003li0112">112</link>, <link linkend="ch0079s0024s0003li0113">113</link>) (<link linkend="ch0079s0008a0005">Table 2</link>).</para>
      <figure id="ch0079s0011f0001"><title><phrase role="figureLabel"><anchor id="ch0079s0011a0003"/><link linkend="ch0079s0010s0001a0003">FIGURE 1</link></phrase> Peripheral blood smear stained with Wright-Giemsa showing a spiral-shaped <emphasis>Borrelia</emphasis> sp. (arrow). Magnification, ×100.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0079f03.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0079s0011p0002">Microscopy can be used to visualize<emphasis>B. burgdorferi sensu lato</emphasis> in skin biopsy samples from patients with EM or ACA with special stains, such as silver stains (<link linkend="ch0079s0024s0003li0112">112</link>, <link linkend="ch0079s0024s0003li0119">119</link>). Nevertheless, this method is infrequently used for diagnostic purposes due to low spirochete density. Unlike other LB <emphasis>Borrelia</emphasis> spp., <emphasis>B. mayonii</emphasis> has been visualized on peripheral blood smears. One of the six patients diagnosed with <emphasis>B. mayonii</emphasis> infection had microscopically detectable spirochetemia of around 8.5 × 10<superscript>4</superscript>/ml; on the basis of quantitative PCR, it was estimated that all cases had a median of 8.1 × 10<superscript>5</superscript> organisms per ml, within the range of microscopic detection. In contrast to <emphasis>B. mayonii</emphasis> patients, 12 patients for whom PCR was positive for <emphasis>B. burgdorferi</emphasis> in blood had a median level of spirochetes of 4.5 × 10<superscript>3</superscript>/ml, making <emphasis>B. burgdorferi</emphasis> less likely to be detected by microscopy of peripheral blood smears (<link linkend="ch0079s0024s0003li0006">6</link>).</para>
      <sect2 id="ch0079s0011s0001">
        <title>CULTURE</title>
        <anchor id="ch0079s0011s0001a0001"/>
        <anchor id="ch0079s0011s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0012">
      <title>Relapsing Fever Borrelia Group</title>
      <anchor id="ch0079s0012a0001"/>
      <anchor id="ch0079s0012a0002"/>
      <para id="ch0079s0012p0001">RF<emphasis>Borrelia</emphasis> can be cultured in Barbour-Stoenner-Kelly (BSK) medium by specialized or research laboratories (<link linkend="ch0079s0024s0003li0117">117</link>, <link linkend="ch0079s0024s0003li0120">120</link>). The formulation of the medium used at the Centers for Disease Control and Prevention (Division of Vector-Borne Diseases Branch, Fort Collins, CO) is BSK-II medium supplemented with 12% young rabbit serum. Variations of the original Kelly medium, such as BSK-II, BSK-H, and modified Kelly-Pettenkofer (MKP) media, also support growth of RF <emphasis>Borrelia</emphasis> species, including <emphasis>B. miyamotoi</emphasis> (<link linkend="ch0079s0024s0003li0061">61</link>, <link linkend="ch0079s0024s0003li0068">68</link>, <link linkend="ch0079s0024s0003li0118">118</link>, <link linkend="ch0079s0024s0003li0121">121</link>). Members of the RF <emphasis>Borrelia</emphasis> group are more diverse in their requirements for cultivation than the LB group, and some are difficult to culture. Special attention to culture <emphasis>B. miyamotoi</emphasis> in the last few years has resulted in improvements in its yield, particularly with the addition of fetal calf serum (<link linkend="ch0079s0024s0003li0122">122</link>, <link linkend="ch0079s0024s0003li0123">123</link>). A 50-μl blood sample collected in an EDTA tube is inoculated into a 5-ml polypropylene tube filled with 4.5 ml of BSK-II medium and incubated at 34°C. Cultures are microscopically examined at different time points for the presence of <emphasis>Borrelia</emphasis> (<link linkend="ch0079s0024s0003li0061">61</link>). A 300-μl blood sample collected without anticoagulant, inoculated in 7-ml tubes with MKP, and incubated at 33°C successfully supported RF <emphasis>Borrelia</emphasis> isolation (<link linkend="ch0079s0024s0003li0118">118</link>). In a facility in Africa with restricted laboratory equipment, RF <emphasis>Borrelia</emphasis> was isolated from blood samples collected without anticoagulant, directly inoculated into BSK-II medium, and incubated at room temperature (<link linkend="ch0079s0024s0003li0124">124</link>).</para>
      <para id="ch0079s0012p0002">Modified Kelly medium containing 5% heat-inactivated rabbit serum, bovine serum albumin, and gelatin was used successfully to recover<emphasis>B. crocidurae</emphasis> from the blood of patients in West Africa (<link linkend="ch0079s0024s0003li0118">118</link>). RF <emphasis>Borrelia</emphasis> might take 2 to 10 days of incubation to be detected in culture. Once the cultures have been confirmed as positive, samples of the culture can be subjected to NAATs and sequencing to identify the species (<link linkend="ch0079s0024s0003li0118">118</link>).</para>
      <para id="ch0079s0012p0003">Since some RF<emphasis>Borrelia</emphasis> species might have a low level of spirochetemia and laboratory confirmation is challenging, animal inoculation has been used as an alternative method. In this method, 250 μl of patient blood is injected intraperitoneally into mice, and the mouse blood is examined microscopically at various intervals or after animal exsanguination (<link linkend="ch0079s0024s0003li0117">117</link>, <link linkend="ch0079s0024s0003li0120">120</link>). Although not widely used for diagnostic purposes, animal inoculation has been employed in research settings and was successfully used in the investigation of TBRF outbreaks in California (<link linkend="ch0079s0024s0003li0120">120</link>) and in European patients returning from Africa (<link linkend="ch0079s0024s0003li0117">117</link>, <link linkend="ch0079s0024s0003li0118">118</link>, <link linkend="ch0079s0024s0003li0120">120</link>, <link linkend="ch0079s0024s0003li0121">121</link>).</para>
    </sect1>
    <sect1 id="ch0079s0013">
      <title>Borrelia burgdorferi sensu lato (LB Borrelia Group)</title>
      <anchor id="ch0079s0013a0001"/>
      <anchor id="ch0079s0013a0002"/>
      <para id="ch0079s0013p0001"><emphasis>B. burgdorferi sensu lato</emphasis> can be cultured <emphasis>in vitro</emphasis> in liquid BSK, MKP, and variations of these media under microaerophilic conditions (<link linkend="ch0079s0024s0003li0114">114</link>, <link linkend="ch0079s0024s0003li0125">125</link>–<link linkend="ch0079s0024s0003li0127">127</link>). The optimum growth temperature for <emphasis>B. burgdorferi sensu lato</emphasis> is 30 to 34°C; cultures are incubated for 9 to 12 weeks before negativity is reported. On average, positive results may be observed after 2 to 3 weeks of incubation, but occasionally borreliae may be observed by dark-field microscopy after 4 days, particularly with skin biopsy samples. For species differentiation of isolated strains, several molecular genetic methods have been used (<link linkend="ch0079s0024s0003li0128">128</link>, <link linkend="ch0079s0024s0003li0129">129</link>).</para>
      <para id="ch0079s0013p0002"><emphasis>B. burgdorferi sensu lato</emphasis> has been cultured in 40 to 88% of skin biopsy samples of patients with EM (<link linkend="ch0079s0024s0003li0112">112</link>, <link linkend="ch0079s0024s0003li0130">130</link>), in about 30% of samples from those with ACA (<link linkend="ch0079s0024s0003li0131">131</link>), and in about 33% of borrelial lymphocytoma samples from European patients (<link linkend="ch0079s0024s0003li0132">132</link>).</para>
      <para id="ch0079s0013p0003">The organism has also been cultured from whole blood, serum, and plasma in 5 to 70.8% of samples collected from patients with early Lyme borreliosis (<link linkend="ch0079s0024s0003li0114">114</link>, <link linkend="ch0079s0024s0003li0133">133</link>, <link linkend="ch0079s0024s0003li0134">134</link>). Better yield of blood culture has been achieved by culturing blood volumes similar to those used in routine bacterial blood cultures (<link linkend="ch0079s0024s0003li0114">114</link>). A modification of blood culture that has given a higher rate of positivity in patients with early Lyme borreliosis and EM is the combination of culturing 9 ml of plasma with periodic testing of culture aliquots by quantitative PCR. With this approach, 45 of 65 (70.8%) patients with clinical diagnosis of EM had a positive result (<link linkend="ch0079s0024s0003li0133">133</link>).</para>
      <para id="ch0079s0013p0004">In Europe (Slovenia),<emphasis>B. burgdorferi sensu lato</emphasis> was cultured from CSF in 12/77 (15.6%) patients with Bannwarth syndrome; 11 CSF isolates were identified as <emphasis>B. garinii</emphasis> and one as <emphasis>B. afzelii</emphasis> (<link linkend="ch0079s0024s0003li0107">107</link>). In 7/51 (13.7%) Slovenian children with acute peripheral facial palsy, <emphasis>Borrelia</emphasis> was isolated from CSF; <emphasis>B. garinii</emphasis> was the only identified species in these patients (<link linkend="ch0079s0024s0003li0135">135</link>). Another European study reported its isolation in CSF culture from three of eight children with Lyme neuroborreliosis (<link linkend="ch0079s0024s0003li0136">136</link>). Unpublished experience supports the use of at least 2 ml of CSF into culture medium for better results.</para>
      <anchor id="ch0079s0013a0003"/>
      <beginpage pagenum="1185"/>
      <para id="ch0079s0013p0005"><emphasis>B. burgdorferi</emphasis> has been infrequently isolated from other sample types. The rate of recovery of <emphasis>B. burgdorferi sensu lato</emphasis> from synovial tissue or fluid by culture is extremely low.</para>
      <sect2 id="ch0079s0013s0001">
        <title>NUCLEIC ACID DETECTION</title>
        <anchor id="ch0079s0013s0001a0001"/>
        <anchor id="ch0079s0013s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0014">
      <title>Relapsing Fever Borrelia Group</title>
      <anchor id="ch0079s0014a0001"/>
      <anchor id="ch0079s0014a0002"/>
      <para id="ch0079s0014p0001">Compared with microscopic detection, NAATs are more sensitive and can be used for species identification. Various genes, such as those encoding 16S rRNA (<emphasis>rrs</emphasis>), flagellin, and glycerophosphodiester phosphodiesterase (<emphasis>glpQ</emphasis>), and the 16S-23S rRNA intergenic spacer region and others have been targeted, often in combination (<link linkend="ch0079s0024s0003li0036">36</link>, <link linkend="ch0079s0024s0003li0061">61</link>, <link linkend="ch0079s0024s0003li0117">117</link>, <link linkend="ch0079s0024s0003li0118">118</link>, <link linkend="ch0079s0024s0003li0121">121</link>, <link linkend="ch0079s0024s0003li0124">124</link>, <link linkend="ch0079s0024s0003li0137">137</link>).</para>
      <para id="ch0079s0014p0002">Because<emphasis>Borrelia</emphasis> spp. are closely related at the molecular level, analysis of 16S rRNA (<emphasis>rrs</emphasis>) gene sequences may not offer good discrimination between species (<link linkend="ch0079s0024s0003li0137">137</link>). For example, there is only one nucleotide difference in <emphasis>rrs</emphasis> between <emphasis>B. crocidurae</emphasis> and <emphasis>B. duttonii</emphasis> (<link linkend="ch0079s0024s0003li0137">137</link>). Other sequences that can be used for species identification include <emphasis>flaB</emphasis> and the 16S-23S rRNA intergenic spacer gene, especially when used in multispacer sequence typing or multilocus sequence typing (MLST) (<link linkend="ch0079s0024s0003li0061">61</link>, <link linkend="ch0079s0024s0003li0117">117</link>, <link linkend="ch0079s0024s0003li0137">137</link>, <link linkend="ch0079s0024s0003li0138">138</link>).</para>
      <para id="ch0079s0014p0003">NAAT of the 16S rRNA gene followed by nested PCR of the 16S-23S intergenic spacer gene and sequencing on positive samples was used in an outbreak due to<emphasis>B. hermsii</emphasis> in the United States to detect RF <emphasis>Borrelia</emphasis> in patient samples and ticks (<link linkend="ch0079s0024s0003li0061">61</link>). The same approach was also successfully applied in European patients (<link linkend="ch0079s0024s0003li0118">118</link>, <link linkend="ch0079s0024s0003li0121">121</link>).</para>
      <para id="ch0079s0014p0004">Several studies have been conducted utilizing multiplex PCR that allows the detection of several RF<emphasis>Borrelia</emphasis> spp. found in Africa. These studies utilized gene targets for the most common RF <emphasis>Borrelia</emphasis> spp. in those regions: <emphasis>B. crocidurae, B. duttonii, B. recurrentis,</emphasis> and <emphasis>B. hispanica</emphasis> (<link linkend="ch0079s0024s0003li0117">117</link>, <link linkend="ch0079s0024s0003li0137">137</link>).</para>
      <para id="ch0079s0014p0005">The<emphasis>glpQ</emphasis> gene is unique to RF <emphasis>Borrelia</emphasis> and therefore has been broadly used for NAAT. This gene discriminates between LB and RF <emphasis>Borrelia</emphasis> and is therefore very useful in diagnostic NAATs, especially in geographic areas where LB and RF <emphasis>Borrelia</emphasis> spp. coexist (<link linkend="ch0079s0024s0003li0075">75</link>, <link linkend="ch0079s0024s0003li0117">117</link>). Within <emphasis>glpQ,</emphasis> there is a 4-bp single nucleotide polymorphism that is unique to <emphasis>B. crocidurae</emphasis> (<link linkend="ch0079s0024s0003li0137">137</link>).</para>
      <para id="ch0079s0014p0006">Studies investigating<emphasis>B. miyamotoi</emphasis> infection in humans suggest the application of the same NAAT used for other RF <emphasis>Borrelia,</emphasis> for either confirming infection or identifying RF <emphasis>Borrelia</emphasis> species (<link linkend="ch0079s0024s0003li0005">5</link>, <link linkend="ch0079s0024s0003li0071">71</link>, <link linkend="ch0079s0024s0003li0074">74</link>, <link linkend="ch0079s0024s0003li0123">123</link>, <link linkend="ch0079s0024s0003li0139">139</link>).</para>
    </sect1>
    <sect1 id="ch0079s0015">
      <title>Borrelia burgdorferi sensu lato (LB Borrelia Group)</title>
      <anchor id="ch0079s0015a0001"/>
      <anchor id="ch0079s0015a0002"/>
      <para id="ch0079s0015p0001">The diagnostic value of PCR varies depending on the clinical disease stage, sample type, and volume, which together determine the concentration of organism present, and on the PCR method used (<link linkend="ch0079s0024s0003li0112">112</link>, <link linkend="ch0079s0024s0003li0113">113</link>). Currently, PCR-based molecular tests are employed mainly in research settings and in commercial or reference laboratories. In addition to direct detection in clinical samples such as skin, blood, CSF, and synovial fluid or tissue, PCR has been used for detection of <emphasis>Borrelia</emphasis> as well as other tick-borne pathogens in <emphasis>Ixodes</emphasis> ticks and, in some laboratories, for confirmation of <emphasis>B. burgdorferi sensu lato</emphasis> growth in culture medium (<link linkend="ch0079s0024s0003li0112">112</link>, <link linkend="ch0079s0024s0003li0133">133</link>).</para>
      <para id="ch0079s0015p0002">Primers used for PCR of<emphasis>B. burgdorferi sensu lato</emphasis> include those targeting <emphasis>flaB</emphasis>, 16S rRNA, 23S rRNA, 5S-23S rRNA spacer, p66, <emphasis>recA, ospA</emphasis>, and <emphasis>oppA1</emphasis> sequences (<link linkend="ch0079s0024s0003li0006">6</link>, <link linkend="ch0079s0024s0003li0112">112</link>). The latter has been used to detect different genospecies of <emphasis>B. burgdorferi sensu lato</emphasis> on the basis of hybridization probes and differential melting temperature characteristics. <emphasis>B. mayonii</emphasis> was discovered with this method, since it had a melting temperature outside what was expected for <emphasis>B. burgdorferi</emphasis> (<link linkend="ch0079s0024s0003li0006">6</link>). <emphasis>Borrelia</emphasis> genospecies has also been determined by other methods, such as analysis of PCR after gel electrophoresis, restriction of the 5S-23S rRNA intergenic spacer, sequencing of <emphasis>flaB, hbb, ospC</emphasis>, and other genes, MLST, and assessing molecular size after gel electrophoresis or whole-genome sequencing (<link linkend="ch0079s0024s0003li0140">140</link>–<link linkend="ch0079s0024s0003li0142">142</link>).</para>
      <para id="ch0079s0015p0003">The sensitivity of PCR for detection of<emphasis>B. burgdorferi sensu lato</emphasis> DNA in skin lesions is usually high, with a median 69% positivity for patients with EM and 76% for patients with ACA (<link linkend="ch0079s0024s0003li0112">112</link>). A European study reported that PCR positivity correlated with EM size or associated systemic symptoms, such as headache and fatigue (<link linkend="ch0079s0024s0003li0143">143</link>).</para>
      <para id="ch0079s0015p0004">In general, the sensitivity of PCR for detection of<emphasis>B. burgdorferi</emphasis> DNA in blood, plasma, or serum samples from patients with Lyme borreliosis is low (&lt;20%), particularly with samples from patients presenting past the early disease stage, due to the lack or low level of spirochetemia (<link linkend="ch0079s0024s0003li0112">112</link>). An analysis at the Mayo Clinic Laboratories of real-time PCR testing on 9,197 samples submitted between 2012 and 2014 demonstrated that the test was rarely contributory. In their experience, only 13 of 3,127 (0.4%) blood samples, 81 of 1,196 (6.7%) synovial fluids, and only 3 of 4,782 (0.06%) CSF samples tested positive by PCR (<link linkend="ch0079s0024s0003li0006">6</link>). However, sensitivity cannot be extrapolated from testing performed at reference laboratories that receive samples from unselected patient populations. A follow-up study of 7,292 clinical samples submitted to Mayo Clinic laboratory for tick-borne pathogens PCR was conducted using a pan-<emphasis>Borrelia</emphasis> PCR followed by MLST at the Minnesota Health Department and CDC. They identified 44 (0.6%) samples positive for <emphasis>Borrelia</emphasis> sp., 25 positive for <emphasis>B. burgdorferi</emphasis>, 9 positive for <emphasis>B. mayonii</emphasis>, 8 positive for <emphasis>B. miyamotoi</emphasis>, and 2 positive for other RF <emphasis>Borrelia</emphasis> spp. (<link linkend="ch0079s0024s0003li0083">83</link>). Interestingly, although samples were collected from 47 U.S. states, <emphasis>B. mayonii</emphasis> was found only in samples from patients from the Midwest (<link linkend="ch0079s0024s0003li0083">83</link>).</para>
      <para id="ch0079s0015p0005">PCR studies on clinically characterized patients are more contributory to the role of this diagnostic modality in diagnosis. PCR on plasma samples from 66 patients with clinical diagnosis of EM was found to be positive in 44.6% (<link linkend="ch0079s0024s0003li0133">133</link>). In a study from Europe, PCR on blood samples of patients presenting with Lyme neuroborreliosis was positive in 11.9% (<link linkend="ch0079s0024s0003li0088">88</link>). A rate of 62% positivity in PCR of plasma samples was achieved by extracting <emphasis>Borrelia</emphasis> DNA from 1.25 ml of EDTA-whole blood, followed by isothermal amplification of seven <emphasis>B. burgdorferi sensu lato</emphasis> targets, for patients with early Lyme borreliosis (<link linkend="ch0079s0024s0003li0144">144</link>). PCR of CSF from well-characterized patient populations with a clinical diagnosis of Lyme neuroborreliosis in Europe yielded sensitivities between 10.7 and 19.4% (<link linkend="ch0079s0024s0003li0088">88</link>, <link linkend="ch0079s0024s0003li0145">145</link>). The sensitivity of CSF PCR in U.S. patients with suspected Lyme neuroborreliosis has been lower than in the European experience. In one study, only 1 of 20 (5%) CSF samples collected from children meeting the criteria for Lyme meningitis had a positive PCR result (<link linkend="ch0079s0024s0003li0146">146</link>).</para>
      <para id="ch0079s0015p0006">In well-selected cases, PCR has been successful on joint fluid or tissues from patients with untreated Lyme arthritis. PCR has a median sensitivity of 78% and is more sensitive than culture for detection of<emphasis>B. burgdorferi</emphasis> in synovial fluid specimens (<link linkend="ch0079s0024s0003li0112">112</link>). Although there are few data on European Lyme arthritis, the identification of borreliae in synovium or synovial fluid in Europe demonstrates different <emphasis>Borrelia</emphasis> species as the causative agents. Nevertheless, although <emphasis>B. burgdorferi sensu stricto</emphasis> is not the predominant species causing Lyme borreliosis in Europe, it is a frequent etiology of Lyme arthritis. A French multicenter retrospective study including 52 patients with Lyme arthritis reported positive PCR results for 16 (39%) patients. <emphasis>B. burgdorferi sensu stricto</emphasis> and <emphasis>B. garinii</emphasis> were found in 5 patients (31.2%) each and <emphasis>B. afzelii</emphasis> in 3 (18.8%), while for 3 (18.8%) samples, the involved species was undetermined (<link linkend="ch0079s0024s0003li0147">147</link>). Another French study of 37 patients with PCR-confirmed Lyme arthritis found <emphasis>B. burgdorferi sensu stricto</emphasis> in 19 (54%), <emphasis>B. afzelii</emphasis> in 10 (29%), and <emphasis>B. garinii</emphasis> in 6 (17%) patients (<link linkend="ch0079s0024s0003li0148">148</link>).</para>
      <anchor id="ch0079s0015a0003"/>
      <beginpage pagenum="1186"/>
      <sect2 id="ch0079s0015s0001">
        <title>SEROLOGY</title>
        <anchor id="ch0079s0015s0001a0001"/>
        <anchor id="ch0079s0015s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0016">
      <title>Relapsing Fever Borrelia Group</title>
      <anchor id="ch0079s0016a0001"/>
      <anchor id="ch0079s0016a0002"/>
      <para id="ch0079s0016p0001">Because RF<emphasis>Borrelia</emphasis> can be directly detected in clinical samples by the methods mentioned above during the recurrent febrile episodes, serological tests have limited utility for diagnosis of acute infections. These tests have been mainly useful in population studies and in confirming infection due to emerging species.</para>
      <para id="ch0079s0016p0002">An indirect immunofluorescent antibody (IFA) assay using whole<emphasis>B. recurrentis</emphasis> cell antigens has been used to detect IgG antibodies (<link linkend="ch0079s0024s0003li0076">76</link>). This method suffers from lack of specificity and requires further confirmation by other more specific antibody detection methods, such as Western blotting.</para>
      <para id="ch0079s0016p0003">Previously used IFA assays and enzyme immunoassays (EIA) containing whole-cell lysate of pure culture of<emphasis>B. recurrentis</emphasis> or <emphasis>B. hermsii</emphasis> have been replaced with EIA using recombinant GlpQ antigen to detect antibodies (<link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0149">149</link>). This antigen, a 39-kDa protein, is present only in RF <emphasis>Borrelia</emphasis> spp.; therefore, this assay is specific for this group of <emphasis>Borrelia</emphasis> (<link linkend="ch0079s0024s0003li0149">149</link>). Otherwise, IgM and/or IgG reactivity to whole-cell lysates must be confirmed with an immunoblot test using the GlpQ antigen.</para>
      <para id="ch0079s0016p0004">Tests with specific recombinant antigens are not commercially available, but several research laboratories are performing them. An assay using a recombinant antigen derived from<emphasis>glpQ</emphasis> of <emphasis>B. miyamotoi</emphasis> was used to detect antibodies to this organism in a group of patients presenting with fever after <emphasis>I. scapularis</emphasis> tick bites in the northeastern United States. Of 29 confirmed cases, 25 (86%) cases with <emphasis>B. miyamotoi</emphasis> developed antibodies to GlpQ recombinant antigen (<link linkend="ch0079s0024s0003li0150">150</link>). Although antibody assays using the GlpQ antigen have been deemed specific to confirm RF infections, recent studies have questioned their specificity and have proposed searching for other antigens to be used in the serology of this organism (<link linkend="ch0079s0024s0003li0151">151</link>).</para>
      <para id="ch0079s0016p0005">Other antigens that are unique to RF<emphasis>Borrelia</emphasis> include a 57-kDa protein named <emphasis>Borrelia</emphasis> immunogenic protein A (BipA) and two antigens from VMPs, the small one (Vsp; 20 kDa) and the large one (Vlp; 37 kDa) (<link linkend="ch0079s0024s0003li0004">4</link>, <link linkend="ch0079s0024s0003li0046">46</link>, <link linkend="ch0079s0024s0003li0122">122</link>, <link linkend="ch0079s0024s0003li0152">152</link>). These antigens were not found in the Lyme borreliosis <emphasis>Borrelia</emphasis> group of spirochetes and therefore can distinguish RF from LB but cannot discriminate within the RF <emphasis>Borrelia</emphasis> group. The combination of several antigens increases the sensitivity and specificity of tests compared to the use of a single antigen, mainly GlpQ (<link linkend="ch0079s0024s0003li0122">122</link>).</para>
      <para id="ch0079s0016p0006">Patients with RF<emphasis>Borrelia</emphasis> infections develop antibody responses against several borrelial antigens that can be reactive in <emphasis>B. burgdorferi</emphasis> EIAs, including the C6 antibody assay (<link linkend="ch0079s0024s0003li0150">150</link>, <link linkend="ch0079s0024s0003li0153">153</link>). However, most serum samples from these patients do not fulfill the Western blot criteria used for detection of <emphasis>B. burgdorferi</emphasis> antibodies (see details later in this chapter) (<link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0117">117</link>, <link linkend="ch0079s0024s0003li0150">150</link>). Sera from patients diagnosed with STARI have been found to be negative in the C6 peptide EIA (<link linkend="ch0079s0024s0003li0154">154</link>). Interpretation of serological tests is often complicated in regions where RF is endemic, because of the high background reactivity, but also in regions where LB is endemic, as <emphasis>B. miyamotoi</emphasis> may be present.</para>
      <para id="ch0079s0016p0007">Western blot testing for RF<emphasis>Borrelia</emphasis> is performed at reference laboratories and the CDC (<link linkend="ch0079s0024s0003li0153">153</link>). Reactivity to RF <emphasis>Borrelia</emphasis> can be confirmed by Western blotting by observing IgG and IgM reactions to GlpQ and other antigens.</para>
    </sect1>
    <sect1 id="ch0079s0017">
      <title>Borrelia burgdorferi sensu lato (LB Borrelia Group)</title>
      <anchor id="ch0079s0017a0001"/>
      <anchor id="ch0079s0017a0002"/>
      <para id="ch0079s0017p0001">Because of their fastidious nature and the paucity of<emphasis>B. burgdorferi sensu lato</emphasis> organisms in clinical samples, the detection of antibodies in serum samples is the mainstay of laboratory diagnosis of Lyme borreliosis (<link linkend="ch0079s0024s0003li0112">112</link>, <link linkend="ch0079s0024s0003li0113">113</link>). In recent years, significant improvements have been made in serological diagnostics by use of an extended spectrum of recombinant antigens, including VlsE, and new techniques such as line blotting and multiplex testing.</para>
    </sect1>
    <sect1 id="ch0079s0018">
      <title>Antigens</title>
      <anchor id="ch0079s0018a0001"/>
      <anchor id="ch0079s0018a0002"/>
      <para id="ch0079s0018p0001"><emphasis>B. burgdorferi sensu lato</emphasis> has several immunodominant antigens, which are used in diagnostic testing. These determinants play a role in dissemination, immune evasion, and elicitation of antibody responses in the host (<link linkend="ch0079s0024s0003li0155">155</link>) (<anchor id="ch0079s0018a0003"/><link linkend="ch0079s0018a0005">Table 3</link>).</para>
      <para id="ch0079s0018p0002">Most important surface-exposed lipoproteins (Osps) are encoded on plasmids, but some are encoded on the chromosome. OspC (23 kDa) is expressed on the surface of the organism after the tick has obtained a blood meal. OspC allows the dissemination of<emphasis>B. burgdorferi sensu lato</emphasis> to the tick salivary glands and is upregulated during early disease (<link linkend="ch0079s0024s0003li0155">155</link>). It is one of the most immunodominant and specific <emphasis>Borrelia</emphasis> antigens; antibodies appear early in disease (<link linkend="ch0079s0024s0003li0156">156</link>). Other surface plasmid-encoded antigens include OspA (31 kDa), OspB (34 kDa), and OspD (28 kDa), each of which is involved in adherence of <emphasis>B. burgdorferi</emphasis> to tick midgut epithelium. Although specific, these antibodies arise slowly during infection and are not suitable for early diagnosis.</para>
      <para id="ch0079s0018p0003">Besides OspC, one of the most immunogenic antigens is the chromosomally encoded flagellin (FlaB, 41 kDa). Flagellin is very cross-reactive with flagellar antigens of other motile bacteria. Although antibodies can be detected in very early infection, this approach suffers from nonspecificity due to cross-reactivity (<link linkend="ch0079s0024s0003li0157">157</link>).</para>
      <para id="ch0079s0018p0004">VlsE (about 35 kDa) is an important immunodominant antigen in early and late disease and is mostly expressed in mammalian hosts but not on cultured spirochetes (<link linkend="ch0079s0024s0003li0158">158</link>–<link linkend="ch0079s0024s0003li0161">161</link>). Antigenic variation of VlsE allows <emphasis>B. burgdorferi sensu lato</emphasis> to persist in its natural reservoir, facilitating efficient acquisition by the tick (<link linkend="ch0079s0024s0003li0155">155</link>, <link linkend="ch0079s0024s0003li0160">160</link>). An invariable and highly immunogenic region of VlsE (C6) has been synthesized and used in antibody assays (<link linkend="ch0079s0024s0003li0158">158</link>, <link linkend="ch0079s0024s0003li0161">161</link>). VlsE is one of the most specific <emphasis>Borrelia burgdorferi</emphasis> antigens and has high significance in LB serology.</para>
      <para id="ch0079s0018p0005">BmpA (39 kDa), a chromosomally encoded protein, is highly immunogenic in early disease (<link linkend="ch0079s0024s0003li0162">162</link>). P66, a chromosomally encoded protein of 66 kDa, is a porin-like protein that functions as an adhesin by binding to mammalian cell receptors (<link linkend="ch0079s0024s0003li0155">155</link>). Decorin-binding protein A (DbpA; 17 kDa) allows <emphasis>Borrelia</emphasis> to interact with connective tissue. BBK32 (47 kDa) is also plasmid encoded and can bind to fibronectin (<link linkend="ch0079s0024s0003li0163">163</link>, <link linkend="ch0079s0024s0003li0164">164</link>). BBK32, along with OspE and related proteins, is mostly expressed <emphasis>in vivo</emphasis> (<link linkend="ch0079s0024s0003li0155">155</link>).</para>
      <para id="ch0079s0018p0006">The complex antigenic composition of<emphasis>B. burgdorferi sensu lato</emphasis> and differential expression of these antigens under various conditions and stages of the infection make the selection of antigenic preparations for serology quite challenging. The first antibody assays for serodiagnosis of Lyme borreliosis used high-passage-number <emphasis>B. burgdorferi</emphasis> that had lost plasmids encoding highly immunogenic antigens such as OspC (<link linkend="ch0079s0024s0003li0157">157</link>). In Europe, the presence of different Lyme <emphasis>Borrelia</emphasis> species has further complicated test design (<link linkend="ch0079s0024s0003li0165">165</link>). Subsequent antibody assays have used low-passage-number strains, mostly the B31 strain in the United States, and purified natural antigens, and some have added recombinant antigens of importance. As knowledge about antigen characteristics and antibody development has increased, there have been improvements in serologic tests. Recombinant and peptide antigens have been used in diagnostic tests in the United States and Europe and have significantly improved the performance of immunoassays (<link linkend="ch0079s0024s0003li0166">166</link>–<link linkend="ch0079s0024s0003li0175">175</link>).</para>
      <anchor id="ch0079s0018a0004"/>
      <beginpage pagenum="1187"/>
      <table id="ch0079s0018t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0079s0018a0005"/><link linkend="ch0079s0018a0003">TABLE 3</link></phrase></emphasis> Immunodominant antigens of LB <emphasis>Borrelia</emphasis><superscript><emphasis><anchor id="ch0079s0018a0006"/><link linkend="ch0079s0018a0007">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="4">
          <tbody>
            <row>
              <entry><phrase role="center">Protein (MW [kDa])</phrase>
              </entry>
              <entry><phrase role="center">Function/localization</phrase>
              </entry>
              <entry><phrase role="center">Cross-reactivity</phrase>
              </entry>
              <entry><phrase role="center">Comments</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">p83/93/100 (83 to 100)</phrase>
              </entry>
              <entry><phrase role="left">Associated with protoplasmic cylinder (or flagella?)</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Chromosomally encoded</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">p66 (66)</phrase>
              </entry>
              <entry><phrase role="left">Membrane-associated porin</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Chromosomally encoded</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">p58 (58)</phrase>
              </entry>
              <entry><phrase role="left">Oligopeptide permease</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Chromosomally encoded</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">BBK32 (47)</phrase>
              </entry>
              <entry><phrase role="left">Outer surface protein; binds to fibronectin</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Plasmid encoded; expressed <emphasis>in vivo</emphasis></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">p41, FlaB (41)</phrase>
              </entry>
              <entry><phrase role="left">Flagellin subunit</phrase>
              </entry>
              <entry><phrase role="left">Broad</phrase>
              </entry>
              <entry><phrase role="left">Chromosomally encoded; central variable and flanking conserved genes</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">p39, BmpA (39)</phrase>
              </entry>
              <entry><phrase role="left">Membrane associated; binds to laminin</phrase>
              </entry>
              <entry><phrase role="left">Low (occasionally with sera from syphilis patients)</phrase>
              </entry>
              <entry><phrase role="left">Chromosomally encoded</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">VlsE (34 to 37)</phrase>
              </entry>
              <entry><phrase role="left">Outer membrane protein; important in immune evasion</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Plasmid encoded; expressed only <emphasis>in vivo</emphasis></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">OspB (34)</phrase>
              </entry>
              <entry><phrase role="left">Outer surface protein important in tick colonization</phrase>
              </entry>
              <entry><phrase role="left">Unknown</phrase>
              </entry>
              <entry><phrase role="left">Plasmid encoded; strain variability; not present in some species</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">OspA (31)</phrase>
              </entry>
              <entry><phrase role="left">Outer surface protein important in tick colonization</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Plasmid encoded; strain variability; differentially expressed</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">p30 (30)</phrase>
              </entry>
              <entry><phrase role="left">Unknown</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Might be mistaken for OspA</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">p28 (28)</phrase>
              </entry>
              <entry><phrase role="left">Adhesion to tick midgut</phrase>
              </entry>
              <entry><phrase role="left">Unknown</phrase>
              </entry>
              <entry><phrase role="left">Plasmid encoded</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">OspC (21 to 24)</phrase>
              </entry>
              <entry><phrase role="left">Outer surface protein; dissemination from tick midgut to salivary gland</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Plasmid encoded; differentially expressed</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Osp17, DbpA (17)</phrase>
              </entry>
              <entry><phrase role="left">Outer surface protein; binds decorin</phrase>
              </entry>
              <entry><phrase role="left">Low</phrase>
              </entry>
              <entry><phrase role="left">Plasmid encoded; strain variability</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0018a0007"/><link linkend="ch0079s0018a0006">a</link></emphasis></superscript>Adapted from reference <link linkend="ch0079s0024s0003li0179">179</link>.</para>
    </sect1>
    <sect1 id="ch0079s0019">
      <title>Methods</title>
      <anchor id="ch0079s0019a0001"/>
      <anchor id="ch0079s0019a0002"/>
      <para id="ch0079s0019p0001">Several methods have been used to detect antibodies to<emphasis>B. burgdorferi sensu lato</emphasis>, including the following: IFA assays; EIA, such as enzyme-linked immunosorbent assay (ELISA); chemiluminescence immunoassays (CLIA); and immunoblotting (IB). The current recommendation in the United States is to use two-step testing, either standard two-tier testing (STTT), where IFA assay, ELISA, or CLIA is the first step, followed by Western blotting (WB) or IB as the second step for samples that are reactive in first-step testing (<link linkend="ch0079s0024s0003li0176">176</link>), or modified two-tier testing (MTTT), where two EIAs are used sequentially (<link linkend="ch0079s0024s0003li0177">177</link>). The two EIAs used in the MTTT should have different antigenic compositions, i.e., whole-cell antigens or recombinant/purified antigens. Although some research laboratories use in-house-developed tests, most testing performed for clinical use employs commercially available assays. Over 100 assays have been cleared by FDA in the United States since 1987, most using <emphasis>B. burgdorferi</emphasis> strain B31 as the source of antigens (<link linkend="ch0079s0024s0003li0178">178</link>). There is no evidence to support the use of different <emphasis>Borrelia</emphasis> genospecies in serodiagnostic testing in Europe. In the case of whole-cell-lysate EIA, it is sufficient to use a single genospecies in the screening assay in Europe. The highest sensitivity is achieved with <emphasis>B. afzelii</emphasis> strain Pko (<link linkend="ch0079s0024s0003li0179">179</link>). However, the U.S. immunoblot interpretation criteria (<link linkend="ch0079s0024s0003li0176">176</link>) are not suitable for use in Europe.</para>
    </sect1>
    <sect1 id="ch0079s0020">
      <title>Indirect Immunofluorescent Antibody Assay</title>
      <anchor id="ch0079s0020a0001"/>
      <anchor id="ch0079s0020a0002"/>
      <para id="ch0079s0020p0001">The IFA assay was one of the first assays used in Lyme serology. It uses cultured<emphasis>Borrelia</emphasis> fixed onto glass slides. Serum specimens are diluted in preparations that may include an absorbent material, such as material derived from <emphasis>Treponema</emphasis> biotype Reiter or egg yolk sac, to block binding of nonspecific antibodies. After addition of fluorescein isothiocyanate-labeled anti-human IgG or IgM, the presence of <emphasis>Borrelia</emphasis>-specific antibodies is detected by fluorescence microscopy. Specimens reactive at the screening dilution are serially diluted. In general, antibody titers of ≥64 and ≥256 in IFA assays with and without prior absorption, respectively, are considered positive (<link linkend="ch0079s0024s0003li0180">180</link>). Limitations of this assay include the need for fluorescence microscopy and well-trained personnel and the subjectivity in reading and interpreting fluorescence microscopy results. Although IFA assays are still commercially available, they have been largely replaced by EIA and CLIA.</para>
    </sect1>
    <sect1 id="ch0079s0021">
      <title>Enzyme Immunoassays</title>
      <anchor id="ch0079s0021a0001"/>
      <anchor id="ch0079s0021a0002"/>
      <para id="ch0079s0021p0001">The most common methods for detection of antibodies to<emphasis>B. burgdorferi sensu lato</emphasis> are ELISA (or other EIA) and CLIA (<link linkend="ch0079s0024s0003li0178">178</link>, <link linkend="ch0079s0024s0003li0181">181</link>). The original commercially available or in-house assays using a whole-cell lysate of <emphasis>B. burgdorferi</emphasis> strain B31 as the source of antigen have been largely replaced by those using purified antigens, and, more recently, selected recombinant antigens (<link linkend="ch0079s0024s0003li0174">174</link>, <link linkend="ch0079s0024s0003li0178">178</link>). Besides B31, other strains of <emphasis>B. burgdorferi</emphasis> are used in assays developed in the United States, while various LB <emphasis>Borrelia</emphasis> species and strains (<emphasis>B. burgdorferi, B. garinii,</emphasis> and <emphasis>B. afzelii</emphasis>) are employed in in-house or commercial assays available in Europe (<link linkend="ch0079s0024s0003li0182">182</link>). ELISAs that detect IgM and IgG antibodies to <emphasis>B. burgdorferi</emphasis> antigens routinely include a low-positive control used to assess the reactivity of patient samples. Patient reactivity (optical density [OD]) is divided by the low-positive control and an index is calculated. Specific index values defined by the test manufacturer can be used to determine negative, equivocal, and positive results (<link linkend="ch0079s0024s0003li0178">178</link>).</para>
      <anchor id="ch0079s0021a0003"/>
      <beginpage pagenum="1188"/>
      <para id="ch0079s0021p0002">An EIA introduced over 15 years ago uses a synthetic peptide that reproduces invariable region 6 of the VlsE (C6) as the antigen (<link linkend="ch0079s0024s0003li0183">183</link>). The C6 assay is FDA cleared for use in first-step testing (<link linkend="ch0079s0024s0003li0178">178</link>), and it shows sensitivity similar to that of whole-cell EIA, 75% and 81.7%, respectively (<link linkend="ch0079s0024s0003li0184">184</link>). The C6 assay also performs well as a second-step test, showing greater sensitivity than the standard two-tier testing (<link linkend="ch0079s0024s0003li0185">185</link>, <link linkend="ch0079s0024s0003li0186">186</link>). Moreover, it has been investigated as a single-step test in the United States, showing marginally lower specificity than two-tier testing, 98.9% versus 99.5%, respectively (<link linkend="ch0079s0024s0003li0184">184</link>). However, patients infected with <emphasis>B. miyamotoi</emphasis> can test positive in the C6 assay (<link linkend="ch0079s0024s0003li0150">150</link>).</para>
      <para id="ch0079s0021p0003">A commercial EIA that separately detects IgM antibodies to recombinant DbpA and OspC and IgG antibodies to VlsE, DbpA, and OspC was evaluated with the CDC serum panel (<link linkend="ch0079s0024s0003li0187">187</link>). The authors compared the performance of this dissociated IgG and IgM ELISA versus combined IgG/IgM ELISA as first steps in the two-tier algorithm and found similar sensitivities (83% and 85%, respectively) and specificities (88% and 88%, respectively). The advantage of this assay includes the selection of the corresponding IB as a second tier, theoretically decreasing the number of IBs performed. In this study, the number of blots performed decreased by 27% (<link linkend="ch0079s0024s0003li0187">187</link>).</para>
      <para id="ch0079s0021p0004">Another commercial test that is widely applied as a primary test in Europe is a CLIA that separately detects IgM antibodies to recombinant OspC and VlsE and IgG antibodies to VlsE. Significant differences in sensitivity and specificity compared to a C6 assay were not observed; advantages of this assay is that it is automated and the first step can discriminate between IgM and IgG antibodies (<link linkend="ch0079s0024s0003li0175">175</link>, <link linkend="ch0079s0024s0003li0188">188</link>).</para>
      <para id="ch0079s0021p0005">The sensitivity of immunoassays depends on the duration of infection. The sensitivity (of ELISA and CLIA) is in general less than 50% in acute-phase sera of patients with EM with a duration of less than 1 week (<link linkend="ch0079s0024s0003li0189">189</link>). Sensitivity of these assays increases after the first week for untreated patients with EM. Sensitivity is also high for samples from patients with EM presenting with constitutional signs and symptoms and those who have multiple EMs (<link linkend="ch0079s0024s0003li0189">189</link>). Sensitivity is high for patients with objective evidence of extracutaneous involvement during early infection (e.g., carditis or Lyme neuroborreliosis). Immunoassays (ELISA and CLIA) are almost invariably positive in sera of patients with late disease manifestations, such as arthritis and ACA (<link linkend="ch0079s0024s0003li0187">187</link>, <link linkend="ch0079s0024s0003li0190">190</link>, <link linkend="ch0079s0024s0003li0191">191</link>). A systematic literature review on the diagnostic accuracy of serological tests for Lyme borreliosis in Europe reported on the heterogeneity of available tests that limited the recommendations on their use in clinical practice. Nevertheless, as has been reported in the United States, the sensitivity of these tests increased according to duration of infection (<link linkend="ch0079s0024s0003li0175">175</link>).</para>
      <para id="ch0079s0021p0006">The Lyme borreliosis EIA has advantages over other immunoassays, including ease of testing, objective quantitative results that correlate in relative terms with the quantity of antibodies present, and the capability of automation. One of the limitations of EIA for detection of<emphasis>B. burgdorferi sensu lato</emphasis> antibodies is lack of standardization. Variations exist between assays in terms of antigenic composition used by different manufacturers and in the detection of specific immunoglobulin classes, particularly in the detection of IgM antibodies. Variations can occur between lots of the same kit. One limitation of LB EIA tests is the lack of specificity due to the use of whole-cell antigen preparations. In Europe, there is now mandatory certification (CE marking) of the tests. However, this provides only minimum consistency and is not an overall guarantee of quality. Comprehensive demonstration of performance in multicenter studies is not yet required for certification. The specificity of EIA for detection of <emphasis>B. burgdorferi sensu lato</emphasis> antibodies is, in general, below 97% (<link linkend="ch0079s0024s0003li0184">184</link>). Samples from patients with confirmed <emphasis>B. miyamotoi</emphasis> infection will also react in these assays; 90% of such cases seroconverted in an IgM EIA used by a reference laboratory, but only 10% met the two-tier testing criteria by IB (<link linkend="ch0079s0024s0003li0044">44</link>). Similar findings were reported in a seroreactivity and seroprevalence study conducted in the northeastern United States (<link linkend="ch0079s0024s0003li0150">150</link>).</para>
    </sect1>
    <sect1 id="ch0079s0022">
      <title>Immunoblots</title>
      <anchor id="ch0079s0022a0001"/>
      <anchor id="ch0079s0022a0002"/>
      <para id="ch0079s0022p0001">Detection of antibodies to different antigenic components of<emphasis>B. burgdorferi</emphasis> has greatly contributed to the understanding of the immune response during different stages of the disease (<link linkend="ch0079s0024s0003li0162">162</link>, <link linkend="ch0079s0024s0003li0189">189</link>, <link linkend="ch0079s0024s0003li0192">192</link>). Traditionally, Western blots (WB) contain whole-cell preparations of <emphasis>B. burgdorferi</emphasis> that are electrophoretically separated into proteins by size, after which they are transferred to membranes to be used as antigens. Recent modifications of the IB assays include the use of purified or recombinant borrelial antigens that are applied in well-defined positions on the strip (lines, spots, or bands) or as a microarray onto the membranes (<link linkend="ch0079s0024s0003li0193">193</link>). The use of recombinant antigens in line IB reduces the background reactivity commonly observed with classic WB. For IB, diluted serum samples are reacted with membrane strips to detect IgG and IgM antibodies to the different antigenic components. Currently, there are few commercially available, FDA-approved IB kits in the United States (<link linkend="ch0079s0024s0003li0178">178</link>). Some of these have the capability of densitometric reading to score bands of significance. Bands are scored visually by comparing the band intensity to that of control materials used as intensity controls. This approach is cumbersome and is prone to subjective interpretation, particularly for overreading of IgM IBs. Densitometric readings have been used to address this, but this approach has shown slightly lower sensitivity compared with visual scoring (<link linkend="ch0079s0024s0003li0187">187</link>). The microarray IB is an automated assay and is performed using multiwell plates that contain a membrane at the bottom of each well with spotted antigens. These antigens are those recommended by CDC in the STTT criteria. Reaction intensity is read using a colorimetric imaging system; the automatic detection of multiple immunoreactive antigens performed simultaneously on numerous samples, with short turnaround time, reduces the labor cost and eliminates the need for manual handling and reading (<link linkend="ch0079s0024s0003li0193">193</link>). This assay has not yet been cleared by the FDA for use in the United States.</para>
    </sect1>
    <sect1 id="ch0079s0023">
      <title>Two-Tier Testing</title>
      <anchor id="ch0079s0023a0001"/>
      <anchor id="ch0079s0023a0002"/>
      <sect2 id="ch0079s0023s0001">
        <title>STTT</title>
        <anchor id="ch0079s0023s0001a0001"/>
        <anchor id="ch0079s0023s0001a0002"/>
        <para id="ch0079s0023s0001p0001">Consensus on the criteria for using serology to support the diagnosis of Lyme borreliosis in the United States was achieved in 1994 during the second conference on standardization of LB testing (<link linkend="ch0079s0024s0003li0176">176</link>). One of the organizers of this conference was the CDC, and the proposed criteria became known as the CDC criteria. According to the CDC criteria, samples should first be tested by a sensitive screening ELISA, CLIA, or IFA assay that detects IgG and IgM antibodies to <emphasis>B. burgdorferi,</emphasis> and reactive samples should be tested with separate IgG and IgM IB. A positive result in the IgM IB requires reactivity to at least two of three antigens (bands): 23 (OspC), 39, and 41 kDa (<link linkend="ch0079s0024s0003li0162">162</link>). A positive result in the IgG IB requires reactivity to at least five of 10 antigens: 18, 23, 28, 30, 39, 41, 45, 58, 66, and 93 kDa (<link linkend="ch0079s0024s0003li0192">192</link>) (<anchor id="ch0079s0023s0001a0003"/><link linkend="ch0079s0023s0001a0006">Fig. 2</link>). It was further recommended to use IgM IB only within the first 30 days of early disease (the 30-day rule) and to use IgG IB at any stage of the disease (<link linkend="ch0079s0024s0003li0176">176</link>).</para>
        <anchor id="ch0079s0023s0001a0004"/>
        <beginpage pagenum="1189"/>
        <para id="ch0079s0023s0001p0002">Similar to the CDC criteria, STTT was also introduced into many European laboratories, but few countries developed national guidelines (<link linkend="ch0079s0024s0003li0194">194</link>). This is due to the availability of many different serological assays on the European market, differences in geographic seroprevalence of Lyme borreliosis, and laboratory/clinician experience in diagnosing Lyme borreliosis (<link linkend="ch0079s0024s0003li0175">175</link>, <link linkend="ch0079s0024s0003li0194">194</link>, <link linkend="ch0079s0024s0003li0195">195</link>). European guidelines were first published in 1996 by the European Union Concerted Action on Lyme Borreliosis (EUCALB), updated in 2010, and reviewed in 2018 by the ESCMID Study Group for Lyme Borreliosis (ESGBOR) (<link linkend="ch0079s0024s0003li0096">96</link>, <link linkend="ch0079s0024s0003li0195">195</link>, <link linkend="ch0079s0024s0003li0196">196</link>). These guidelines emphasize the appropriate use of testing to support the clinical diagnosis.</para>
        <para id="ch0079s0023s0001p0003">The STTT algorithm has low sensitivity in patients presenting with early disease such as EM, approximately 25 to 50% and 55 to 68% in the acute and convalescent phases, respectively (<link linkend="ch0079s0024s0003li0187">187</link>, <link linkend="ch0079s0024s0003li0189">189</link>–<link linkend="ch0079s0024s0003li0191">191</link>, 197) (<anchor id="ch0079s0023s0001a0005"/><link linkend="ch0079s0023s0002a0004">Table 4</link>). This is mostly due to the low sensitivity of the second-step IB, since almost half of samples from patients with early disease that are reactive by first-step testing do not fulfill the IB criteria. The limited sensitivity in early disease should not constitute a problem, since it is recommended that diagnosis at this stage be based on clinical findings. Nevertheless, modifications of two-tier testing are proposed to increase the sensitivity of serology in early disease (discussed below). The sensitivity of STTT is over 90% in early disseminated disease, except for samples tested after the 30-day cutoff with the IgM IB criteria. The sensitivity of STTT is close to 100% in late disease (<link linkend="ch0079s0024s0003li0187">187</link>, <link linkend="ch0079s0024s0003li0190">190</link>, <link linkend="ch0079s0024s0003li0198">198</link>).</para>
        <figure id="ch0079s0023s0001f0001"><title><phrase role="figureLabel"><anchor id="ch0079s0023s0001a0006"/><link linkend="ch0079s0023s0001a0003">FIGURE 2</link></phrase> <emphasis>B. burgdorferi</emphasis> immunoblots prepared with purified antigens of strain B31. (Lane 1) Positive IgG immunoblot showing over 5 of the 10 significant bands. (Lane 2) Positive IgM immunoblot showing all 3 significant bands (<link linkend="ch0079s0024s0003li0041">41</link>, <link linkend="ch0079s0024s0003li0039">39</link> and 23 kDa).</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0079f02.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0079s0023s0001p0004">The specificity of the two-tier testing for Lyme borreliosis is over 98% (<link linkend="ch0079s0024s0003li0198">198</link>). Caution should be used in areas where <emphasis>B. miyamotoi</emphasis> is prevalent, since about 10% of patients with this infection test positive in the two-tier approach used for Lyme borreliosis (<link linkend="ch0079s0024s0003li0044">44</link>, <link linkend="ch0079s0024s0003li0150">150</link>). <emphasis>B. miyamotoi</emphasis> shares several antigens with <emphasis>B. burgdorferi sensu lato</emphasis>, including the 66-, 41-, and 39-kDa and heat shock proteins; therefore, sera from people infected with <emphasis>B. miyamotoi</emphasis> can react with several antigens in <emphasis>B. burgdorferi sensu lato</emphasis> IB. However, they might not reach the 5-band requirement for a positive IgG IB (<link linkend="ch0079s0024s0003li0150">150</link>).</para>
        <para id="ch0079s0023s0001p0005">The serodiagnosis of Lyme borreliosis in Europe is more complex because of the presence of different<emphasis>B. burgdorferi sensu lato</emphasis> genospecies causing disease in different geographic areas along with the large number of assays in use (<link linkend="ch0079s0024s0003li0199">199</link>, <link linkend="ch0079s0024s0003li0200">200</link>). The European Union Concerted Action on Lyme Borreliosis promotes a two-tier testing protocol, but it is not used routinely in all European countries. The first step consists of an ELISA with a specificity of at least 90%, and the second step consists of an IB with a specificity of at least 95%. Some European assays use a whole-cell preparation including all <emphasis>B. burgdorferi sensu lato</emphasis> organisms that cause disease in Europe, with or without added recombinant antigens. Other assays use only recombinant antigens. IB interpretations vary according to manufacturer, and so the instructions for the specific kit should be consulted (<link linkend="ch0079s0024s0003li0201">201</link>, <link linkend="ch0079s0024s0003li0202">202</link>). As per European experience, first-step tests that include selected recombinant antigens may be sufficient for confirming borrelial infection when correlating with clinical presentation, antibody development, and data on seroprevalence in a given geographic area (<link linkend="ch0079s0024s0003li0175">175</link>, <link linkend="ch0079s0024s0003li0195">195</link>).</para>
      </sect2>
      <sect2 id="ch0079s0023s0002">
        <title>MTTT</title>
        <anchor id="ch0079s0023s0002a0001"/>
        <anchor id="ch0079s0023s0002a0002"/>
        <para id="ch0079s0023s0002p0001">Modifications to the two-tier testing protocols have been proposed in attempts to improve sensitivity in early disease and include the use of EIA rather than IB as a second step. The EIA included in both steps should be based on different antigen preparations (whole-cell versus purified or recombinant antigen). European authors first proposed the use of the C6 assay as a second-step EIA in Lyme borreliosis testing (<link linkend="ch0079s0024s0003li0185">185</link>). Two-tier testing using the C6 assay as the second step has higher sensitivity than two-tier testing using IB as the second step in early Lyme borreliosis, while maintaining the high specificity of the STTT algorithm (<link linkend="ch0079s0024s0003li0186">186</link>, <link linkend="ch0079s0024s0003li0187">187</link>, <link linkend="ch0079s0024s0003li0191">191</link>, <link linkend="ch0079s0024s0003li0197">197</link>) (<link linkend="ch0079s0023s0002a0004">Table 4</link>). In 2019, the CDC published recommendations for LB serologic testing in the United States that included the use of the MTTT (<link linkend="ch0079s0024s0003li0177">177</link>). Several commercial assays were then approved by the FDA to be used in MTTT algorithms (<link linkend="ch0079s0024s0003li0178">178</link>).</para>
        <para id="ch0079s0023s0002p0002">The use of MTTT algorithms using combinations of EIA as the first and second steps has shown sensitivities and specificities similar to those of the previously described modified two-tier approaches (<link linkend="ch0079s0024s0003li0191">191</link>). In this study, serum samples were tested by several two-EIA algorithms: whole-cell EIA was used as a first step, followed by a commercially available CLIA that uses full-length VlsE as the antigen or the C6 assay as a second step. The VlsE CLIA was also used as the first step, followed by the C6 assay. These modified two-tier algorithms have improved sensitivity in early Lyme borreliosis and specificities approaching that of the STTT (<link linkend="ch0079s0024s0003li0197">197</link>, <link linkend="ch0079s0024s0003li0198">198</link>). Advantages of using MTTT include using assays that can be performed in routine clinical laboratories, decreasing the turnaround time to results, which is longer when IB needs submission to reference laboratories; in addition, it can be used to support the diagnosis of LB for patients acquiring the infection in Europe, since the second-step EIA is not specific to the <emphasis>Borrelia</emphasis> genospecies causing the infection. Another published modification of the STTT involved the use of an IgG IB that includes VlsE as one of the antigens in the blot interpretation (<link linkend="ch0079s0024s0003li0187">187</link>, <link linkend="ch0079s0024s0003li0190">190</link>). With this modification, IgG reactivity to VlsE alone in the second step increased the sensitivity in early disease, including early disseminated disease. Compared with the STTT, this modification showed similar or higher specificity (<link linkend="ch0079s0023s0002a0004">Table 4</link>). This approach has several advantages, including (i) avoiding the use of the IgM IB, which has interpretation challenges and can be used only during the first 30 days of infection; (ii) improved sensitivity in early disease, including early disseminated disease; (iii) retention of high sensitivity in late disease (<link linkend="ch0079s0024s0003li0191">191</link>, <link linkend="ch0079s0024s0003li0192">192</link>), and (iv) the capability of visualizing reactivity to other significant antigens included in the IB. However, IB including VlsE has not been cleared by the FDA in the United States for patient testing.</para>
        <anchor id="ch0079s0023s0002a0003"/>
        <beginpage pagenum="1190"/>
        <table id="ch0079s0023s0002t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0079s0023s0002a0004"/><link linkend="ch0079s0023s0001a0005">TABLE 4</link></phrase></emphasis> Performance of STTT and MTTT for <emphasis>B. burgdorferi</emphasis> antibodies
</title>
          
          <tgroup cols="6">
            <tbody>
              <row>
                <entry><phrase role="left">LB manifestation (number of cases with the different LB manifestations included in each study)</phrase>
                </entry>
                <entry><phrase role="center">Percent positive (or percent sensitivity) except for specificity rows</phrase>
                </entry>
                <entry><phrase role="center">Reference</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="center">STTT (standard 2 tier-testing; WCS EIA/IB)<superscript><emphasis><anchor id="ch0079s0023s0002a0005"/><link linkend="ch0079s0023s0002a0015">a</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">MTTT (modified 2 tier-testing)</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="center">WCS EIA/C6 EIA<superscript><emphasis><anchor id="ch0079s0023s0002a0006"/><link linkend="ch0079s0023s0002a0016">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">VlsE EIA/C6 EIA<superscript><emphasis><anchor id="ch0079s0023s0002a0007"/><link linkend="ch0079s0023s0002a0017">c</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">WCS EIA/VlsE EIA<superscript><emphasis><anchor id="ch0079s0023s0002a0008"/><link linkend="ch0079s0023s0002a0018">d</link></emphasis></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">EM (114)</phrase>
                </entry>
                <entry><phrase role="center"> 42</phrase>
                </entry>
                <entry><phrase role="center"> 53</phrase>
                </entry>
                <entry><phrase role="center">ND<superscript><emphasis><anchor id="ch0079s0023s0002a0009"/><link linkend="ch0079s0023s0002a0019">e</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0186">186</link>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0079s0023s0002a0010"/>
                        <link linkend="ch0079s0023s0002a0020">f</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Acute carditis/CNS (26)</phrase>
                </entry>
                <entry><phrase role="center"> 73</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0186">186</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0020">f</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Arthritis/late CNS</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0186">186</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0020">f</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Specificity</phrase>
                </entry>
                <entry><phrase role="center"> 99.5</phrase>
                </entry>
                <entry><phrase role="center"> 99.5</phrase>
                </entry>
                <entry/>
                <entry/>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0186">186</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0020">f</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">EM acute (55)</phrase>
                </entry>
                <entry><phrase role="center"> 25</phrase>
                </entry>
                <entry><phrase role="center"> 38</phrase>
                </entry>
                <entry><phrase role="center"> 54</phrase>
                </entry>
                <entry><phrase role="center"> 36</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0191">191</link>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0079s0023s0002a0011"/>
                        <link linkend="ch0079s0023s0002a0021">g</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">EM convalescence (47)</phrase>
                </entry>
                <entry><phrase role="center"> 55</phrase>
                </entry>
                <entry><phrase role="center"> 72</phrase>
                </entry>
                <entry><phrase role="center"> 72</phrase>
                </entry>
                <entry><phrase role="center"> 66</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0191">191</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0021">g</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Specificity</phrase>
                </entry>
                <entry><phrase role="center"> 99.5</phrase>
                </entry>
                <entry><phrase role="center"> 99.5</phrase>
                </entry>
                <entry><phrase role="center"> 9.3</phrase>
                </entry>
                <entry><phrase role="center"> 99.5</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0191">191</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0021">g</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">EM acute (40)</phrase>
                </entry>
                <entry><phrase role="center">40–48<superscript><emphasis><anchor id="ch0079s0023s0002a0012"/><link linkend="ch0079s0023s0002a0022">h</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center"> 50</phrase>
                </entry>
                <entry/>
                <entry/>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0187">187</link>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0079s0023s0002a0013"/>
                        <link linkend="ch0079s0023s0002a0023">i</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">EM convalescence (38)</phrase>
                </entry>
                <entry><phrase role="center">61–68<superscript><emphasis><link linkend="ch0079s0023s0002a0022">h</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center"> 79</phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center"> 48</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0187">187</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0023">i</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Acute NB (10)</phrase>
                </entry>
                <entry><phrase role="center"> 90</phrase>
                </entry>
                <entry><phrase role="center"> 90</phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center"> 74</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0187">187</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0023">i</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Acute carditis (7)</phrase>
                </entry>
                <entry><phrase role="center">86–100<superscript><emphasis><link linkend="ch0079s0023s0002a0022">h</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center"> 86</phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center"> 86</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0187">187</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0023">i</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Late Lyme arthritis (29)</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">ND</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0187">187</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0023">i</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Specificity</phrase>
                </entry>
                <entry><phrase role="center">97–98</phrase>
                </entry>
                <entry><phrase role="center"> 98</phrase>
                </entry>
                <entry/>
                <entry><phrase role="center"> 98</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0187">187</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0023">i</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">EM acute (40)</phrase>
                </entry>
                <entry><phrase role="center"> 50</phrase>
                </entry>
                <entry><phrase role="center"> 55</phrase>
                </entry>
                <entry><phrase role="center"> 50</phrase>
                </entry>
                <entry><phrase role="center"> 58</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0197">197</link>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0079s0023s0002a0014"/>
                        <link linkend="ch0079s0023s0002a0024">j</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">EM convalescence (38)</phrase>
                </entry>
                <entry><phrase role="center"> 63</phrase>
                </entry>
                <entry><phrase role="center"> 79</phrase>
                </entry>
                <entry><phrase role="center"> 76</phrase>
                </entry>
                <entry><phrase role="center"> 79</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0197">197</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0024">j</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Acute NB (10)</phrase>
                </entry>
                <entry><phrase role="center"> 90</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0197">197</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0024">j</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Lyme carditis (7)</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center"> 86</phrase>
                </entry>
                <entry><phrase role="center"> 71</phrase>
                </entry>
                <entry><phrase role="center"> 71</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0197">197</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0024">j</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Late Lyme arthritis (29)</phrase>
                </entry>
                <entry><phrase role="center"> 97</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">100</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0197">197</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0024">j</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Specificity</phrase>
                </entry>
                <entry><phrase role="center"> 96</phrase>
                </entry>
                <entry><phrase role="center"> 98</phrase>
                </entry>
                <entry><phrase role="center"> 99</phrase>
                </entry>
                <entry><phrase role="center"> 99</phrase>
                </entry>
                <entry><phrase role="center">
                    <link linkend="ch0079s0024s0003li0197">197</link>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0079s0023s0002a0024">j</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0015"/><link linkend="ch0079s0023s0002a0005">a</link></emphasis></superscript>Whole-cell sonicate (WCS)-EIA as the first step; IgG and IgM IB as the second step (CDC criteria).</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0016"/><link linkend="ch0079s0023s0002a0006">b</link></emphasis></superscript>WCS ELISA as the first step; C6 ELISA as the second step.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0017"/><link linkend="ch0079s0023s0002a0007">c</link></emphasis></superscript>VlsE EIA as the first step; C6 ELISA as the second step.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0018"/><link linkend="ch0079s0023s0002a0008">d</link></emphasis></superscript>WCS ELISA as the first step; VlsE EIA as the second step.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0019"/><link linkend="ch0079s0023s0002a0009">e</link></emphasis></superscript>ND, not done.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0020"/><link linkend="ch0079s0023s0002a0010">f</link></emphasis></superscript>Wampole IgG/M ELISA and Vidas IgG/M as WCS ELISAs; Liaison VlsE CLIA; Virablot IgG and IgM IB.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0021"/><link linkend="ch0079s0023s0002a0011">g</link></emphasis></superscript>Same WCS and VlsE CLIA as in footnote <emphasis>e</emphasis>; Virablot or Virastripe as the second-step IB.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0022"/><link linkend="ch0079s0023s0002a0012">h</link></emphasis></superscript>Lower values with Marblot IB and higher values with Virastripe IB as second steps.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0023"/><link linkend="ch0079s0023s0002a0013">i</link></emphasis></superscript>Vidas WCS IgG/M ELISA; Marblot and Virastripe as second steps (IB).</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0079s0023s0002a0024"/><link linkend="ch0079s0023s0002a0014">j</link></emphasis></superscript>Trinity WCS ELISA; Liaison VlsE (from <emphasis>B. burgdorferi</emphasis> and <emphasis>B. garinii</emphasis>) EIA; Virastripe IBs.</para>
        <para id="ch0079s0023s0002p0003">Regarding the diagnostic accuracy of serological tests for Lyme borreliosis in Europe, the European Centre for Disease Control and Prevention (ECDC) has not found evidence that the accuracy of the two-tier approaches is higher than that of single tests (<link linkend="ch0079s0024s0003li0175">175</link>). Several factors are relevant in the diagnosis of LB in Europe. Because Lyme borreliosis includes several varied clinical manifestations, patients may present with other conditions and can seek medical attention in different health care institutions, some not familiar with Lyme borreliosis. Health care providers should be aware of the local seroprevalence when selecting a diagnostic test as well as its interpretation; negative and positive predictive values of the test need to be taken into account. European recommendations also support patient follow-up long enough to obtain data for final diagnosis. Significant changes (e.g., rising levels of antibodies in EIA or increases in immunoreactive bands in IB) in serological findings during the follow-up support the diagnosis of Lyme borreliosis. Similarly, persisting negative or unchanged either negative or positive findings in long-lasting disease do not support ongoing borrelial infection (<link linkend="ch0079s0024s0003li0175">175</link>). The use of serological assays with a narrow spectrum of antigens is also preferred in early disease (<link linkend="ch0079s0024s0003li0175">175</link>, <link linkend="ch0079s0024s0003li0195">195</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0079s0024">
      <title>Cerebrospinal Fluid Testing for Intrathecal Production of Antibodies</title>
      <anchor id="ch0079s0024a0001"/>
      <anchor id="ch0079s0024a0002"/>
      <para id="ch0079s0024p0001">Determination of intrathecal production of<emphasis>B. burgdorferi sensu lato</emphasis> antibodies involves the parallel measurement of specific antibodies in CSF and serum at equivalent immunoglobulin concentrations by EIA. CSF must be taken simultaneously with or within 2 h of serum samples. Serum and CSF samples must be analyzed in the same run. The ratio of reactivity in the CSF and serum is calculated to determine the antibody index (AI) (<link linkend="ch0079s0024s0003li0100">100</link>, <link linkend="ch0079s0024s0003li0203">203</link>, <link linkend="ch0079s0024s0003li0204">204</link>). This approach has been more rewarding in European patients than in U.S. patients, most likely due to the higher incidence of Lyme neuroborreliosis in Europe and perhaps to the different strains that cause central nervous system manifestations in each location (<link linkend="ch0079s0024s0003li0205">205</link>). Depending on the test used to determine the AI, its calculation and cutoff value vary slightly. In general, an AI of &gt;1.3 is considered positive for intrathecal production of antibody along with pleocytosis and is the main method to support Lyme neuroborreliosis in Europe. The sensitivity of the AI for detection of neuroborreliosis has raised concerns. Several European studies reported on the superiority of recombinant or peptide antigen assays to confirm the presence of intrathecal antibodies. Candidate antigens/peptides with good performance include DpbA, BBK32, OspC, VlsE, and C6 (<link linkend="ch0079s0024s0003li0194">194</link>, <link linkend="ch0079s0024s0003li0206">206</link>, <link linkend="ch0079s0024s0003li0207">207</link>). Studies on 25 clinically well-characterized Slovenian patients with Lyme neuroborreliosis, including some with microbiological detection in CSF and with previously confirmed positive intrathecal AIs, found that assays using the recombinant VlsE peptide of the IR6 region of <emphasis>B. garinii</emphasis> (strain IP90) had a sensitivity of 88% and specificity of 96%. This study found that the presence of a positive intrathecal AI correlated with disease duration and that an IgG AI was preferred over an IgM AI (<link linkend="ch0079s0024s0003li0208">208</link>). Other European studies found that a multiplex bead assay had a superior performance over recombinant protein assays on conventional EIA platforms (<link linkend="ch0079s0024s0003li0092">92</link>).</para>
      <anchor id="ch0079s0024a0003"/>
      <beginpage pagenum="1191"/>
      <para id="ch0079s0024p0002">Unfortunately, there is less experience with the AI in the United States. Many commercial U.S. laboratories offer CSF testing using the<emphasis>B. burgdorferi</emphasis> antibody assays that have been FDA cleared for serum. Few laboratories offer an actual AI and should be selected as reference laboratories when seeking confirmation of intrathecal LB <emphasis>Borrelia</emphasis> antibody production (<link linkend="ch0079s0024s0003li0116">116</link>).</para>
      <para id="ch0079s0024p0003">Early antibiotic treatment in patients can prevent the development of detectable antibodies and cause the<emphasis>Borrelia</emphasis>-specific AI to remain negative. Moreover, during the course of infection (presumably because of short duration of disease and fast <emphasis>Borrelia</emphasis> invasion of the central nervous system), elevated levels of <emphasis>Borrelia</emphasis> antibodies in the CSF can sometimes be detected despite negative results for <emphasis>Borrelia</emphasis> antibodies in the serum (<link linkend="ch0079s0024s0003li0209">209</link>, <link linkend="ch0079s0024s0003li0210">210</link>). After Lyme neuroborreliosis has resolved, the <emphasis>Borrelia</emphasis>-specific antibodies can remain detectable in CSF for months or years in symptom-free patients (<link linkend="ch0079s0024s0003li0211">211</link>).</para>
      <para id="ch0079s0024p0004">In addition to detecting intrathecal production of antibodies, some studies suggest using the measurement of the chemokine CXCL13 in CSF. This chemokine is a B-cell chemoattractant expressed in secondary lymphoid organs that is found at increased levels in CSF before the specific immune response is detectable. CXCL13 can be helpful in suspected very early cases of Lyme neuroborreliosis before the AI becomes positive, but caution in interpretation is needed because it can also be present in other central nervous system (CNS) diseases. In earlier studies, at a 100-pg/ml cutoff, it was found to have 73% sensitivity and 87% specificity in 30 patients with suspected Lyme neuroborreliosis and 45 controls (<link linkend="ch0079s0024s0003li0212">212</link>–<link linkend="ch0079s0024s0003li0214">214</link>). In the last decade, several commercial assays detecting CXCL13 have become available in Europe with different cutoffs and claiming different sensitivities and specificities (up to 100%). Nevertheless, CXCL13 has been promoted as an additional diagnostic marker in Lyme neuroborreliosis and is not recommended for routine diagnosis (<link linkend="ch0079s0024s0003li0215">215</link>–<link linkend="ch0079s0024s0003li0217">217</link>).</para>
      <sect2 id="ch0079s0024s0001">
        <title>ANTIMICROBIAL SUSCEPTIBILITY</title>
        <anchor id="ch0079s0024s0001a0001"/>
        <anchor id="ch0079s0024s0001a0002"/>
        <para id="ch0079s0024s0001p0001">Members of the genus<emphasis>Borrelia</emphasis> are mostly found in wild-animal reservoirs; therefore, they are unlikely to be subjected to antimicrobial pressure and are unlikely to acquire resistance. They are invariably susceptible to tetracyclines and beta-lactam antibiotics such as cephalosporins and aminopenicillins (<link linkend="ch0079s0024s0003li0218">218</link>). The preferred treatment for relapsing fever, including <emphasis>B. miyamotoi</emphasis> infection, is tetracycline, although its use is associated with a higher rate of Jarisch-Herxheimer reaction, which could potentially be life-threatening (<link linkend="ch0079s0024s0003li0005">5</link>, <link linkend="ch0079s0024s0003li0055">55</link>, <link linkend="ch0079s0024s0003li0057">57</link>, <link linkend="ch0079s0024s0003li0089">89</link>). Doxycycline has been used successfully to treat TBRF and is the preferred antimicrobial to treat Lyme borreliosis. Beta-lactam antibiotics have also been used to treat Lyme borreliosis, particularly in children. Parenteral ceftriaxone is the drug of choice to treat Lyme neuroborreliosis (<link linkend="ch0079s0024s0003li0048">48</link>, <link linkend="ch0079s0024s0003li0219">219</link>).</para>
      </sect2>
      <sect2 id="ch0079s0024s0002">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF LYME BORRELIOSIS TEST RESULTS</title>
        <anchor id="ch0079s0024s0002a0001"/>
        <anchor id="ch0079s0024s0002a0002"/>
        <para id="ch0079s0024s0002p0001">Although the most commonly used methods to support the diagnosis of Lyme borreliosis involve the detection of antibodies, methods for direct detection of<emphasis>B. burgdorferi sensu lato</emphasis> in clinical samples are available in research settings and commercial laboratories. Use of these methods in well-controlled research settings offers the best performance. Use of NAATs in unselected populations, and particularly on blood and CSF, is of very low yield and should be discouraged. Several Lyme borreliosis “specialty” laboratories use non-FDA-approved methods, including culture for <emphasis>B. burgdorferi sensu lato</emphasis>, that have been found to produce questionable results (<link linkend="ch0079s0024s0003li0220">220</link>).</para>
        <para id="ch0079s0024s0002p0002">Recent guidelines for serologic testing have been published (<link linkend="ch0079s0024s0003li0095">95</link>). These guidelines do not recommend using serology for patients living in areas where Lyme borreliosis is endemic who present with EM, but it is indicated for patients presenting with atypical skin lesions, cardiac manifestations, suspected Lyme neuroborreliosis, or Lyme arthritis in the appropriate epidemiological setting (<link linkend="ch0079s0024s0003li0095">95</link>).</para>
        <para id="ch0079s0024s0002p0003">Lyme borreliosis serodiagnosis has low sensitivity in early disease, but since the diagnosis of EM is based on clinical findings, this does not constitute a limitation. Nevertheless, most antibody tests in the United States are done in patients with EM (<link linkend="ch0079s0024s0003li0221">221</link>). Thus, a negative serologic test does not rule out an early infection. The use of MTTT has increased the sensitivity of serology in early disease.</para>
        <para id="ch0079s0024s0002p0004">In late LB, IgG antibodies can be detected in nearly 100% of cases, whereas IgM is not diagnostic of late diseases. Thus, a seronegative result in a patient with suspected signs and symptoms of late LB makes the diagnosis very unlikely.</para>
        <para id="ch0079s0024s0002p0005">Antibody detection can be the result of a clinically manifested or a past infection, whether adequately treated or spontaneously resolved. In the case of negative antibody detection and further suspicion of early Lyme borreliosis, a second blood sample should be taken after 2 to 4 weeks.</para>
        <para id="ch0079s0024s0002p0006">Once specific IgG or even IgM antibodies have developed, they can persist for a long time after successful therapy; therefore, they should not be used to monitor the effect of therapy. Repeated detection of isolated IgM antibodies without IgG antibody detection speaks against the presence of active or silent infection.</para>
        <anchor id="ch0079s0024s0002a0003"/>
        <beginpage pagenum="1192"/>
        <para id="ch0079s0024s0002p0007">Until consensus on a new antibody-testing modality is accepted and recommended, the two-tier testing approach, using either the STTT or MTTT and adhering to the CDC criteria, should be used to support the clinical diagnosis of Lyme borreliosis in the United States. It has proven to offer the best specificity, although with lower sensitivity in early disease. As for any infectious disease, antibodies can be confirmed during convalescence. Efforts should be made to avoid scoring weak bands in IBs and to use densitometry as an objective measure when available.</para>
        <para id="ch0079s0024s0002p0008">Serology should not be used for patients presenting with ill-defined conditions and particularly those from areas where the reservoir and competent vector do not exist. Even under the best conditions, two-tier testing has 99.5% specificity. It is estimated that close to 3 million Lyme borreliosis serology tests are done in the United States annually; therefore, 15,000 results could be false positive (<link linkend="ch0079s0024s0003li0222">222</link>). Consequently, patients testing positive for antibodies who show no serologic changes on follow-up could be suffering from conditions other than Lyme borreliosis.</para>
      </sect2>
      <sect2 id="ch0079s0024s0003">
        <title>REFERENCES</title>
        <anchor id="ch0079s0024s0003a0001"/>
        <anchor id="ch0079s0024s0003a0002"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0079s0024s0003li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Margos G, Vollmer SA, Ogden NH, Fish D.</emphasis> 2011. Population genetics, taxonomy, phylogeny and evolution of <citetitle><emphasis>Borrelia burgdorferi sensu lato. Infect Genet Evol</emphasis></citetitle> <emphasis role="strong">11:</emphasis>1545–1563.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Qiu WG, Martin CL.</emphasis> 2014. Evolutionary genomics of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle>: findings, hypotheses, and the rise of hybrids. <citetitle><emphasis>Infect Genet Evol</emphasis></citetitle> <emphasis role="strong">27:</emphasis>576–593.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Binetruy F, Garnier S, Boulanger N, Talagrand-Reboul É, Loire E, Faivre B, Noël V, Buysse M, Duron O.</emphasis> 2020. A novel <citetitle><emphasis>Borrelia</emphasis></citetitle> species, intermediate between Lyme disease and relapsing fever groups, in neotropical passerine-associated ticks. <citetitle><emphasis>Sci Rep</emphasis></citetitle> <emphasis role="strong">10:</emphasis>10596.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Talagrand-Reboul E, Boyer PH, Bergström S, Vial L, Boulanger N.</emphasis> 2018. Relapsing fevers: neglected tick-borne diseases. <citetitle><emphasis>Front Cell Infect Microbiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>98.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Platonov AE, Karan LS, Kolyasnikova NM, Makhneva NA, Toporkova MG, Maleev VV, Fish D, Krause PJ.</emphasis> 2011. Humans infected with relapsing fever spirochete <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle>, Russia. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1816–1823.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Pritt BS, Respicio-Kingry LB, Sloan LM, Schriefer ME, Replogle AJ, Bjork J, Liu G, Kingry LC, Mead PS, Neitzel DF, Schiffman E, Hoang Johnson DK, Davis JP, Paskewitz SM, Boxrud D, Deedon A, Lee X, Miller TK, Feist MA, Steward CR, Theel ES, Patel R, Irish CL, Petersen JM.</emphasis> 2016. <citetitle><emphasis>Borrelia mayonii</emphasis></citetitle> sp. nov., a member of the <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> complex, detected in patients and ticks in the upper midwestern United States. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">66:</emphasis>4878–4880.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Margos G, Fingerle V, Cutler S, Gofton A, Stevenson B, Estrada-Peña A.</emphasis> 2020. Controversies in bacterial taxonomy: the example of the genus <citetitle><emphasis>Borrelia. Ticks Tick Borne Dis</emphasis></citetitle> <emphasis role="strong">11:</emphasis>101335.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Oppler ZJ, O’Keeffe KR, McCoy KD, Brisson D.</emphasis> 2021. Evolutionary genetics of <citetitle><emphasis>Borrelia. Curr Issues Mol Biol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>97–112.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Barbour AG, Gupta RS.</emphasis> 2021. The family <citetitle><emphasis>Borreliaceae</emphasis></citetitle> (<citetitle><emphasis>Spirochaetales</emphasis></citetitle>), a diverse group in two genera of tick-borne spirochetes of mammals, birds, and reptiles. <citetitle><emphasis>J Med Entomol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>1513–1524.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Krieg NR, Staley JT, Brown DR, Hedlund BP, Paster BJ, Ward NL, Ludwig W, Whitman WB (ed).</emphasis> 2011. <citetitle><emphasis>The Bacteroidetes, Spirochaetes, Tenericutes (Mollicutes), Acidobacteria, Fibrobacteres, Fusobacteria, Dictyoglomi, Gemmatimonadetes, Lentisphaerae, Verrucomicrobia, Chlamydiae, and Planctomycetes</emphasis></citetitle>, 2nd ed, vol 4. Springer, New York, NY.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Gupta RS, Mahmood S, Adeolu M.</emphasis> 2013. A phylogenomic and molecular signature based approach for characterization of the phylum <citetitle><emphasis>Spirochaetes</emphasis></citetitle> and its major clades: proposal for a taxonomic revision of the phylum. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">4:</emphasis>217.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Adeolu M, Gupta RS.</emphasis> 2014. A phylogenomic and molecular marker based proposal for the division of the genus <citetitle><emphasis>Borrelia</emphasis></citetitle> into two genera: the emended genus <citetitle><emphasis>Borrelia</emphasis></citetitle> containing only the members of the relapsing fever <citetitle><emphasis>Borrelia</emphasis></citetitle>, and the genus <citetitle><emphasis>Borreliella</emphasis></citetitle> gen. nov. containing the members of the Lyme disease <citetitle><emphasis>Borrelia</emphasis></citetitle> (<citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> complex). <citetitle><emphasis>Antonie van Leeuwenhoek</emphasis></citetitle> <emphasis role="strong">105:</emphasis>1049–1072.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Margos G, Castillo-Ramirez S, Cutler S, Dessau RB, Eikeland R, Estrada-Peña A, Gofton A, Graña-Miraglia L, Hunfeld KP, Krause A, Lienhard R, Lindgren PE, Oskam C, Rudolf I, Schwartz I, Sing A, Stevenson B, Wormser GP, Fingerle V.</emphasis> 2020. Rejection of the name <citetitle><emphasis>Borreliella</emphasis></citetitle> and all proposed species comb. nov. placed therein. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">70:</emphasis>3577–3581.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Estrada-Peña A, Cabezas-Cruz A.</emphasis> 2019. Phyloproteomic and functional analyses do not support a split in the genus <citetitle><emphasis>Borrelia</emphasis></citetitle> (phylum <citetitle><emphasis>Spirochaetes</emphasis></citetitle>). <citetitle><emphasis>BMC Evol Biol</emphasis></citetitle> <emphasis role="strong">19:</emphasis>54.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Margos G, Gofton A, Wibberg D, Dangel A, Marosevic D, Loh SM, Oskam C, Fingerle V.</emphasis> 2018. The genus <citetitle><emphasis>Borrelia</emphasis></citetitle> reloaded. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">13</emphasis><emphasis role="strong">:</emphasis>e0208432.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Schwartz I, Margos G, Casjens SR, Qiu WG, Eggers CH.</emphasis> 2021. Multipartite genome of Lyme disease <citetitle><emphasis>Borrelia</emphasis></citetitle>: structure, variation and prophages. <citetitle><emphasis>Curr Issues Mol Biol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>409–454.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, Mead PS.</emphasis> 2016. <citetitle><emphasis>Lyme borreliosis. Nat Rev Dis Primers</emphasis></citetitle> <emphasis role="strong">2:</emphasis>16090.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Stanek G, Wormser GP, Gray J, Strle F.</emphasis> 2012. Lyme borreliosis. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">379:</emphasis>461–473.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Stanek G, Reiter M.</emphasis> 2011. The expanding Lyme <citetitle><emphasis>Borrelia</emphasis></citetitle> complex—clinical significance of genomic species? <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">17:</emphasis>487–493.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Margos G, Wilske B, Sing A, Hizo-Teufel C, Cao WC, Chu C, Scholz H, Straubinger RK, Fingerle V.</emphasis> 2013. <citetitle><emphasis>Borrelia bavariensis</emphasis></citetitle> sp. nov. is widely distributed in Europe and Asia. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">63:</emphasis>4284–4288.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Golovchenko M, Vancová M, Clark K, Oliver JH Jr, Grubhoffer L, Rudenko N.</emphasis> 2016. A divergent spirochete strain isolated from a resident of the southeastern United States was identified by multilocus sequence typing as <citetitle><emphasis>Borrelia bissettii. Parasit Vectors</emphasis></citetitle> <emphasis role="strong">9:</emphasis>68–72.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0022" role="bibliographyEntry">
            <anchor id="ch0079s0024s0003a0003"/>
            <para>22.<emphasis role="strong">Kingry LC, Batra D, Replogle A, Rowe LA, Pritt BS, Petersen JM.</emphasis> 2016. Whole genome sequence and comparative genomics of the novel Lyme borreliosis causing pathogen, <citetitle><emphasis>Borrelia mayonii. PLoS One</emphasis></citetitle> <emphasis role="strong">11</emphasis><emphasis role="strong">:</emphasis>e0168994.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Barbour AG, Hayes SF.</emphasis> 1986. Biology of <citetitle><emphasis>Borrelia</emphasis></citetitle> species. <citetitle><emphasis>Microbiol Rev</emphasis></citetitle> <emphasis role="strong">50:</emphasis>381–400.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Cutler SJ, Moss J, Fukunaga M, Wright DJM, Fekade D, Warrell D.</emphasis> 1997. <citetitle><emphasis>Borrelia recurrentis</emphasis></citetitle> characterization and comparison with relapsing-fever, Lyme-associated, and other <citetitle><emphasis>Borrelia</emphasis></citetitle> spp. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>958–968.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Fraser CM, Casjens S, Huang WM, Sutton GG, Clayton R, Lathigra R, White O, Ketchum KA, Dodson R, Hickey EK, Gwinn M, Dougherty B, Tomb JF, Fleischmann RD, Richardson D, Peterson J, Kerlavage AR, Quackenbush J, Salzberg S, Hanson M, van Vugt R, Palmer N, Adams MD, Gocayne J, Weidman J, Utterback T, Watthey L, McDonald L, Artiach P, Bowman C, Garland S, Fuji C, Cotton MD, Horst K, Roberts K, Hatch B, Smith HO, Venter JC.</emphasis> 1997. Genomic sequence of a Lyme disease spirochaete, <citetitle><emphasis>Borrelia burgdorferi. Nature</emphasis></citetitle> <emphasis role="strong">390:</emphasis>580–586.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Casjens S, Palmer N, van Vugt R, Huang WM, Stevenson B, Rosa P, Lathigra R, Sutton G, Peterson J, Dodson RJ, Haft D, Hickey E, Gwinn M, White O, Fraser CM.</emphasis> 2000. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete <citetitle><emphasis>Borrelia burgdorferi. Mol Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>490–516.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Casjens SR, Mongodin EF, Qiu WG, Luft BJ, Schutzer SE, Gilcrease EB, Huang WM, Vujadinovic M, Aron JK, Vargas LC, Freeman S, Radune D, Weidman JF, Dimitrov GI, Khouri HM, Sosa JE, Halpin RA, Dunn JJ, Fraser CM.</emphasis> 2012. Genome stability of Lyme disease spirochetes: comparative genomics of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> plasmids. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e33280.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Barbour AG.</emphasis> 2014. Phylogeny of a relapsing fever <citetitle><emphasis>Borrelia</emphasis></citetitle> species transmitted by the hard tick <citetitle><emphasis>Ixodes scapularis. Infect Genet Evol</emphasis></citetitle> <emphasis role="strong">27:</emphasis>551–558.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Chaconas G, Kobryn K.</emphasis> 2010. Structure, function, and evolution of linear replicons in <citetitle><emphasis>Borrelia. Annu Rev Microbiol</emphasis></citetitle> <emphasis role="strong">64:</emphasis>185–202.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Xu Y, Johnson RC.</emphasis> 1995. Analysis and comparison of plasmid profiles of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> strains. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>2679–2685.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Lescot M, Audic S, Robert C, Nguyen TT, Blanc G, Cutler SJ, Wincker P, Couloux A, Claverie JM, Raoult D, Drancourt M.</emphasis> 2008. The genome of <citetitle><emphasis>Borrelia recurrentis</emphasis></citetitle>, the agent of deadly louse-borne relapsing fever, is a degraded subset of tick-borne <citetitle><emphasis>Borrelia duttonii. PLoS Genet</emphasis></citetitle> <emphasis role="strong">4</emphasis><emphasis role="strong">:</emphasis>e1000185.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Elbir H, Abi-Rached L, Pontarotti P, Yoosuf N, Drancourt M.</emphasis> 2014. African relapsing fever borreliae genomospecies revealed by comparative genomics. <citetitle><emphasis>Front Public Health</emphasis></citetitle> <emphasis role="strong">2:</emphasis>43.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Ojaimi C, Brooks C, Casjens S, Rosa P, Elias A, Barbour A, Jasinskas A, Benach J, Katona L, Radolf J, Caimano M, Skare J, Swingle K, Akins D, Schwartz I.</emphasis> 2003. Profiling of temperature-induced changes in <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> gene expression by using whole genome arrays. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">71:</emphasis>1689–1705.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Jauris-Heipke S, Liegl G, Preac-Mursic V, Rössler D, Schwab E, Soutschek E, Will G, Wilske B.</emphasis> 1995. Molecular analysis of genes encoding outer surface protein C (OspC) of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle>: relationship to <citetitle><emphasis>ospA</emphasis></citetitle> genotype and evidence of lateral gene exchange of <citetitle><emphasis>ospC. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1860–1866.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Zhang JR, Hardham JM, Barbour AG, Norris SJ.</emphasis> 1997. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. <citetitle><emphasis>Cell</emphasis></citetitle> <emphasis role="strong">89:</emphasis>275–285.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Warrell DA.</emphasis> 2019. Louse-borne relapsing fever (<citetitle><emphasis>Borrelia recurrentis</emphasis></citetitle> infection). <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">147:</emphasis>e106.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Bryceson AD, Parry EH, Perine PL, Warrell DA, Vukotich D, Leithead CS.</emphasis> 1970. Louse-borne relapsing fever. <citetitle><emphasis>Q J Med</emphasis></citetitle> <emphasis role="strong">39:</emphasis>129–170.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Antinori S, Mediannikov O, Corbellino M, Raoult D.</emphasis> 2016. Louse-borne relapsing fever among East African refugees in Europe. <citetitle><emphasis>Travel Med Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>110–114.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Rebaudet S</emphasis>, <emphasis role="strong">Parola P.</emphasis> 2006. Epidemiology of relapsing fever borreliosis in Europe. <citetitle><emphasis>FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>11–15.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Fukunaga M, Sohnaka M, Takahashi Y, Nakao M, Miyamoto K.</emphasis> 1993. Antigenic and genetic characterization of <citetitle><emphasis>Borrelia</emphasis></citetitle> species isolated from <citetitle><emphasis>Ixodes persulcatus</emphasis></citetitle> in Hokkaido, Japan. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>1388–1391.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Hovius JW, de Wever B, Sohne M, Brouwer MC, Coumou J, Wagemakers A, Oei A, Knol H, Narasimhan S, Hodiamont CJ, Jahfari S, Pals ST, Horlings HM, Fikrig E, Sprong H, van Oers MH.</emphasis> 2013. A case of meningoencephalitis by the relapsing fever spirochaete <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> in Europe. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">382:</emphasis>658.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Chowdri HR, Gugliotta JL, Berardi VP, Goethert HK, Molloy PJ, Sterling SL, Telford SR.</emphasis> 2013. <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> infection presenting as human granulocytic anaplasmosis: a case report. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">159:</emphasis>21–27.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Sato K, Takano A, Konnai S, Nakao M, Ito T, Koyama K, Kaneko M, Ohnishi M, Kawabata H.</emphasis> 2014. Human infections with <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle>, Japan. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1391–1393.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Molloy PJ, Telford SR III, Chowdri HR, Lepore TJ, Gugliotta JL, Weeks KE, Hewins ME, Goethert HK, Berardi VP.</emphasis> 2015. <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> disease in the northeastern United States: a case series. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">163:</emphasis>91–98.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Varela AS, Luttrell MP, Howerth EW, Moore VA, Davidson WR, Stallknecht DE, Little SE.</emphasis> 2004. First culture isolation of <citetitle><emphasis>Borrelia lonestari</emphasis></citetitle>, putative agent of southern tick-associated rash illness. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1163–1169.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Hinnebusch BJ, Barbour AG, Restrepo BI, Schwan TG.</emphasis> 1998. Population structure of the relapsing fever spirochete <citetitle><emphasis>Borrelia hermsii</emphasis></citetitle> as indicated by polymorphism of two multigene families that encode immunogenic outer surface lipoproteins. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">66:</emphasis>432–440.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Mead PS.</emphasis> 2015. Epidemiology of Lyme disease. <citetitle><emphasis>Infect Dis Clin North Am</emphasis></citetitle> <emphasis role="strong">29:</emphasis>187–210.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Stanek G, Strle F.</emphasis> 2018. Lyme borreliosis-from tick bite to diagnosis and treatment. <citetitle><emphasis>FEMS Microbiol Rev</emphasis></citetitle> <emphasis role="strong">42:</emphasis>233–258.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Picken RN, Cheng Y, Strle F, Picken MM.</emphasis> 1996. Patient isolates of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> with genotypic and phenotypic similarities of strain 25015. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">174:</emphasis>1112–1115.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Collares-Pereira M, Couceiro S, Franca I, Kurtenbach K, Schäfer SM, Vitorino L, Gonçalves L, Baptista S, Vieira ML, Cunha C.</emphasis> 2004. First isolation of <citetitle><emphasis>Borrelia lusitaniae</emphasis></citetitle> from a human patient. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1316–1318.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Vollmer SA, Feil EJ, Chu CY, Raper SL, Cao WC, Kurtenbach K, Margos G.</emphasis> 2013. Spatial spread and demographic expansion of Lyme borreliosis spirochaetes in Eurasia. <citetitle><emphasis>Infect Genet Evol</emphasis></citetitle> <emphasis role="strong">14:</emphasis>147–155.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Gatzmann F, Metzler D, Krebs S, Blum H, Sing A, Takano A, Kawabata H, Fingerle V, Margos G, Becker NS.</emphasis> 2015. NGS population genetics analyses reveal divergent evolution of a Lyme borreliosis agent in Europe and Asia. <citetitle><emphasis>Ticks Tick Borne Dis</emphasis></citetitle> <emphasis role="strong">6:</emphasis>344–351.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Margos G, Fedorova N, Becker NS, Kleinjan JE, Marosevic D, Krebs S, Hui L, Fingerle V, Lane RS.</emphasis> 2020. <citetitle><emphasis>Borrelia maritima</emphasis></citetitle> sp. nov., a novel species of the <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> complex, occupying a basal position to North American species. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">70:</emphasis>849–856.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Ivanova LB, Tomova A, González-Acuña D, Murúa R, Moreno CX, Hernández C, Cabello J, Cabello C, Daniels TJ, Godfrey HP, Cabello FC.</emphasis> 2014. <citetitle><emphasis>Borrelia chilensis</emphasis></citetitle>, a new member of the <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> complex that extends the range of this genospecies in the Southern Hemisphere. <citetitle><emphasis>Environ Microbiol</emphasis></citetitle> <emphasis role="strong">16:</emphasis>1069–1080.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Elbir H, Raoult D, Drancourt M.</emphasis> 2013. Relapsing fever borreliae in Africa. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">89:</emphasis>288–292.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Cutler SJ.</emphasis> 2006. Possibilities for relapsing fever reemergence. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>369–374.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Dworkin MS, Schwan TG, Anderson DE Jr, Borchardt SM.</emphasis> 2008. Tick-borne relapsing fever. <citetitle><emphasis>Infect Dis Clin North Am</emphasis></citetitle> <emphasis role="strong">22:</emphasis>449–468, viii.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Cutler SJ.</emphasis> 2010. Relapsing fever—a forgotten disease revealed. <citetitle><emphasis>J Appl Microbiol</emphasis></citetitle> <emphasis role="strong">108:</emphasis>1115–1122.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Trape JF, Diatta G, Arnathau C, Bitam I, Sarih M, Belghyti D, Bouattour A, Elguero E, Vial L, Mané Y, Baldé C, Prugnolle F, Chauvancy G, Mahé G, Granjon L, Duplantier JM, Durand P, Renaud F.</emphasis> 2013. The epidemiology and geographic distribution of relapsing fever borreliosis in West and North Africa, with a review of the <citetitle><emphasis>Ornithodoros erraticus</emphasis></citetitle> complex (Acari: Ixodida). <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e78473.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Forrester JD, Kjemtrup AM, Fritz CL, Marsden-Haug N, Nichols JB, Tengelsen LA, Sowadsky R, DeBess E, Cieslak PR, Weiss J, Evert N, Ettestad P, Smelser C, Iralu J, Nett RJ, Mosher E, Baker JS, Van Houten C, Thorp E, Geissler AL, Kugeler K, Mead P, Centers for Disease Control and Prevention (CDC).</emphasis> 2015. Tickborne relapsing fever - United States, 1990-2011. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">64:</emphasis>58–60.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Jones JM, Hranac CR, Schumacher M, Horn K, Lee DM, Terriquez J, Engelthaler DM, Peoples M, Corrigan J, Replogle A, Souders N, Komatsu KK, Nieto NC.</emphasis> 2016. Tick-borne relapsing fever outbreak among a high school football team at an outdoor education camping trip, Arizona, 2014. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">95:</emphasis>546–550.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Gaither M, Schumacher M, Nieto N, Corrigan J, Murray H, Maurer M.</emphasis> 2016. Where are the ticks? Solving the mystery of a tickborne relapsing fever outbreak at a youth camp. <citetitle><emphasis>J Environ Health</emphasis></citetitle> <emphasis role="strong">78:</emphasis>8–11.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Mafi N, Yaglom HD, Levy C, Taylor A, O’Grady C, Venkat H, Komatsu KK, Roller B, Seville MT, Kusne S, Po JL, Thorn S, Ampel NM.</emphasis> 2019. Tick-borne relapsing fever in the White Mountains, Arizona, USA, 2013-2018. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">25:</emphasis>649–653.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0064" role="bibliographyEntry">
            <anchor id="ch0079s0024s0003a0004"/>
            <para>64.<emphasis role="strong">Bechtel MJ, Drake KK, Esque TC, Nieto NC, Foster JT, Teglas MB.</emphasis> 2021. Borreliosis transmission from ticks associated with desert tortoise burrows: examples of tick-borne relapsing fever in the Mojave Desert. <citetitle><emphasis>Vector Borne Zoonotic Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>635–637.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Bissett JD, Ledet S, Krishnavajhala A, Armstrong BA, Klioueva A, Sexton C, Replogle A, Schriefer ME, Lopez JE.</emphasis> 2018. Detection of tickborne relapsing fever spirochete, Austin, Texas, USA. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>2003–2009.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Saldaña MP, Nieto RE, Espejo EG.</emphasis> 2017. Relapsing fever epidemiology in Spain according to hospitalization-based records, 2004-2013. <citetitle><emphasis>J Fever</emphasis></citetitle> <emphasis role="strong">1:</emphasis>1004.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Nunes M, Parreira R, Maia C, Lopes N, Fingerle V, Vieira ML.</emphasis> 2016. Molecular identification of <citetitle><emphasis>Borrelia</emphasis></citetitle> genus in questing hard ticks from Portugal: phylogenetic characterization of two novel relapsing fever-like <citetitle><emphasis>Borrelia</emphasis></citetitle> sp. <citetitle><emphasis>Infect Genet Evol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>266–274.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Cutler SJ.</emphasis> 2015. Relapsing fever borreliae: a global review. <citetitle><emphasis>Clin Lab Med</emphasis></citetitle> <emphasis role="strong">35:</emphasis>847–865.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Cutler SJ, Abdissa A, Trape JF.</emphasis> 2009. New concepts for the old challenge of African relapsing fever borreliosis. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">15:</emphasis>400–406.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Assous MV, Wilamowski A.</emphasis> 2009. Relapsing fever borreliosis in Eurasia—forgotten, but certainly not gone! <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">15:</emphasis>407–414.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Krause PJ, Fish D, Narasimhan S, Barbour AG.</emphasis> 2015. <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> infection in nature and in humans. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">21:</emphasis>631–639.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Takano A, Goka K, Une Y, Shimada Y, Fujita H, Shiino T, Watanabe H, Kawabata H.</emphasis> 2010. Isolation and characterization of a novel <citetitle><emphasis>Borrelia</emphasis></citetitle> group of tick-borne borreliae from imported reptiles and their associated ticks. <citetitle><emphasis>Environ Microbiol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>134–146.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Fukunaga M, Takahashi Y, Tsuruta Y, Matsushita O, Ralph D, McClelland M, Nakao M.</emphasis> 1995. Genetic and phenotypic analysis of <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> sp. nov., isolated from the ixodid tick <citetitle><emphasis>Ixodes persulcatus</emphasis></citetitle>, the vector for Lyme disease in Japan. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>804–810.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Kubiak K, Szczotko M, Dmitryjuk M.</emphasis> 2021. <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle>—an emerging human tick-borne pathogen in Europe. <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">9:</emphasis>154.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Hoch M, Wieser A, Löscher T, Margos G, Pürner F, Zühl J, Seilmaier M, Balzer L, Guggemos W, Rack-Hoch A,</emphasis> von <emphasis role="strong">Both U, Hauptvogel K, Schönberger K, Hautmann W, Sing A, Fingerle V.</emphasis> 2015. Louse-borne relapsing fever (<citetitle><emphasis>Borrelia recurrentis</emphasis></citetitle>) diagnosed in 15 refugees from northeast Africa: epidemiology and preventive control measures, Bavaria, Germany, July to October 2015. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">20</emphasis>.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Brouqui P, Stein A, Dupont HT, Gallian P, Badiaga S, Rolain JM, Mege JL, La Scola B, Berbis P, Raoult D.</emphasis> 2005. Ectoparasitism and vector-borne diseases in 930 homeless people from Marseilles. <citetitle><emphasis>Medicine (Baltimore)</emphasis></citetitle> <emphasis role="strong">84:</emphasis>61–68.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Adams DA, Thomas KR, Jajosky RA, Foster L, Sharpt P, Ohweh DH, Schley AW, Anderson WJ, Nationally Notifiable Infectious Conditions Group.</emphasis> 2016. Summary of notifiable infectious diseases and conditions – United States. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">63:</emphasis>1–152.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2019. Lyme data surveillance. <ulink url="https://www.cdc.gov/lyme/stats/survfaq.html">https://www.cdc.gov/lyme/stats/survfaq.html</ulink>. Accessed 10 May 2022.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Müller I, Freitag MH, Poggensee G, Scharnetzky E, Straube E, Schoerner C, Hlobil H, Hagedorn HJ, Stanek G, Schubert-Unkmeir A, Norris DE, Gensichen J, Hunfeld K-P.</emphasis> 2012. Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: a retrospective model analysis. <citetitle><emphasis>Clin Dev Immunol</emphasis></citetitle> <emphasis role="strong">2012:</emphasis>595427.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Fingerle V, Bergmeister H, Liegl G, Vanek E, Wilske B.</emphasis> 1994. Prevalence of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> in <citetitle><emphasis>Ixodes ricinus</emphasis></citetitle> in southern Germany. <citetitle><emphasis>J Spirochetal Tick-Borne Di</emphasis></citetitle><citetitle><emphasis>s</emphasis></citetitle> <emphasis role="strong">1:</emphasis>41–45.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Rauter C, Hartung T.</emphasis> 2005. Prevalence of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> genospecies in <citetitle><emphasis>Ixodes ricinus</emphasis></citetitle> ticks in Europe: a metaanalysis. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">71:</emphasis>7203–7216.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Schötta AM, Wijnveld M, Stockinger H, Stanek G.</emphasis> 2017. Approaches for reverse line blot-based detection of microbial pathogens in <citetitle><emphasis>Ixodes ricinus</emphasis></citetitle> ticks collected in Austria and impact of the chosen method. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">83:</emphasis>e00489–17.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Kingry LC, Anacker M, Pritt B, Bjork J, Respicio-Kingry L, Liu G, Sheldon S, Boxrud D, Strain A, Oatman S, Berry J, Sloan L, Mead P, Neitzel D, Kugeler KJ, Peter JM.</emphasis> 2018. Surveillance for and discovery of <citetitle><emphasis>Borrelia</emphasis></citetitle> species in US patients suspected of tickborne illness. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1864–1871.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Stanek G, Wewalka G, Groh V, Neumann R, Kristoferitsch W.</emphasis> 1985. Differences between Lyme disease and European arthropod-borne <citetitle><emphasis>Borrelia</emphasis></citetitle> infections. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">i:</emphasis>401.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Wilske B, Preac-Mursic V, Schierz G.</emphasis> 1985. Antigenic heterogeneity of European <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> strains isolated from patients and ticks. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">i:</emphasis>1099.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Wilske B, Preac-Mursic V, Göbel UB, Graf B, Jauris S, Soutschek E, Schwab E, Zumstein G.</emphasis> 1993. An OspA serotyping system for <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> based on reactivity with monoclonal antibodies and OspA sequence analysis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>340–350.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Wolcott KA, Margos G, Fingerle V, Becker NS.</emphasis> 2021. Host association of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle>: a review. <citetitle><emphasis>Ticks Tick Borne Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>101766.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Cerar T, Strle F, Stupica D, Ruzic-Sabljic E, McHugh G, Steere AC, Strle K.</emphasis> 2016. Differences in genotype, clinical features, and inflammatory potential of <citetitle><emphasis>Borrelia burgdorferi sensu stricto</emphasis></citetitle> strains from Europe and the United States. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>818–827.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Lopez J, Hovius JW, Bergström S.</emphasis> 2021. Pathogenesis of relapsing fever. <citetitle><emphasis>Curr Issues Mol Biol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>519–550.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Keller C, Zumblick M, Streubel K, Eickmann M, Müller D, Kerwat M, Becker S, Gress T.</emphasis> 2016. Hemorrhagic diathesis in <citetitle><emphasis>Borrelia recurrentis</emphasis></citetitle> infection imported to Germany. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>917–919.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Diallo MA, Kane BS, Ndiaye M, Dieng M, Diongue K, Badiane AS, Seck MC, Ndiaye D.</emphasis> 2017. <citetitle><emphasis>Plasmodium falciparum</emphasis></citetitle> malaria co-infection with tick-borne relapsing fever in Dakar. <citetitle><emphasis>Malar J</emphasis></citetitle> <emphasis role="strong">16:</emphasis>24.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Henningsson AJ, Asgeirsson H, Hammas B, Karlsson E, Parke Å, Hoornstra D, Wilhelmsson P, Hovius JW.</emphasis> 2019. Two cases of <citetitle><emphasis>Borrelia miyamoto</emphasis></citetitle>i meningitis, Sweden, 2018. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">25:</emphasis>1965–1968.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Marcos LA, Smith K, Reardon K, Weinbaum F, Spitzer ED.</emphasis> 2020. Presence of <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> infection in a highly endemic area of Lyme disease. <citetitle><emphasis>Ann Clin Microbiol Antimicrob</emphasis></citetitle> <emphasis role="strong">19:</emphasis>22.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Masters EJ, Grigery CN, Masters RW.</emphasis> 2008. STARI, or Masters disease: lone star tick-vectored Lyme-like illness. <citetitle><emphasis>Infect Dis Clin North Am</emphasis></citetitle> <emphasis role="strong">22:</emphasis>361–376, viii.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ Jr, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Cody Meissner H, Nigrovic LE, Nocton JJJ, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS.</emphasis> 2021. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. <citetitle><emphasis>Arthritis Rheumatol</emphasis></citetitle> <emphasis role="strong">73:</emphasis>12–20.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Stanek G, Fingerle V, Hunfeld K-P, Jaulhac B, Kaiser R, Krause A, Kristoferitsch W, O’Connell S, Ornstein K, Strle F, Gray J.</emphasis> 2011. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">17:</emphasis>69–79.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Marques AR, Strle F, Wormser GP.</emphasis> 2021. Comparison of Lyme disease in the United States and Europe. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>2017–2024.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Ogrinc K, Kastrin A, Lotric-Furlan S, Bogovic P, Rojko T, Maraspin V, Ruzic-Sabljic E, Strle K, Strle F.</emphasis> 2021. Colocalization of radicular pain and erythema migrans in patients with Bannwarth syndrome suggests a direct spread of <citetitle><emphasis>Borrelia</emphasis></citetitle> into the central nervous system. <citetitle><emphasis>Clin Infect Dist</emphasis></citetitle> <emphasis role="strong">75:</emphasis>81–87.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0099" role="bibliographyEntry">
            <anchor id="ch0079s0024s0003a0005"/>
            <para>99.<emphasis role="strong">Maraspin V, Bogovič P, Ogrinc K, Rojko T, Ružić-Sabljić E, Kastrin A, Strle K, Wormser GP, Strle F.</emphasis> 2021. Are differences in presentation of early Lyme borreliosis in Europe and North America a consequence of a more frequent spirochetemia in American patients? <citetitle><emphasis>J Clin Med</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1448.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Halperin JJ.</emphasis> 2015. Nervous system Lyme disease. <citetitle><emphasis>Clin Lab Med</emphasis></citetitle> <emphasis role="strong">35:</emphasis>779–795.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Hanincova K, Mukherjee P, Ogden NH, Margos G, Wormser GP, Reed KD, Meece JK, Vandermause MF, Schwartz I.</emphasis> 2013. Multilocus sequence typing of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> suggests existence of lineages with differential pathogenic properties in humans. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e73066.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Glatz M, Resinger A, Semmelweis K, Ambros-Rudolph CM, Müllegger RR.</emphasis> 2015. Clinical spectrum of skin manifestations of Lyme borreliosis in 204 children in Austria. <citetitle><emphasis>Acta Derm Venereol</emphasis></citetitle> <emphasis role="strong">95:</emphasis>565–571.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Müllegger RR, Glatz M.</emphasis> 2008. Skin manifestations of Lyme borreliosis: diagnosis and management. <citetitle><emphasis>Am J Clin Dermatol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>355–368.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Herzer P, Wilske B, Preac-Mursic V, Schierz G, Schattenkirchner M, Zöllner N.</emphasis> 1986. Lyme arthritis: clinical features, serological, and radiographic findings of cases in Germany. <citetitle><emphasis>Klin Wochenschr</emphasis></citetitle> <emphasis role="strong">64:</emphasis>206–215.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Halperin JJ, Krupp LB, Golightly MG, Volkman DJ.</emphasis> 1990. Lyme borreliosis-associated encephalopathy. <citetitle><emphasis>Neurology</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1340–1343.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Hansen K, Crone C, Kristoferitsch W.</emphasis> 2013. Lyme neuroborreliosis. <citetitle><emphasis>In</emphasis></citetitle> Said G, Krarup C (ed), <citetitle><emphasis>Handbook of Clinical Neurology</emphasis></citetitle>, vol 115. Elsevier BV, Amsterdam, The Netherlands.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Ogrinc K, Lusa L, Lotrič-Furlan S, Bogovi</emphasis>č <emphasis role="strong">P, Stupica D, Cerar T, Ružić-Sabljić E, Strle F.</emphasis> 2016. Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): clinical and laboratory findings. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>346–353.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Cetin E, Sotoudeh M, Auer H, Stanek G.</emphasis> 2006. Paradigm Burgenland: risk of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> infection indicated by variable seroprevalence rates in hunters. <citetitle><emphasis>Wien Klin Wochenschr</emphasis></citetitle> <emphasis role="strong">118:</emphasis>677–681.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A.</emphasis> 2001. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">345:</emphasis>85–92.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA.</emphasis> 2008. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. <citetitle><emphasis>Neurology</emphasis></citetitle> <emphasis role="strong">70</emphasis><emphasis role="strong">:</emphasis>992–1003.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Feder HM Jr, Johnson BJ, O’Connell S, Shapiro ED, Steere AC, Wormser GP, Agger WA, Artsob H, Auwaerter P, Dumler JS, Bakken JS, Bockenstedt LK, Green J, Dattwyler RJ, Munoz J, Nadelman RB, Schwartz I, Draper T, McSweegan E, Halperin JJ, Klempner MS, Krause PJ, Mead P, Morshed M, Porwancher R, Radolf JD, Smith RP Jr, Sood S, Weinstein A, Wong SJ, Zemel L, Ad Hoc International Lyme Disease Group.</emphasis> 2007. A critical appraisal of “chronic Lyme disease”. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">357:</emphasis>1422–1430.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP.</emphasis> 2005. Diagnosis of Lyme borreliosis. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">18:</emphasis>484–509.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Branda JA, Steere AC.</emphasis> 2021. Laboratory diagnosis of Lyme borreliosis. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">34:</emphasis>e00018–19.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Wormser GP, Bittker S, Cooper D, Nowakowski J, Nadelman RB, Pavia C.</emphasis> 2001. Yield of large-volume blood cultures in patients with early Lyme disease. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">184:</emphasis>1070–1072.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Marques AR, Yang X, Smith AA, Zhuang X, Turk S-P, Williams CD, Law MA, Barbour AG, Pal U.</emphasis> 2017. Citrate anticoagulant improves the sensitivity of <citetitle><emphasis>Borreliella</emphasis></citetitle> (<citetitle><emphasis>Borrelia</emphasis></citetitle>) <citetitle><emphasis>burgdorferi</emphasis></citetitle> plasma culture. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>3297–3299.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Theel ES, Aguero-Rosenfeld ME, Pritt B, Adem PV, Wormser GP.</emphasis> 2019. Limitations and confusing aspects of diagnostic testing for neurologic Lyme disease in the United States. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e01406–18.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Fotso Fotso A, Drancourt M.</emphasis> 2015. Laboratory diagnosis of tick-borne African relapsing fevers: latest developments. <citetitle><emphasis>Front Public Health</emphasis></citetitle> <emphasis role="strong">3:</emphasis>254.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">van Dam AP, van Gool T, Wetsteyn JC, Dankert J.</emphasis> 1999. Tick-borne relapsing fever imported from West Africa: diagnosis by quantitative buffy coat analysis and in vitro culture of <citetitle><emphasis>Borrelia crocidurae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>2027–2030.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Aberer E, Duray PH.</emphasis> 1991. Morphology of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle>: structural patterns of cultured borreliae in relation to staining methods. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">29:</emphasis>764–772.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Fritz CL, Bronson LR, Smith CR, Schriefer ME, Tucker JR, Schwan TG.</emphasis> 2004. Isolation and characterization of <citetitle><emphasis>Borrelia hermsii</emphasis></citetitle> associated with two foci of tick-borne relapsing fever in California. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1123–1128.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Anda P, Sánchez-Yebra W, del Mar Vitutia M, Pérez Pastrana E, Rodríguez I, Miller NS, Backenson PB, Benach JL.</emphasis> 1996. A new <citetitle><emphasis>Borrelia</emphasis></citetitle> species isolated from patients with relapsing fever in Spain. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">348:</emphasis>162–165.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Koetsveld J, Kolyasnikova NM, Wagemakers A, Toporkova MG, Sarksyan DS, Oei A, Platonov AE, Hovius JW.</emphasis> 2017. Development and optimization of an in vitro cultivation protocol allows for isolation of <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> from patients with hard tick-borne relapsing fever. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">23:</emphasis>480–484.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Replogle AJ, Sexton C, Young J, Kingry LC, Schriefer ME, Dolan M, Johnson TL, Connally NP, Padgett KA, Petersen JM.</emphasis> 2021. Isolation of <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> and other borreliae using a modified BSK medium. <citetitle><emphasis>Sci Rep</emphasis></citetitle> <emphasis role="strong">11:</emphasis>1926.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Cutler SJ, Akintunde CO, Moss J, Fukunaga M, Kurtenbach K, Talbert A, Zhang H, Wright DJ, Warrell DA.</emphasis> 1999. Successful in vitro cultivation of <citetitle><emphasis>Borrelia duttonii</emphasis></citetitle> and its comparison with <citetitle><emphasis>Borrelia recurrentis. Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1793–1799.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Barbour AG.</emphasis> 1984. Isolation and cultivation of Lyme disease spirochetes. <citetitle><emphasis>Yale J Biol Med</emphasis></citetitle> <emphasis role="strong">57:</emphasis>521–525.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Preac-Mursic V, Wilske B, Reinhardt S.</emphasis> 1991. Culture of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> on six solid media. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1076–1079.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Ružić-Sabljić E, Maraspin V, Stupica D, Rojko T, Bogovi</emphasis>č <emphasis role="strong">P, Strle F, Cerar T.</emphasis> 2017. Comparison of MKP and BSK-H media for the cultivation and isolation of <citetitle><emphasis>Borrelia burgdorferi sensu lato. PLoS One</emphasis></citetitle> <emphasis role="strong">12</emphasis><emphasis role="strong">:</emphasis>e0171622.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Richter D, Postic D, Sertour N, Livey I, Matuschka FR, Baranton G.</emphasis> 2006. Delineation of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> species by multilocus sequence analysis and confirmation of the delineation of <citetitle><emphasis>Borrelia spielmanii</emphasis></citetitle> sp. nov. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>873–881.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Margos G, Vollmer SA, Cornet M, Garnier M, Fingerle V, Wilske B, Bormane A, Vitorino L, Collares-Pereira M, Drancourt M, Kurtenbach K.</emphasis> 2009. A new <citetitle><emphasis>Borrelia</emphasis></citetitle> species defined by multilocus sequence analysis of housekeeping genes. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">75:</emphasis>5410–5416.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Berger BW, Johnson RC, Kodner C, Coleman L.</emphasis> 1992. Cultivation of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> from erythema migrans lesions and perilesional skin. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>359–361.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Ogrinc K, Maraspin V, Lusa L, Cerar Kišek T, Ružić-Sabljić E, Strle F.</emphasis> 2021. Acrodermatitis chronica atrophicans: clinical and microbiological characteristics of a cohort of 693 Slovenian patients. <citetitle><emphasis>J Intern Med</emphasis></citetitle> <emphasis role="strong">290:</emphasis>335–348.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Maraspin V, Nahtigal Klevišar M, Ružić-Sabljić E, Lusa L, Strle F.</emphasis> 2016. Borrelial lymphocytoma in adult patients. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>914–921.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Liveris D, Schwartz I, McKenna D, Nowakowski J, Nadelman R, Demarco J, Iyer R, Bittker S, Cooper D, Holmgren D, Wormser GP.</emphasis> 2012. Comparison of five diagnostic modalities for direct detection of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> in patients with early Lyme disease. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>243–245.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Ruzić-Sabljić E, Maraspin V, Lotric-Furlan S, Jurca T, Logar M, Pikelj-Pecnik A, Strle F.</emphasis> 2002. Characterization of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> strains isolated from human material in Slovenia. <citetitle><emphasis>Wien Klin Wochenschr</emphasis></citetitle> <emphasis role="strong">114:</emphasis>544–550.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Roži</emphasis>č <emphasis role="strong">M, Lah LL, Ružić-Sabljić E, Kastrin A, Arnež M.</emphasis> 2019. Lyme neuroborreliosis in children: etiology and comparison of clinical findings of Lyme neuroborreliosis caused by <citetitle><emphasis>Borrelia garinii</emphasis></citetitle> and <citetitle><emphasis>Borrelia afzelii. Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">38:</emphasis>e279–e284.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0136" role="bibliographyEntry">
            <anchor id="ch0079s0024s0003a0006"/>
            <para>136.<emphasis role="strong">Millner MM, Müllegger RR, Spork KD, Stanek G.</emphasis> 1991. Lyme borreliosis of central nervous system (CNS) in children: a diagnostic challenge. <citetitle><emphasis>Infection</emphasis></citetitle> <emphasis role="strong">19:</emphasis>273–278.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Elbir H, Henry M, Diatta G, Mediannikov O, Sokhna C, Tall A, Socolovschi C, Cutler SJ, Bilcha KD, Ali J, Campelo D, Barker SC, Raoult D, Drancourt M.</emphasis> 2013. Multiplex real-time PCR diagnostic of relapsing fevers in Africa. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e2042.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Ras NM, Lascola B, Postic D, Cutler SJ, Rodhain F, Baranton G, Raoult D.</emphasis> 1996. Phylogenesis of relapsing fever <citetitle><emphasis>Borrelia</emphasis></citetitle> spp. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>859–865.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Tobudic S, Burgmann H, Stanek G, Winkler S, Schötta AM, Obermüller M, Markowicz M, Lagler H.</emphasis> 2020. Human <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> infection, Austria. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">26:</emphasis>2201–2204.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Ružić-Sabljić E, Cerar T.</emphasis> 2017. Progress in the molecular diagnosis of Lyme disease. <citetitle><emphasis>Expert Rev Mol Diagn</emphasis></citetitle> <emphasis role="strong">17:</emphasis>19–30.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Ruzić-Sabljić E, Zore A, Strle F.</emphasis> 2008. Characterization of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> isolates by pulsed-field gel electrophoresis after MluI restriction of genomic DNA. <citetitle><emphasis>Res Microbiol</emphasis></citetitle> <emphasis role="strong">159:</emphasis>441–448.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Ferdin J, Cerar T, Strle F, Ruzić-Sabljić E.</emphasis> 2010. Evaluation of real-time PCR targeting <citetitle><emphasis>hbb</emphasis></citetitle> gene for <citetitle><emphasis>Borrelia</emphasis></citetitle> species identification. <citetitle><emphasis>J Microbiol Methods</emphasis></citetitle> <emphasis role="strong">82:</emphasis>115–119.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Stupica D, Lusa L, Maraspin V, Bogovi</emphasis>č <emphasis role="strong">P, Vidmar D, O’Rourke M, Traweger A, Livey I, Strle F.</emphasis> 2015. Correlation of culture positivity, PCR positivity, and burden of <citetitle><emphasis>Borrelia burgdorferi sensu lato</emphasis></citetitle> in skin samples of erythema migrans patients with clinical findings. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">10</emphasis><emphasis role="strong">:</emphasis>e0136600.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Eshoo MW, Crowder CC, Rebman AW, Rounds MA, Matthews HE, Picuri JM, Soloski MJ, Ecker DJ, Schutzer SE, Aucott JN.</emphasis> 2012. Direct molecular detection and genotyping of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> from whole blood of patients with early Lyme disease. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e36825.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Ornstein K, Berglund J, Bergström S, Norrby R, Barbour AG.</emphasis> 2002. Three major Lyme <citetitle><emphasis>Borrelia</emphasis></citetitle> genospecies (<citetitle><emphasis>Borrelia burgdorferi sensu stricto</emphasis></citetitle>, <citetitle><emphasis>B. afzelii</emphasis></citetitle> and <citetitle><emphasis>B. garinii</emphasis></citetitle>) identified by PCR in cerebrospinal fluid from patients with neuroborreliosis in Sweden. <citetitle><emphasis>Scand J Infect Dis</emphasis></citetitle> <emphasis role="strong">34:</emphasis>341–346.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Avery RA, Frank G, Eppes SC.</emphasis> 2005. Diagnostic utility of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> cerebrospinal fluid polymerase chain reaction in children with Lyme meningitis. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">24:</emphasis>705–708.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Corre C, Coiffier G, Le Goff B, Ferreyra M, Guennic X, Patrat-Delon S, Degeilh B, Albert J-D, Tattevin P.</emphasis> 2022. Lyme arthritis in Western Europe: a multicentre retrospective study. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>21–27.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Grillon A, Scherlinger M, Boyer P-H, De Martino S, Perdriger A, Blasquez A, Wipff J, Korganow A-S, Bonnard C, Cantagrel A, Eyer D, Guérin F, Monteiro I, Woehl J-M, Moreau P, Pennaforte J-L, Lechevallier J, Bastides F, Colombey A, Imbert I, Maugars Y, Gicquel P, Cuchet F, Brax M, Sibilia J, Zilliox L, Barthel C, Arnaud L, Jaulhac B.</emphasis> 2019. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. <citetitle><emphasis>Semin Arthritis Rheum</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1105–1112.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Schwan TG, Schrumpf ME, Hinnebusch BJ, Anderson DE Jr, Konkel ME.</emphasis> 1996. GlpQ: an antigen for serological discrimination between relapsing fever and Lyme borreliosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">34:</emphasis>2483–2492.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Krause PJ, Narasimhan S, Wormser GP, Barbour AG, Platonov AE, Brancato J, Lepore T, Dardick K, Mamula M, Rollend L, Steeves TK, Diuk-Wasser M, Usmani-Brown S, Williamson P, Sarksyan DS, Fikrig E, Fish D, Tick Borne Diseases Group.</emphasis> 2014. <citetitle><emphasis>Borrelia miyamotoi sensu lato</emphasis></citetitle> seroreactivity and seroprevalence in the northeastern United States. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1183–1190.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Reiter M, Stelzer T, Schötta AM, Markowicz M, Leschnik M, Harsch A, Reiß E, Kneusel RE, Stockinger H, Stanek G.</emphasis> 2020. Glycerophosphodiester phosphodiesterase identified as non-reliable serological marker for <citetitle><emphasis>Borrelia miyamotoi</emphasis></citetitle> disease. <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">8:</emphasis>1846.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Lopez JE, Schrumpf ME, Nagarajan V, Raffel SJ, McCoy BN, Schwan TG.</emphasis> 2010. A novel surface antigen of relapsing fever spirochetes can discriminate between relapsing fever and Lyme borreliosis. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>564–571.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Christensen AM, Pietralczyk E, Lopez JE, Brooks C, Schriefer ME, Wozniak E, Stermole B.</emphasis> 2017. Diagnosis and management of <citetitle><emphasis>Borrelia turicatae</emphasis></citetitle> infection in febrile soldier. Texas, USA. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>883–884.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Philipp MT, Masters E, Wormser GP, Hogrefe W, Martin D.</emphasis> 2006. Serologic evaluation of patients from Missouri with erythema migrans-like skin lesions with the C6 Lyme test. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">13:</emphasis>1170–1171.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Kenedy MR, Lenhart TR, Akins DR.</emphasis> 2012. The role of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> outer surface proteins. <citetitle><emphasis>FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1–19.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Aguero-Rosenfeld ME, Nowakowski J, McKenna DF, Carbonaro CA, Wormser GP.</emphasis> 1993. Serodiagnosis in early Lyme disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>3090–3095.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Craft JE, Fischer DK, Shimamoto GT, Steere AC.</emphasis> 1986. Antigens of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. <citetitle><emphasis>J Clin Invest</emphasis></citetitle> <emphasis role="strong">78:</emphasis>934–939.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Liang FT, Aberer E, Cinco M, Gern L, Hu CM, Lobet YN, Ruscio M, Voet PE Jr, Weynants VE, Philipp MT.</emphasis> 2000. Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> SL. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">182:</emphasis>1455–1462.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Liang FT, Yan J, Mbow ML, Sviat SL, Gilmore RD, Mamula M, Fikrig E.</emphasis> 2004. <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> changes its surface antigenic expression in response to host immune responses. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">72:</emphasis>5759–5767.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Bankhead T, Chaconas G.</emphasis> 2007. The role of VlsE antigenic variation in the Lyme disease spirochete: persistence through a mechanism that differs from other pathogens. <citetitle><emphasis>Mol Microbiol</emphasis></citetitle> <emphasis role="strong">65:</emphasis>1547–1558.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Lawrenz MB, Hardham JM, Owens RT, Nowakowski J, Steere AC, Wormser GP, Norris SJ.</emphasis> 1999. Human antibody responses to VlsE antigenic variation protein of <citetitle><emphasis>Borrelia burgdorferi. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>3997–4004.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Engstrom SM, Shoop E, Johnson RC.</emphasis> 1995. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>419–427.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Heikkilä T, Seppälä I, Saxén H, Panelius J, Peltomaa M, Julin T, Carlsson SA, Lahdenne P.</emphasis> 2002. Recombinant BBK32 protein in serodiagnosis of early and late Lyme borreliosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1174–1180.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Jauris-Heipke S, Rössle B, Wanner G, Habermann C, Rössler D, Fingerle V, Lehnert G, Lobentanzer R, Pradel I, Hillenbrand B, Schulte-Spechtel U, Wilske B.</emphasis> 1999. Osp17, a novel immunodominant outer surface protein of <citetitle><emphasis>Borrelia afzelii</emphasis></citetitle>: recombinant expression in <citetitle><emphasis>Escherichia coli</emphasis></citetitle> and its use as a diagnostic antigen for serodiagnosis of Lyme borreliosis. <citetitle><emphasis>Med Microbiol Immunol (Berl)</emphasis></citetitle> <emphasis role="strong">187:</emphasis>213–219.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Hauser U, Krahl H, Peters H, Fingerle V, Wilske B.</emphasis> 1998. Impact of strain heterogeneity on Lyme disease serology in Europe: comparison of enzyme-linked immunosorbent assays using different species of <citetitle><emphasis>Borrelia burgdorferi sensu lato. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>427–436.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Padula SJ, Dias F, Sampieri A, Craven RB, Ryan RW.</emphasis> 1994. Use of recombinant OspC from <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> for serodiagnosis of early Lyme disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1733–1738.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Rauer S, Spohn N, Rasiah C, Neubert U, Vogt A.</emphasis> 1998. Enzyme-linked immunosorbent assay using recombinant OspC and the internal 14-kDa flagellin fragment for serodiagnosis of early Lyme disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>857–861.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Mathiesen MJ, Christiansen M, Hansen K, Holm A, Asbrink E, Theisen M.</emphasis> 1998. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>3474–3479.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore RD Jr, Philipp MT, Steere AC, Wormser GP, Marques AR, Johnson BJ.</emphasis> 2003. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> compared with 2-tiered testing using whole-cell lysates. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">187:</emphasis>1187–1199.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0170" role="bibliographyEntry">
            <anchor id="ch0079s0024s0003a0007"/>
            <para>170.<emphasis role="strong">Lahdenne P, Panelius J, Saxen H, Heikkilä T, Sillanpää H, Peltomaa M, Arnez M, Huppertz HI, Seppälä IJT.</emphasis> 2003. Improved serodiagnosis of erythema migrans using novel recombinant borrelial BBK32 antigens. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>563–567.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Panelius J, Lahdenne P, Saxén H, Carlsson SA, Heikkilä T, Peltomaa M, Lauhio A, Seppälä I.</emphasis> 2003. Diagnosis of Lyme neuroborreliosis with antibodies to recombinant proteins DbpA, BBK32, and OspC, and VlsE IR6 peptide. <citetitle><emphasis>J Neurol</emphasis></citetitle> <emphasis role="strong">250:</emphasis>1318–1327.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Porwancher RB, Hagerty CG, Fan J, Landsberg L, Johnson BJB, Kopnitsky M, Steere AC, Kulas K, Wong SJ.</emphasis> 2011. Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">18:</emphasis>851–859.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Ledue TB, Collins MF, Young J, Schriefer ME.</emphasis> 2008. Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> and diagnosis of Lyme disease. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">15:</emphasis>1796–1804.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Molins CR, Delorey MJ, Replogle A, Sexton C, Schriefer ME.</emphasis> 2017. Evaluation of bioMerieux’s dissociated Vidas Lyme IgM II and IgG II as a first-tier diagnostic assay for Lyme disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1698–1706.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Leeflang MMG, Ang CW, Berkhout J, Bijlmer HA, Van Bortel W, Brandenburg AH, Van Burgel ND, Van Dam AP, Dessau RB, Fingerle V, Hovius JW, Jaulhac B, Meijer B, Van Pelt W, Schellekens JFP, Spijker R, Stelma FF, Stanek G, Verduyn-Lunel F, Zeller H, Sprong H.</emphasis> 2016. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. <citetitle><emphasis>BMC Infect D</emphasis></citetitle><citetitle><emphasis>is</emphasis></citetitle> <emphasis role="strong">16:</emphasis>140.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 1995. Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">44:</emphasis>590–591.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Mead P, Petersen J, Hinckley A.</emphasis> 2019. Updated CDC recommendations for serologic diagnosis of Lyme disease. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">68:</emphasis>703.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Aguero-Rosenfeld ME.</emphasis> 2021. Detection of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> antibodies, 11.5. <citetitle><emphasis>In</emphasis></citetitle> Leber AL, Burnham CAB (ed), <citetitle><emphasis>Clinical Microbiology Procedures Handbook</emphasis></citetitle>, 4th ed. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Fingerle F, Eiffert H, Gessner A, Göbel UB, Hofmann H, Hunfeld KP, Krause A, Pfister HW, Reischl U, Sing A, Stanek G, Wilske B, Zöller L.</emphasis> 2017. Lyme-Borreliose, p 1–68. <citetitle><emphasis>In</emphasis></citetitle> Podbielski A, Aberle-Horn M, Becker K, Herrmann M, Kniehl E, Mauch H, Rüssmann H (ed), <citetitle><emphasis>MiQ 12 2017</emphasis></citetitle> Lyme-Borreliose. Quality Standards in Microbiologic-Infectiologic Diagnostics Commissioned by the German Society for Hygiene and Microbiology together with the German Society for Infectiology and the German Society for Virology, 2nd ed. Elsevier GmbH, Urban &amp; Fischer Verlag, Munich, Germany.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Magnarelli LA, Meegan JM, Anderson JF, Chappell WA.</emphasis> 1984. Comparison of an indirect fluorescent-antibody test with an enzyme-linked immunosorbent assay for serological studies of Lyme disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">20:</emphasis>181–184.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Tugwell P, Dennis DT, Weinstein A, Wells G, Shea B, Nichol G, Hayward R, Lightfoot R, Baker P, Steere AC.</emphasis> 1997. Laboratory evaluation in the diagnosis of Lyme disease. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">127:</emphasis>1109–1123.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Busson L, Reynders M, Van den Wijngaert S, Dahma H, Decolvenaer M, Vasseur L, Vandenberg O.</emphasis> 2012. Evaluation of commercial screening tests and blot assays for the diagnosis of Lyme borreliosis. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>246–251.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT.</emphasis> 1999. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of <citetitle><emphasis>Borrelia burgdorferi vlsE. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>3990–3996.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB, Nowakowski J, Marques A, Johnson BJB, Dumler JS.</emphasis> 2013. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">75:</emphasis>9–15.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Jansson C, Carlsson SA, Granlund H, Wahlberg P, Nyman D.</emphasis> 2005. Analysis of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISA. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">11:</emphasis>147–150.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ.</emphasis> 2011. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">53:</emphasis>541–547.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Molins CR, Delorey MJ, Sexton C, Schriefer ME.</emphasis> 2016. Lyme borreliosis serology: performance of several commonly used laboratory diagnostic tests and a large resource panel of well-characterized patient samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2726–2734.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Riesbeck K, Hammas B.</emphasis> 2007. Comparison of an automated <citetitle><emphasis>Borrelia</emphasis></citetitle> indirect chemiluminescent immunoassay (CLIA) with a VlsE/C6 ELISA and immunoblot. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">26:</emphasis>517–519.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP.</emphasis> 1996. Evolution of the serologic response to <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> in treated patients with culture-confirmed erythema migrans. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">34:</emphasis>1–9.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">Branda JA, Aguero-Rosenfeld ME, Ferraro MJ, Johnson BJ, Wormser GP, Steere AC.</emphasis> 2010. 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>20–26.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">Branda JA, Strle K, Nigrovic LE, Lantos PM, Lepore TJ, Damle NS, Ferraro MJ, Steere AC.</emphasis> 2017. Evaluation of modified 2-tiered serodiagnostic testing algorithms for early Lyme disease. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">64:</emphasis>1074–1080.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0192" role="bibliographyEntry">
            <para>192.<emphasis role="strong">Dressler F, Whalen JA, Reinhardt BN, Steere AC.</emphasis> 1993. Western blotting in the serodiagnosis of Lyme disease. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">167:</emphasis>392–400.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0193" role="bibliographyEntry">
            <para>193.<emphasis role="strong">Theel ES, Sorenson M, Granger D.</emphasis> 2018. Evaluation of a novel microarray immunoblot assay for detection of IgM and IgG class antibodies to <citetitle><emphasis>Borrelia burgdorferi. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e00992–e18.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0194" role="bibliographyEntry">
            <para>194.<emphasis role="strong">Eldin C, Raffetin A, Bouiller K, Hansmann Y, Roblot F, Raoult D, Parola P.</emphasis> 2019. Review of European and American guidelines for the diagnosis of Lyme borreliosis. <citetitle><emphasis>Med Mal Infect</emphasis></citetitle> <emphasis role="strong">49:</emphasis>121–132.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0195" role="bibliographyEntry">
            <para>195.<emphasis role="strong">Dessau RB, van Dam AP, Fingerle V, Gray J, Hovius JW, Hunfeld K-P, Jaulhac B, Kahl O, Kristoferitsch W, Lindgren P-E, Markowicz M, Mavin S, Ornstein K, Rupprecht T, Stanek G, Strle F.</emphasis> 2018. To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">24:</emphasis>118–124.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0196" role="bibliographyEntry">
            <para>196.<emphasis role="strong">Stanek G, O’Connell S, Cimmino M, Aberer E, Kristoferitsch W, Granström M, Guy E, Gray J.</emphasis> 1996. European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis. <citetitle><emphasis>Wien Klin Wochenschr</emphasis></citetitle> <emphasis role="strong">108</emphasis><emphasis role="strong">:</emphasis>741–747.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0197" role="bibliographyEntry">
            <para>197.<emphasis role="strong">Pegalajar-Jurado A, Schriefer ME, Welch RJ, Couturier MR, MacKenzie T, Clark RJ, Ashton LV, Delorey MJ, Molins CR.</emphasis> 2018. Evaluation of modified two-tiered testing algorithms for Lyme disease laboratory diagnosis using well-characterized serum samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e01943–17.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0198" role="bibliographyEntry">
            <para>198.<emphasis role="strong">Branda JA, Body BA, Boyle J, Branson BM, Dattwyler RJ, Fikrig E, Gerald NJ, Gomes-Solecki M, Kintrup M, Ledizet M, Levin AE, Lewinski M, Liotta LA, Marques A, Mead PS, Mongodin EF, Pillai S, Rao P, Robinson WH, Roth KM, Schriefer ME, Slezak T, Snyder J, Steere AC, Witkowski J, Wong SJ, Schutzer SE.</emphasis> 2018. Advances in serodiagnosis testing for Lyme disease are at hand. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1133–1139.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0199" role="bibliographyEntry">
            <para>199.<emphasis role="strong">Wilske B.</emphasis> 2003. Diagnosis of Lyme borreliosis in Europe. <citetitle><emphasis>Vector Borne Zoonotic Dis</emphasis></citetitle> <emphasis role="strong">3:</emphasis>215–227.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0200" role="bibliographyEntry">
            <anchor id="ch0079s0024s0003a0008"/>
            <para>200.<emphasis role="strong">Robertson J, Guy E, Andrews N, Wilske B, Anda P, Granström M, Hauser U, Moosmann Y, Sambri V, Schellekens J, Stanek G, Gray J.</emphasis> 2000. A European multicenter study of immunoblotting in serodiagnosis of Lyme borreliosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>2097–2102.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0201" role="bibliographyEntry">
            <para>201.<emphasis role="strong">Wilske B, Fingerle V, Schulte-Spechtel U.</emphasis> 2007. Microbiological and serological diagnosis of Lyme borreliosis. <citetitle><emphasis>FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>13–21.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0202" role="bibliographyEntry">
            <para>202.<emphasis role="strong">Brouqui P, Bacellar F, Baranton G, Birtles RJ, Bjoërsdorff A, Blanco JR, Caruso G, Cinco M, Fournier PE, Francavilla E, Jensenius M, Kazar J, Laferl H, Lakos A, Lotric Furlan S, Maurin M, Oteo JA, Parola P, Perez-Eid C, Peter O, Postic D, Raoult D, Tellez A, Tselentis Y, Wilske B, ESCMID Study Group on Coxiella, Anaplasma, Rickettsia and Bartonella, European Network for Surveillance of Tick-Borne Diseases.</emphasis> 2004. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1108–1132.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0203" role="bibliographyEntry">
            <para>203.<emphasis role="strong">Wilske B, Schierz G, Preac-Mursic V, von Busch K, Kühbeck R, Pfister HW, Einhäupl K.</emphasis> 1986. Intrathecal production of specific antibodies against <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> in patients with lymphocytic meningoradiculitis (Bannwarth’s syndrome). <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">153:</emphasis>304–314.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0204" role="bibliographyEntry">
            <para>204.<emphasis role="strong">Rauer S, Kastenbauer S, Hoffman H, Fingerle V, Huppertz H-I, Hunfeld K-P, Krause A, Ruf B, Dersch R.</emphasis> 2020. Guidelines for diagnosis and treatment in neurology-Lyme neuroborreliosis. <citetitle><emphasis>German Med Sci</emphasis></citetitle> <emphasis role="strong">18:</emphasis>Doc03. 10.3205/000279.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0205" role="bibliographyEntry">
            <para>205.<emphasis role="strong">Mygland A, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I, European Federation of Neurological Societies.</emphasis> 2010. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. <citetitle><emphasis>Eur J Neurol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>8–16, e1–e4.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0206" role="bibliographyEntry">
            <para>206.<emphasis role="strong">Skogman BH, Croner S, Forsberg P, Ernerudh J, Lahdenne P, Sillanpää H, Seppälä I.</emphasis> 2008. Improved laboratory diagnostics of Lyme neuroborreliosis in children by detection of antibodies to new antigens in cerebrospinal fluid. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">27:</emphasis>605–612.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0207" role="bibliographyEntry">
            <para>207.<emphasis role="strong">van Burgel ND, Brandenburg A, Gerritsen HJ, Kroes ACM, van Dam AP.</emphasis> 2011. High sensitivity and specificity of the C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1495–1500.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0208" role="bibliographyEntry">
            <para>208.<emphasis role="strong">Stanek G, Lusa L, Ogrinc K, Markowicz M, Strle F.</emphasis> 2014. Intrathecally produced IgG and IgM antibodies to recombinant VlsE, VlsE peptide, recombinant OspC and whole cell extracts in the diagnosis of Lyme neuroborreliosis. <citetitle><emphasis>Med Microbiol Immunol</emphasis></citetitle> <emphasis role="strong">203:</emphasis>125–132.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0209" role="bibliographyEntry">
            <para>209.<emphasis role="strong">Cerar T, Ogrinc K, Strle F, Ruzić-Sabljić E.</emphasis> 2010. Humoral immune responses in patients with Lyme neuroborreliosis. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>645–650.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0210" role="bibliographyEntry">
            <para>210.<emphasis role="strong">Djukic M, Schmidt-Samoa C, Lange P, Spreer A, Neubieser K, Eiffert H, Nau R, Schmidt H.</emphasis> 2012. Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. <citetitle><emphasis>J Neurol</emphasis></citetitle> <emphasis role="strong">259:</emphasis>630–636.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0211" role="bibliographyEntry">
            <para>211.<emphasis role="strong">Hammers-Berggren S, Hansen K, Lebech AM, Karlsson M.</emphasis> 1993. <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle>-specific intrathecal antibody production in neuroborreliosis: a follow-up study. <citetitle><emphasis>Neurology</emphasis></citetitle> <emphasis role="strong">43:</emphasis>169–175.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0212" role="bibliographyEntry">
            <para>212.<emphasis role="strong">Tjernberg I, Henningsson AJ, Eliasson I, Forsberg P, Ernerudh J.</emphasis> 2011. Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">62:</emphasis>149–158.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0213" role="bibliographyEntry">
            <para>213.<emphasis role="strong">Wutte N, Berghold A, Löffler S, Zenz W, Daghofer E, Krainberger I, Kleinert G, Aberer E.</emphasis> 2011. CXCL13 chemokine in pediatric and adult neuroborreliosis. <citetitle><emphasis>Acta Neurol Scand</emphasis></citetitle> <emphasis role="strong">124:</emphasis>321–328.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0214" role="bibliographyEntry">
            <para>214.<emphasis role="strong">Wutte N, Archelos J, Crowe BA, Zenz W, Daghofer E, Fazekas F, Aberer E.</emphasis> 2014. Laboratory diagnosis of Lyme neuroborreliosis is influenced by the test used: comparison of two ELISAs, immunoblot and CXCL13 testing. <citetitle><emphasis>J Neurol Sci</emphasis></citetitle> <emphasis role="strong">347:</emphasis>96–103.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0215" role="bibliographyEntry">
            <para>215.<emphasis role="strong">Eckman EA, Pacheco-Quinto J, Herdt AR, Halperin JJ.</emphasis> 2018. Neuroimmunomodulators in neuroborreliosis and Lyme encephalopathy. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>80–88.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0216" role="bibliographyEntry">
            <para>216.<emphasis role="strong">Knudtzen FC, Nilsson AC, Hovius JW, Skarphedinsson S.</emphasis> 2020. The predictive value of CXCL13 in suspected Lyme neuroborreliosis: a retrospective cross-sectional study. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">39:</emphasis>1461–1470.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0217" role="bibliographyEntry">
            <para>217.<emphasis role="strong">van Gorkom T, van Arkel GHJ, Voet W, Thijsen SFT, Kremer K.</emphasis> 2021. Consequences of the edge effect in a commercial enzyme-linked immunosorbent assay for the diagnosis of Lyme neuroborreliosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e03280–20.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0218" role="bibliographyEntry">
            <para>218.<emphasis role="strong">Johnson JC.</emphasis> 1998. <citetitle><emphasis>Borrelia</emphasis></citetitle>, p 1277–1286. <citetitle><emphasis>In</emphasis></citetitle> Collier LH, Topley WW (ed), <citetitle><emphasis>Topley &amp; Wilson’s Microbiology and Microbial Infections.</emphasis></citetitle> Arnold, London, United Kingdom.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0219" role="bibliographyEntry">
            <para>219.<emphasis role="strong">Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB.</emphasis> 2006. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">43:</emphasis>1089–1134.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0220" role="bibliographyEntry">
            <para>220.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2005. Notice to readers: caution regarding testing for Lyme disease. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">44:</emphasis>590–591.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0221" role="bibliographyEntry">
            <para>221.<emphasis role="strong">Brett ME, Hinckley AF, Zielinski-Gutierrez EC, Mead PS.</emphasis> 2014. U.S. healthcare providers’ experience with Lyme and other tick-borne diseases. <citetitle><emphasis>Ticks Tick Borne Dis</emphasis></citetitle> <emphasis role="strong">5:</emphasis>404–408.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0222" role="bibliographyEntry">
            <para>222.<emphasis role="strong">Hinckley AF, Connally NP, Meek JI, Johnson BJB, Kemperman MM, Feldman KA, White JL, Mead PS.</emphasis> 2014. Lyme disease testing by large commercial laboratories in the United States. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">59:</emphasis>676–681.</para>
          </listitem>
          <listitem id="ch0079s0024s0003li0223" role="bibliographyEntry">
            <para>223.<emphasis role="strong">Wang G, Aguero-Rosenfeld ME.</emphasis> 2016. Lyme disease, relapsing fever and leptospirosis, p 419. <citetitle><emphasis>In Manual of Molecular and Clinical Laboratory Immunology</emphasis></citetitle>, 8th ed. ASM Press, Washington, DC.</para>
          </listitem>
        </itemizedlist>
        <orderedlist role="notesList">
          <listitem role="noteEntry">
            <para><anchor id="ch0079s0024s0003a0009"/><link linkend="ch0079s0001a0002">*</link>This chapter contains information presented by Gerold Stanek in <ulink url="ch0078#ch0078s0001">chapter 61</ulink> of the 12th edition of this <emphasis role="strong">Manual.</emphasis></para>
          </listitem>
        </orderedlist>
      </sect2>
    </sect1>
  </chapter>
